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Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin that is responsible for causing 
the symptoms of type A food poisoning, a leading cause of bacterial foodborne illness in the US.  
CPE-induced pore formation on intestinal epithelial cells results in ion permeability alterations 
leading to Ca2+ influx and activation of cell death pathways.  Upon binding to its receptor, 
certain claudins, the interactions between CPE and the target membrane result in the formation 
of a series of toxin complexes (CH-1 and CH-2) that represent the formation of the functional 
CPE pore.  Many bacterial toxins, particularly, pore-forming toxins, hijack cholesterol-rich lipid 
raft domains in the target cell membrane to aid in their virulence.  Lipid rafts serve as platforms 
to cluster receptor proteins to allow for more efficient binding and oligomerization.  Due to the 
pore-forming activity of CPE, we wished to determine if membrane rafts play a role in the 
mechanism of action of CPE.  Interestingly, CPE was found to be a novel pore-forming toxin 
that does not require raft domains for its action in that CPE complexes do not form within lipid 
rafts and cholesterol depletion had no effect on CPE-induced cytotoxicity.  These findings 
illustrate the unique interactions between CPE and target cells.  Despite recent research findings 
indicating the presence of claudins in the various CPE complexes, these intricate interactions 
have not been fully elucidated, and the exact composition of the toxin complexes is unknown.  
Therefore, the research presented here describes the development of a two-step method of 
electroelution/immunoprecipitation that allows for the isolation and purification of the CPE 
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complexes for compositional analysis by mass spectrometry.  Finally, a mouse model has been 
developed and characterized to show that the molecular interactions that occur in cell culture 
models, such as complex formation and inflammatory cell death, also occur in vivo.  
Furthermore, the mouse model mimics the lethality that is occasionally seen in humans that 
suffer from type A food poisoning-related deaths. 
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1.0  INTRODUCTION 
1.1 GENERAL BACTERIOLOGY OF CLOSTRIDIUM PERFRINGENS 
Originally isolated and identified as Bacillus aerogenes in 1892 by Welch and Nuttall, and 
transiently named Clostridum welchii, C. perfringens is a Gram-positive bacterium of great 
medical importance as it is a well-recognized cause of both human and veterinary diseases (30).  
Historically, C. perfringens first gained notoriety during World War I when it was discovered 
that this bacterium was responsible for causing the deaths of many soldiers suffering from gas 
gangrene wound infections.  Known for its wide environmental distribution, C. perfringens is a 
ubiquitous pathogen that can be found in water, soil, and as part of the normal flora of the 
digestive tract of humans and other mammals; C. perfringens is known as the most widely 
occurring pathogenic bacteria.  This ubiquitous nature allows this pathogen ample opportunity to 
come in contact with humans and other animals in order to cause disease.  Additionally, C. 
perfringens has the largest arsenal of toxins within the Clostridium genus, with >14 toxins and 
enzymes, which give this pathogen its exceptional virulence. 
As a member of the Clostridium genus, C. perfringens is part of a diverse group of 
bacteria that are anaerobic endospore-forming rods of size 0.6-2.4 µm X 1.3-19 µm and form 
large, regular, round, and slightly opaque and shiny colonies on the surface of agar plates (30).  
Other distinguishing characteristics include:  non-motility, catalase/oxidase negative, optimal 
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growth at 42°C, lecithinase-positive, double zone of hemolysis on blood agar, and the reduction 
of sulphite.  Additionally, C. perfringens alpha toxin works in synergy with Group B 
Streptococcus toxins, serving as the basis for the Reverse CAMP test (30).  In the phylum 
Firmicutes, C. perfringes belongs to the class Clostridia where other medically relevant bacteria 
such as C. difficile, C. botulinum, and C. tetani are classified. 
As a member of the Firmicutes, C. perfringens has a low GC content of 24-54%, with the 
average being 28%.  Recently, the genomes of three C. perfringens strains were sequenced (140, 
174).  It was revealed that there is considerable diversity among the strains, with genome sizes 
ranging from 3 to 4 Mbp.  This diversity was explained by the presence of ~300 mobile genetic 
elements that vary among isolates and encode factors involved in metabolism, capsule synthesis, 
and toxin production.  These mobile elements, thus, convey different virulence advantages 
between strains which lead to the varying human and veterinary diseases caused by C. 
perfringens. 
1.2 TOXINS AND DISEASES ASSOCIATED WITH C. PERFRINGENS 
1.2.1 Toxinotyping 
As mentioned above, C. perfringens produces an impressive array of toxins.  However, not all 
these toxins are produced by all strains or at the same time.  This allows for a systematic 
classification of C. perfringens isolates based on the expression of four major typing toxins: α, β, 
ε, and ι.  This typing scheme allows for the classification of isolates into five types, A-E, and is 
illustrated in Table 1.1.  Each toxinotype is associated with a particular disease due to the 
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production of a different set of toxins (Table 1.1).  All five types carry the plc gene, encoding for 
α-toxin, on their chromosome, while the other major toxins are located on large virulence 
plasmids which are variably present in isolates.  Plasmid size can vary among isolates within the 
same type based on the compatibility of different toxin genes with one another (104, 134, 167-
168). 
The α-toxin is a lethal dermonecrotic toxin with hemolytic, phospholipase C, and 
sphingomyelinase activities, and has been implicated as the primary cause of myonecrosis (gas 
gangrene) (9, 197).   β-toxin is produced by type B and C strains and is responsible for causing 
enteric disease in both humans and animals.  Specifically, Type B isolates are responsible for 
causing enterotoxemias in sheep and goats, while type C strains cause can enterotoxemias in 
both animals and humans.  Human necrotic enteritis, also known as Pigbel, is an endemic disease 
in Papua New Guinea caused by type C isolates and is associated with diets of foods with high 
amounts of trypsin inhibitor.  Recent studies using a type C rabbit ileal loop model with β-toxin 
knockouts and purified toxin demonstrated that this toxin is responsible for the pathogenic 
effects of necrotic enteritis (169, 207).  Type B and D isolates produce ε-toxin, a potent pore-
forming toxin known for its neurotoxicity, allowing it to be classified as a Class B Select Agent 
by the CDC.  Epsilon toxin is the 3rd most potent toxin of the clostridial toxins, behind tetanus 
and botulinum toxins.  Strains producing ε-toxin cause lethal enterotoxemias in lambs and goats, 
where pathological effects result from the toxin increasing the permeability within the intestine 
allowing for the toxin to enter the circulation where it can target other organs such as the 
kidneys, lungs, and brain.  The fourth major typing toxin is ι-toxin, produced solely by type E 
isolates, and is a member of the classical binary toxin family such as C. botulinum C2 toxin with 
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ADP-ribosyltransferase activity.  So far, type E isolates have been identified as only associated 
with veterinary enterotoxemias. 
 
Table 1.1  Toxinotyping classification scheme and associated diseases for C. perfringens isolates 
Toxinotype α β ε ι Genotypes Diseases
A + - - - plc Gas grangrene, diarrhea (dogs, pigs)
plc, cpe Food poisoning, antibiotic-associated 
plc, cpb2 diarrhea, sporadic diarrhea, necrotic 
plc, cpb2, cpe enteritis (fowl)
B + + + - plc, cpb, etx Dysentery (lambs)
plc, cpb, etx, cpb2 Enterotoxemia (sheep)
C + + - - plc, cpb Enteritis necroticans (pigbel), Necrotic 
plc, cpb, cpb2 enteritis (piglets, foals)
plc, cpb, cpe Acute enterotoxemia (adult sheep)
plc, cpb,cpb2, cpe
D + - + - plc, etx
plc, etx, cpb2 Enterotoxemia (goats, sheep, etc)
plc, etx, cpb2, cpe
plc, etx, cpe
E + - - + plc, iap/iab, cpe Enterotoxemia (calves, rabbits)
plc, iap/iab, cpe, cpb2
       Major Toxins
 
1.2.2 Non-typing Toxins 
In addition to the four major typing toxins, C. perfringens produces other biomedically relevant 
toxins not used in the typing scheme.  Theta toxin, also known as perfringolysin O (PFO), is a 
member of the cholesterol-dependent cytolysin (CDC) family of pore-forming toxins, with 
structural homology to Streptococcus pyogenes streptolysin O, S. pneumoniae pneumolysin, and 
Listeria monocytogenes listerolysin O.  PFO has been shown to act synergistically with α-toxin 
in gas gangrene pathogenesis (10), as well as potentiate the lethal effects of ε-toxin in an 
intravenous mouse model (44).  Additionally, PFO has been suggested to be the primary factor in 
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the killing of macrophages, an aspect which would aid in persistence of the bacterium within 
muscle tissue during gas gangrene infections (146). 
Another example of a non-typing toxin is beta2 toxin, which has been implicated in 
several animal GI diseases, including equine typhlocolitis, diarrheic disease in piglets and dogs, 
and bovine enterotoxaemia, as well as some human non-foodborne diseases (47).  Other toxins 
requiring further characterization include lambda protease, collagenase, and the many sialidases 
that are encoded by C. perfringens.  Perhaps the most relevant C. perfringens toxin, as it relates 
to human disease, is C. pefringens enterotoxin (CPE) which is responsible for mediating the 
effects of human C. perfringens type A food poisoning. 
1.3 CLOSTRIDIUM PERFRINGENS ENTEROTOXIN 
1.3.1 Role in Type A Food Poisoning 
1.3.1.1 Clinical and Epidemiological Aspects of Type A Food Poisoning 
Clostridium perfringens type A food poisoning ranks among the top 3 causes of bacterial food-
borne illness in the US and UK (2, 113) and is a great economic burden (198).  This illness was 
first reported in large-scale outbreaks in England in 1943 and in the US in 1945 (84) and occurs 
in large institutions such as nursing homes and mental hospitals.  A recent outbreak occurred in 
August 2008 where >100 inmates in a Wisconsin prison became ill due to contaminated food 
(154).  Clinical symptoms of the illness include diarrhea, abdominal pain and cramping, and to a 
lesser extent, nausea, vomiting, and fever (172).  Type A food poisoning is usually mild and 
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somewhat self-limiting, however, there are deaths commonly associated with this illness, 
especially within the elderly population.  Symptoms usually resolve with 24 hours. 
The source of type A food poisoning (Fig. 1.1) is most commonly exposure to high 
numbers (108 organisms) of cpe+ vegetative C. perfringens present in contaminated meat 
products, usually beef stews, which have been inadequately cooked or improperly stored.  
Typically, within 12 hours after ingestion of the high numbers of vegetative cells, exposure to 
the harsh environment of the gastrointestinal tract will trigger sporulation (through an unknown 
mechanism, possibly the presence of inorganic phosphate (150)) of these vegetative bacteria.  It 
is during sporulation that CPE production begins, resulting in a buildup of CPE protein within an 
inclusion body in the sporulating mother cell.  At the conclusion of sporulation, the mother cell 
lyses to release the mature spore, as well as the large amount of CPE, into the intestinal lumen 
where it can act on target cells of the intestinal epithelium. 
1.3.1.2 In vivo Effects of Type A Food Poisoning 
The in vivo effects of CPE-induced type A diarrhea have been elucidated in rabbit animal 
studies, where it was shown that the rabbit small intestine is the major target of CPE in vivo, with 
the ileum being the most sensitive (123).  A recent study additionally showed that CPE binds to 
human ileal epithelium and induces morphological damage concurrent with reduced 
transepithelial resistance and net water absorption (45).  When tested in rabbit ileal loop models, 
CPE induces significant damage to the ileum within 15-30 minutes (173).  This damage includes 
villus blunting, epithelial desquamation and some inflammation.  Development of this 
histopathological damage coincides with the arrest of fluid absorption and reverse in fluid 
transport, suggesting a cause and effect relationship that gives rise to the secretion of fluid into 
the intestinal lumen which is characteristic of diarrhea.  Additionally, doses of CPE within the 
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range measured in the stool samples of human patients are only able to cause histopathological 
damage and are capable of eliciting changes in fluid and electrolyte transport. 
     
 
After ingestion of improperly stored or cooked food contaminated with vegetative cpe+ C. 
perfringens, bacteria begin to sporulate and produce CPE.  CPE is released at the conclusion of 
sporulation within the lumen of the small intestine where it causes destruction of the epithelial 
cells, leading to cramping and diarrhea symptoms.  Modified from (183). 
 
A recent study (183) has illuminated the relevance of the CPE cytotoxicity seen in vitro 
(see below) and the entertoxicity seen in vivo as described above.  This study used two rCPE 
variants, which are non-cytotoxic to cells in vitro, in a rabbit ileal loop model of CPE 
enterotoxicity in vivo.  It was revealed that these non-cytotoxic CPE variants did not produce 
damage of the villus tips such as the necrosis of epithelium and lamina propria, villus blunting 
Figure 1.1  C. perfringens Type A Food Poisoning.   
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and fusion, and transmural edema and hemorrhage as is seen with wild-type CPE.  From this data 
it was concluded that cytotoxicity is necessary for the enterotoxic effects associated with CPE. 
1.3.1.3 Direct Evidence for CPE’s Role in Food Poisoning 
As illustrated above, there is strong evidence for the role of CPE in the pathological effects of 
type A food poisoning.  Further evidence supporting a role for CPE includes the observation that 
individuals suffering from food poisoning, but not healthy individuals, have CPE found within 
their feces (12, 15).  Additionally, the levels of CPE found in the feces of patients suffering from 
food poisoning are similar to those that cause histopathological damage in animals as described 
above (125).  Furthermore, the histopathology and fluid accumulation observed in rabbit ileal 
loop models can be prevented by neutralizing antibodies against CPE (72).  Another piece of 
evidence comes from a study of human volunteers that were orally administered purified CPE 
and displayed symptoms consistent with type A food poisoning (181).  Lastly, a study in which 
the cpe gene was inactivated in two C. perfringens isolates resulted in the complete absence of 
fluid accumulation and epithelial damage in the rabbit ileal loop model; however, when the wild-
type cpe gene was complemented back into the isolate, fluid accumulation and blunting and 
desquamation of the villi returned in the same manner as observed for the parent isolate, thus, 
satisfying molecular Koch’s postulates (165). 
1.3.1.4 What is the Reservoir for cpe+ Isolates? 
Despite being found within retail foods (212), a question that remains regarding the role of cpe+ 
C. perfringens in food poisoning is what the reservoir of these isolates is and where it originates 
within the food supply.  Recent efforts have been undertaken to try to answer this important 
question.  A recent study by Li et al. surveyed the presence of chromosomal cpe+ type A isolates, 
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which are responsible for food poisoning (see Section 1.3.3.1), within Pittsburgh-area soil and 
home kitchens (105).  The survey did not find any C. perfringens spores or vegetative cells from 
the 300 samples collected from different kitchen surfaces from 30 homes.  Despite being 
ubiquitous in soil, this study did not find any C. perfringens isolates harboring the chromosomal 
cpe gene associated with food poisoning.  This is in agreement with a previous US-wide soil 
survey which found no C. perfringens isolates harboring the enterotoxin gene (96). 
In addition to environmental reservoirs, the human digestive tract could be a possible 
reservoir for carrying enterotoxigenic C. perfringens, and thus, many studies are now being 
published examining the presence of these isolates in healthy humans.  A 2006 Finnish study 
examined the distribution of C. perfringens fecal carriage in 136 healthy food workers and found 
11 (8%) to be cpe+, however, only one was found to be carrying the enterotoxin gene on the 
chromosome (74).  A Japanese survey of the presence of C. perfringens isolates in healthy 
individuals also found a low frequency of chromosomal cpe+ isolates, with only two isolates as 
positive in the sample group (194).  Lastly, when fecal samples were examined from 43 North 
American healthy subjects, no chromosomal-positive isolates were found (28).  Taking these 
studies together, among those surveyed there is only a low incidence of colonization of healthy 
humans by C. perfringens carrying a chromosomal enterotoxin gene.  Larger numbers of samples 
are needed, but one can conclude that healthy humans are most likely not the reservoir for food 
poisoning isolates.  Unfortunately, the question of the reservoir remains unknown.  However, 
additional sites that are likely guesses for the cpe reservoir including livestock digestive tracts or 
slaughter houses and warrant further investigation. 
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1.3.2 Role of CPE in Non-foodborne Disease 
In addition to type A food poisoning, CPE also has a role in non-foodborne related diseases.  An 
example of CPE-related non-foodborne disease is antibiotic-associated diarrhea (AAD).  Most 
commonly implicated by C. difficile nosocomal infections, AAD is the result of the disruption of 
normal flora of the intestine by administration of antibiotics.  The gut microflora acts as a barrier 
against enteropathogens, and as a result, any bacterium that is insensitive or resistant to the 
prescribed antibiotic can colonize and multiply within the intestine, leading to diarrheal disease.   
C. difficile is the most often documented cause of AAD because of the severe, and often fatal, 
pseudomembranous colitis that can result, but accounts for only 20-25% of AAD cases.  In both 
North American and Europe, recent attention has been focused on C. difficile-related AAD 
because of the emergence of a hypervirulent, toxin-producing strain that results in not only 
nosocomal AAD, but also community-acquired infections (160).   However, CPE-producing C. 
perfringens has been estimated to cause 5-15% of AAD cases.  In 1984, Borriello et al. first 
described 11 cases of C. difficile toxin-negative AAD which harbored enterotoxin-positive C. 
perfringens strains (17).  This first study has been extended by many others, confirming a 
relationship between patients suffering from diarrheal symptoms and receiving antibiotic therapy 
and CPE-positive C. perfringens with varying degrees of incidence (7-8, 16, 18, 80, 162, 203).  It 
must be noted, however, that cases of AAD have been reported where enterotoxin-negative C. 
perfringens have been found within feces of patients (26, 153).  In addition to AAD, cpe+-
positive C. perfringens has been implicated in cases of sporadic diarrhea (SD) in the community, 
particularly with elderly individuals (20, 139). 
Unlike CPE-related food poisoning, symptoms resulting from CPE-positive C. 
perfringens AAD/SD tend to be more protracted and severe with blood and mucous in feces of 
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patients (138).  The symptomatic differences between these CPE-associated diseases were not 
well understood until recently.  In 2005, Fisher et al. performed a survey of the presence of the 
cpb2 toxin gene in 61 cpe+-positive isolates (48 AAD/SD isolates and 13 FP isolates) (47).  The 
cpb2 gene encodes the beta2 toxin (CPB2) which is mainly associated with animal GI diseases.  
This PCR study showed that 79% of AAD/SD isolates carried the cpb2 gene whereas only 2 of 
the 13 (~15 %) FP isolates had the cpb2 gene.  This relationship of cpb2 with AAD/SD isolates 
was later confirmed by Harrison et al. (69).  Taken together, these studies indicate CPB2 may 
serve as an accessory toxin in AAD/SD cases, acting to prolong symptoms not normally seen 
with CPE alone (i.e. food poisoning). 
1.3.3 CPE Genetics 
1.3.3.1 The cpe Gene and Locus 
The cpe gene is approximately 1.3 kbp in length and encodes a 319 amino acid CPE protein with 
a molecular weight of 35,317 Da (36).  There exists no significant DNA or amino acid homology 
with any other known bacterial toxins, except for some limited homology with the non-toxic 
hemagglutinin from botulinum C1 neurotoxin gene complex (73).  The significance of this 
limited homology is unknown; however, the region of greatest homology lies within the N-
terminal cytotoxicity domain of CPE (see below).  As described above, CPE can be responsible 
for both foodborne disease and non-foodborne disease.  When the cpe gene was sequenced from 
isolates of each of these types of diseases, no difference in the deduced amino acid sequence was 
found between the types (33).  Yet, cpe+ isolates are capable of producing quite different disease. 
In 1995, Cornillot et al. first demonstrated that the cpe gene could be located on either the 
chromosome or an episomal plasmid (35).  Complete sequencing of two types of plasmids 
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carrying the cpe gene revealed that cpe-plasmids can vary significantly in their size, encoded 
open reading frames, and IS elements (134).  The chromosomal cpe gene can be distinguished 
from plasmid-encoded cpe genes by a PCR assay which amplifies the flanking IS1470 element 
of the chromosomal cpe gene versus the IS1151 or IS1470-like elements on the cpe plasmids 
(135).  The significance of these IS elements is most likely to allow for the mobilization of the 
cpe gene which could allow for horizontal gene transfer. 
Collie and McClane demonstrated a strong correlation in which isolates carrying a 
plasmid-borne cpe gene were associated with AAD and SD (non-foodborne disease) while food 
poisoning isolates typically carry the cpe gene on the chromosome (34).  Additional observations 
regarding chromosomal vs. plasmid cpe isolates revealed that the vegetative cells and spores of 
chromosomal cpe isolates are much more resistant to heat and chemical treatments than are 
plasmid isolates (101-102, 166).  Insight into the mechanism of this resistance was recently 
investigated by Li and McClane (103).  This study identified a novel member of the DNA 
binding small acid soluble protein (SASP) family, Ssp4, in which a single amino acid 
substitution existed in chromosomal cpe isolates which conferred greater resistance to 
temperature and chemical treatments as compared to plasmid cpe isolates.  A final observation 
regarding the relationship between FP and chromosomal cpe genes comes from a study which 
described the presence of cpe+ C. perfringens in raw meats in local grocery stores where all 
samples harbored a chromosomal gene (212). 
1.3.3.2 Transcriptional Regulation of CPE 
As described previously, CPE expression is tightly controlled and is associated with sporulation 
of the bacterium.  After the development of sporulation media, early investigations demonstrated 
the sporulation-specific production of CPE that, when purified and administered to, resulted in 
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diarrhea in human volunteers and fluid accumulation in rabbit ileal loops (39, 71).  This 
transcriptional control is attributed to, at least in part, the presence of three sporulation-specific 
sigma factor promoters (one SigK and 2 SigE) upstream of the cpe gene (225).  Sigma factors are 
transcriptional regulators that direct RNA polymerases to promoter-specific genes that allow for 
the temporal transcription during sporulation which compartmentalizes the endospore and 
mother cell.  In fact, as CPE is produced, it accumulates in a paracrystalline inclusion body 
within the mother cell and can account for up to 20% of total protein (36, 109).  CPE has 
additionally been shown to be controlled by the CcpA transcriptional regulator which is a 
mediator of catabolite repression.  CcpA was shown to act as a repressor of CPE expression 
during vegetative growth but positively regulates CPE synthesis during sporulation conditions 
(206).  Although CPE synthesis is regulated with sporulation in C. perfringens, it is not required 
for expression when transformed and recombinantly-expressed in E. coli (36).  Furthermore, the 
mechanisms of sporulation-dependent regulation seem to vary among sporulating Gram-positive 
bacteria, as evidenced by only moderate CPE expression when transformed into Bacillus (130).  
As mentioned above, CPE is not secreted, but rather, is released in large amounts at the 
conclusion of sporulation when the mother cell lyses to release the mature endospore. 
1.3.4 Mechanism of Action 
1.3.4.1 Binding 
After release of CPE into the intestinal lumen at the conclusion of sporulation, CPE is able to act 
on target cells of the intestinal epithelia to induce the pathological effects characteristic of type A 
food poisoning.  Considered a membrane-active toxin, binding of the enterotoxin to target cells is 
the first step required in the action of CPE.  This initial binding event is necessary for the 
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cytotoxicity associated with CPE seen both in vivo and in vitro.  Binding and enterotoxicity has 
been demonstrated in a number of animal models including:  rabbit, mouse, rat, chicken, 
monkey, dog, bovine, pig, and lambs.  Binding was first described in vitro to be necessary for the 
cytopathic effects of CPE in a study where 125I-labeled toxin was shown to bind to sensitive Vero 
cells while a cell line that was resistant to CPE-induced killing was not bound by the toxin (126).  
Early experiments demonstrated that CPE binding to isolated cells from rabbit intestine, kidney, 
and liver is specific (i.e. unlabeled toxin is able to compete away 125I-CPE) and saturable (124).  
This study also showed that bound toxin did not dissociate upon treatment with chaotropic salts, 
suggesting a conformational change that locks the bound toxin in place, possibly due to insertion 
into the membrane.  Additionally, pretreatment of cells with proteases inhibited the ability of 
CPE to bind these cells. 
These initial observations suggested that a specific proteinaceous receptor is responsible 
for CPE binding.  Early attempts to identify the CPE receptor utilized affinity chromatography 
immobilized with CPE.  When isolated intestinal brush border membranes (BBMs) treated with 
CPE were lysed and run through the affinity column, two proteins of sizes 50 kDa and 70 kDa 
co-eluted with CPE, suggesting an association (216-217).  However, whether these two proteins 
served as functional receptors was not proven.  It was not until the late 1990’s that Katahira et al. 
utilized expression cloning to identify the receptor for CPE, which they termed CPE-R (82).  In 
this study, Katahira et al. cloned a cDNA library from the CPE-sensitive Vero cell line into a 
CPE-resistant cell line, L929 cells.  A C-terminal binding fragment of CPE (discussed below) 
was biotinylated to identify L929 clones that successfully bound CPE.  After purifying DNA 
from binding-capable L929 clones, sequence analysis identified an open reading frame of 630 bp 
encoding a 209 amino acid protein with a molecular mass of 22,029 Da with strong homology to 
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the androgen withdrawal apoptosis protein, RVP1.  The RVP1 gene is expressed in ventral 
prostate cells after withdrawal of androgen from the culture medium in vitro or castration in vivo 
(21).  How this related to CPE action was somewhat confusing, but after further sequence 
analysis, the CPE-R was determined to be a member of the multi-gene family of four 
transmembrane proteins, named claudins, an integral component of the tight junction (199).  
The tight junction (TJ) is an integral structure of epithelial and endothelial cells that 
serves to form a seal between adjacent cells and form a link to the actin cytoskeleton (11).  TJs 
are the most apical structure in the junctional complex, forming a network of mesh-like 
intramembrane strands that encircle the entire cell.  The first function of the TJ, referred to as its 
gate function, is to act as a selective barrier, regulating the paracellular transport of ions, solutes, 
and water.  The second functional role of the TJ is to segregate the diffusion of proteins and 
lipids along the plasma membrane.  This property, known as the fence function of TJs, gives rise 
to the distinct compartments of the apical and basolateral membranes.  Both of these functions of 
the TJ serve to separate the lumen and its contents from the underlying tissue.  In addition to 
these structural roles, recent research is now beginning to highlight the importance of TJ proteins 
in intracellular signaling pathways involved in cell proliferation and differentiation (11). 
The main components important for forming the backbone of the TJ are the integral 
membrane proteins: claudins, occludin, tricellulin, and JAM (junctional adhesion molecule) (11).  
The claudin superfamily of proteins consists of 24 members with molecular weights of 20-27 
kDa, and a predicted tetraspan structure containing a short N-terminal intracellular domain, two 
extracellular loop domains (the first being larger than the second), and a long cytoplasmic C-
terminal tail (Fig. 1.2A).  The C-terminal tail contains a PDZ domain which allows for the 
interaction of claudin with ZO-1, ZO-2, and ZO-3 (79), scaffolding proteins which bind actin, 
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thus, linking the tight junction to the actin cytoskeleton.  The extracellular loops (ECLs) interact 
with the ECLs of the claudins present in adjacent cells.  It is this interaction between ECLs that 
gives the charge selective (gate) properties of claudin strands.  Examination of the first ECL 
reveals a high number of charged amino acids, which, when paired with an apposing ECL, forms 
an ion selective pore that regulates the paracellular pathway of ions, solutes, and water (204) 
(Fig. 1.2B).  A functional role for the second ECL in the TJ has yet to be described. 
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Figure 1.2  Proposed Claudin Structure.   
A)  Illustration shows the proposed 4 transmembrane-spanning structure of claudin, with short N-terminal 
and long C-terminal intracellular sequences and 2 extracellular loops (ECL1 and ECL2).  The red star 
indicates the fproposed region of the ECL2 important for CPE binding.  B)  Charged residues of the 
ECL1 are represented by blue circles.  Claudins form continuous strands with apposing cells, allowing for 
electrostatic interactions between ECL1s forming an ion-selective pore. 
 
Upon further characterization, it was discovered that different affinities among CPE and 
the claudin (cldn) family members exists.  For instance, CPE was shown to bind to claudin-3 and 
-4 with high affinity, but failed to bind claudin-1 or -2 (187).  Question of the binding 
capabilities of the other claudin members was further addressed by examining the sensitivity of 
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transfecting a naturally CPE-insensitive cell line with different claudins, and revealed a group of 
binding capable claudins with varying degrees of affinity (cldn-6, -7, -8, and -14), and a group of 
non-binding claudins (cldn-5 and -10) (52).  This same study also shed light onto the region of 
the claudin molecule which is responsible for binding of CPE.  When chimeras containing the N-
terminal half of cldn-1 and the C-terminal half of cldn-3 (and vice versa) were transfected into 
CPE-insensitive cells, only the cells expressing the construct with the C-terminal half of cldn-3 
became sensitive to CPE treatment.  Considering that the N-terminal half contains the first ECL 
while the C-terminal half contains the second ECL, it was concluded that the second ECL is the 
region most likely to be important for CPE binding. 
Recent work has addressed the ability of the second ECL to bind CPE, and a more 
detailed analysis of the region important for binding has been investigated.  When the amino acid 
sequences of binding-capable claudins and non-binding claudins are aligned (Fig. 1.3), a striking 
pattern is seen.  Most of the residues in the second ECL are highly conserved, but at amino acid 
position 149 all of the binding-capable claudins contain an Asparagine (Asn, N) residue, 
whereas, non-binding claudins have either an Aspartic Acid (Asp, D) or Serine (Ser, S) at this 
residue.  Robertson et al. investigated the significance of this difference by performing site-
directed mutagenesis and changing the N to D in cldn-3 (binding) or the D to N in cldn-1 (non-
binding) (157).  After transfection of these mutated claudins into naturally CPE-insensitive rat 
fibroblast cells, cldn-3N149D –expressing cells remained resistant to CPE treatment, while cldn-
1D149N –expressing cells displayed cytotoxic effects after CPE treatment.  In addition, when CPE 
was pre-incubated with a peptide corresponding to the sequence of the second ECL of cldn-3, the 
ability of CPE to kill Caco-2 cells was inhibited.  However, CPE cytotoxicity was not inhibited 
when CPE was pre-incubated with a peptide encoding the second ECL of cldn-2.  The results 
 18 
from this study confirm the importance of the second ECL in CPE binding, but more importantly 
identify one key residue (N149) that confers binding of claudin to CPE. 
 
 
 
      
Figure 1.3 Alignment of CPE-sensitive and CPE-resistant Claudins.  
Amino acid alignment of claudins capable of binding CPE (cldn-3, -4, -6, -7, -8, -14) vs. 
claudins unable to bind CPE (cldn-1, -2, -5, -10) reveals a pattern in which all CPE-sensitive 
claudins contain an asparagine (N)  in the 2nd extracellular domain, while CPE-resistant 
claudins have either aspartic acid (D) or serine (S). 
 
1.3.4.2 Formation of the Small Complex 
After binding of CPE to its receptor, claudin, the toxin rapidly localizes into an SDS-sensitive 
complex of ~90 kDa on the surface of the target membrane (214).  This complex, termed Small 
Complex (SC), readily forms at 4°C, but confers no cytotoxicity to CPE-treated cells (122).  
Although CPE becomes tightly associated with the SC, likely through a post-binding 
conformational change, this complex does not seem to insert into the membrane as it has been 
shown that the SC is sensitive treatment with proteases (213).  The protein composition of the 
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SC has recently been investigated (158).  Through immunoprecipitation (IP) and electroelution 
(EE) studies, cldn-4 was shown to be present within the SC.  This was not a surprising finding 
given cldn-4 serves as a receptor for CPE.  However, the IP and EE studies also found cldn-1 and 
-2 localized within the SC, an interesting result considering these claudins are not functional 
receptors.  Prior experiments showed the presence of a 50 kDa protein in the SC (214), but it 
now seems that this probably represents aggregation of claudins which is an inherent 
characteristic of these proteins (133), however, the presence of a 50 kDa protein as a CPE co-
receptor cannot be ruled out. 
1.3.4.3 Formation of the Pre-Pore and Large Complexes 
Although not sufficient for CPE-induced cytotoxicity, SC formation is the first step required for 
these effects.  At 37°C, formation of the SC is a transitory step in which there is a rapid 
association with additional proteins to form a complex that is SDS-resistant and resolves with a 
higher molecular weight.  Recent studies have demonstrated that after the formation of the SC 
there is a rapid olgimerization event where there is formation of a pre-pore complex on the 
surface of target membranes (158, 184).  The pre-pore was shown to remain loosely attached to 
the membrane as it was highly susceptible to Pronase treatment.  The pre-pore subsequently 
inserts into the membrane where it then forms a complex that is resistant to protease treatment 
with Pronase (213).  Despite its insertion of the membrane, at least part of this complex remains 
exposed on the surface due to the fact that anti-CPE antibodies can recognize this complex (88).  
Initial studies using CHAPS to extract the complex from CPE-treated BBMs demonstrated that 
this larger complex was ~160 kDa in size, and its formation was dependent on temperature, e.g. 
this large complex forms at 24°C and 37°C, but not at 4°C (122, 217).  This temperature 
dependence suggested the requirement of membrane fluidity for proper large complex formation.  
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Additionally, these studies revealed that the formation of the large complex coincided with the 
onset of CPE-induced cytotoxicity.  Later experiments resolved the 160 kDa complex into two 
complexes of molecular weights of ~155 kDa and ~200 kDa on SDS-PAGE when extracted from 
the intestinal epithelial cell line, Caco-2 (179).  Through EE and IP experiments, it was shown 
that the ~200 kDa complex contained the 65 kDa TJ protein occludin, possibly accounting for 
the increase in molecular weight of the ~155 kDa complex.  This suggests that the ~155 kDa 
complex is possibly a precursor for the ~200 kDa complex (179).  It should be noted, however, 
that the formation of the ~155 kDa complex is sufficient for CPE-induced cytotoxicity and can 
occur in the absence of the ~200 kDa complex (178).  Additionally, claudin-deficient rat 
fibroblasts transfected to express occludin remain insensitive to CPE treatment, suggesting that 
occludin does not serve as a functional receptor for CPE action, and only becomes associated 
with the ~200 kDa through indirect associations (179).  Up to this point, isolation of the ~200 
kDa complex in the absence of ~155 kDa complex formation has not been achieved; therefore, 
the exact function of the ~200 kDa has yet to be determined.  However, one consequence of the 
formation of this occludin-containing complex is the coincident removal from the TJ and 
internalization of occludin (179), which is most likely detrimental to the structure and function of 
the TJ barrier. 
Just as was investigated for the SC, the presence of different claudins within the large 
complexes was examined.  Similar to the findings for SC, both binding-proficient claudins (e.g. 
cldn-4) and non-receptor claudins (e.g. cldn-1 and -2) were found to be localized within the ~155 
kDa and ~200 kDa complexes (158).  As alluded to above, by using heteromeric gel shift 
analysis, this study also revealed that at least 6 copies of CPE were present within these 
complexes, suggestive of a hexamerization event.  As a result, the nomenclature has been 
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updated where the ~155 kDa complex is now referred to as the CPE Hexamer-1 (CH-1) and the 
~200 kDa complex is now termed the CPE Hexamer-2 (CH-2).  When considering the number of 
CPE molecules and the varying number of receptor and non-receptor claudins present within 
these large complexes, a reassessment of the sizes of these complexes was prompted.  Using gel 
filtration and Ferguson plot analysis, the sizes of the CH-1 and CH-2 were resized to be much 
larger than originally predicted with molecular weights of ~450 and ~600 kDa, respectively 
(158). 
1.3.4.4 Mechanism of CPE-induced Cell Death 
As mentioned above, concurrent with formation of the CH-1 complex, CPE-induced cytotoxicity 
is observed.  Substantial evidence suggests the CH-1 complex serves as the functional pore of 
CPE action, corresponding to permeability alterations in target cells, leading to changes in water 
and ion fluxes.  These membrane permeability alterations were characterized in Vero cells using 
radiolabeled markers of varying sizes (119).  This study demonstrated that the CPE pores were 
large enough to allow molecules of up to 3000 Da to pass through, but not RNA (molecular size 
of 25000 Da).  Additionally, the onset of the change in permeability occurred within 15 minutes 
of CPE treatment and was dose-dependent.  Osmotic stabilizers such as sucrose, PEG, dextran, 
and BSA were able to protect against CPE-induced changes in cell permeability (121).  The 
formation of functional pores in the membranes of Vero cells results in the complete inhibition 
of DNA, RNA, and macromolecule synthesis, as well as the reversal of glucose transport, within 
30 minutes of CPE treatment (106, 120).  This inhibition has been shown to be directly 
associated with the permeability alterations caused by CPE treatment (77). 
Patch-clamp studies revealed the presence of ion-permeable channels within lipid 
bilayers treated with CPE (191).  Multiple studies have investigated the importance of ions, 
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specifically Ca2+, in the action of CPE (57, 76, 117, 190).  Collectively, these studies determined 
that CPE binding, SC and large complex formation, small molecule membrane permeability 
alterations, and macromolecule synthesis inhibition are independent of the presence of 
extracellular Ca2+.  Conversely, morphologic damage, large molecule permeability alterations, 
cell lysis, villi tip desquamation, and fluid loss were shown to rely on the presence of 
extracellular Ca2+. 
Recently, the relationship between Ca2+ and CPE-induced cell death was further explored 
at the molecular level (31-32).  Chakrabarti et al. investigated the dose-dependent effects of CPE 
treatment on the activation of cell death pathways (32).  In this study, it was found that in the 
case of a low dose (1 µg/ml), CPE caused morphological and biochemical changes in Caco-2 
cells characteristic of apoptosis.  However, in the case of a high CPE dose (10 µg/ml), Caco-2 
cells were killed in a morphological and caspase-independent mechanism characteristic of 
oncosis.  This dose-dependent relationship of cell death was further explored, correlating these 
effects with the role of CPE-induced Ca2+ influx in Caco-2 cells (31).  It was observed that the 
dose of CPE (low vs. high) correlated with the level of Ca2+ entering treated cells.  For instance, 
low doses of CPE caused a mild influx of Ca2+, while a high dose of CPE resulted in a strong 
influx of Ca2+.  The level of Ca2+ influx influenced the cell death pathway activated, and it was 
shown that the Ca2+-dependent, cysteine protease, calpain, was differentially activated by the low 
and high CPE doses.  Therefore, calpain is hypothesized to be implicated in determining which 
pathway, apoptosis or oncosis, is activated.  The observed cell death characteristics are 
summarized in Table 1.2. 
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Table 1.2  Characteristics of CPE-induced Cell Death of Caco-2 Cells at Low (1 µg/ml)  
and High (10 µg/ml) Doses 
Characteristic Low High
Ca2+ Influx Mild Strong
Calpain Activation Mild Strong
Caspase 3/7 Activation Yesa No
Mitochondrial Depolarization Yesb No
Cytochrome c  Release Yesb No
Cell Death Pathway Apoptosis Oncosis
Morphology Cell rounding, membrane buddinga Cell swelling, membrane blebbingc
DNA Cleavage Ladder-likea Shearingc
Nuclear Condensation Yesa No
                                                    CPE Dose
 aObservation seen after 1 h of CPE treatment 
bObservation seen after 15 min of CPE treatment 
cObservation seen after 30 min of CPE treatment 
 
1.3.5 CPE Structure/Function 
1.3.5.1 N-terminal Activation Domain 
Upon examination of the primary sequence encoded by the cpe gene, one can find multiple sites 
of protease cleavage, however, only two active cleavage sites are present.  At amino acid 
position 25 there is a trypsin cleavage site, followed by a chymotrypsin site at amino acid 
position 36.  Upon enzymatic cleavage with trypsin, purified CPE releases a peptide fragment of 
approximately 4000 Da.  This results in a 3-fold increase in the activity of CPE, as first reported 
by Granum et al. (59).  This result was subsequently confirmed in which trypsin-cleaved CPE 
showed 2-3 times more 86Rb release than the native toxin, despite no change in the level of CPE 
binding (67).  Chymotrypsin treatment results in the cleavage of 36 amino acids from the N-
terminus, and this processing increases CPE activity on Vero cells by 3.2-fold (58).  The role of 
the N-terminal activation domain is hypothesized to be important in the intestine of humans 
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during type A food poisoning, where trypsin and chymotrypsin, as well as other proteases, may 
serve to activate CPE, creating a more potent toxin. 
1.3.5.2 N-terminal Cytotoxicity Domain 
Initial studies indicating the importance of the N-terminal half of the CPE molecule in 
cytotoxicity were performed in which a CPE fragment encompassing amino acid residues 171-
319 proved to be non-cytotoxic to Vero cells, yet retained binding activity (67).  The role of the 
N-terminus was further explored in a study using deletion analysis to create recombinant N-
terminal CPE fragments (87), as illustrated in Fig. 1.4.  Findings from this study demonstrated 
that the first 44 amino acids can be removed without any deleterious effect on cytotoxicity; 
however, removal of the first 52 amino acids produces a non-cytotoxic fragment.  Both 
constructs had full binding capability, however, the fragment lacking amino acids 1-52 could not 
form large complex.  These findings suggested an essential role of the region between residues 
45 and 53 required for CPE cytotoxicity.  Random mutagenesis of the cpe gene provided 
additional insight into the role of the N-terminus in large complex formation and CPE-induced 
cytotoxicity (86).  Two point mutations, G49D and S59L, resulted in the complete attenuation of 
cytotoxicity on BBMs, despite being fully binding capable.  Additionally, these mutations were 
able form SC, but could not form large complex, further supporting the role of the N-terminal 
region in formation of the large complex. 
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Figure 1.4  Deletion Analysis of rCPE constructs 
 
Further investigation of the N-terminal cytotoxicity region employed site-directed 
mutagenesis to fine-map this region and its amino acid residues (182).  Each of the residues 
within the 45-53 region was replaced individually by alanine-scanning mutagenesis, and the 
effect on binding, complex formation, and cytotoxicity was measured.  One point mutant, D48A, 
showed a complete defect in the ability to form large complex and induce cytotoxicity, as 
quantified by 86Rb release.  The D48A mutant, however, still retained full binding and SC 
formation ability.  When the D48 residue was replaced by either an E or N, these variants still 
had the characteristics of the D48A variant, indicating both size and charge are important for this 
residue’s ability to confer cytotoxicity and large complex formation.  A second variant, I51A, 
also proved to be deficient in large complex and cytotoxicity.  Other mutants, G47, G49, and 
W50, displayed atypical large complex formation, yet retained the ability to be toxic.  These 
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results indicated the region 47-51 to be particular important for large complex formation and 
cytotoxicity.  Additionally, it is hypothesized that this region serves as a latch domain to allow 
the interaction of CPE molecules during oligomerization, a structural domain similarly seen in 
the pore-forming alpha-hemolysin from Staphylococcus aureus (184-185). 
1.3.5.3 C-terminal Binding Domain 
The first step required for CPE action is binding to the membrane surface of target cells.  The 
CPE171-319 variant used in the study by Hanna et al., as mentioned above, not only revealed the 
importance of the N-terminal domain for cytotoxicity, but also demonstrated the importance of 
the C-terminal half of the CPE molecule for binding (67).  Further mapping of the C-terminal 
region important for binding, showed that a short fragment of CPE290-319 recombinantly 
expressed in E. coli was able to compete for binding against native CPE on BBMs as well as 
inhibit CPE-induced cytotoxicity of Vero cells (66).  Moreover, a synthetic peptide 
corresponding to amino acids 290-319 of CPE was also able to specifically block CPE binding 
and competitively inhibit cytotoxicity.  Additionally, when mice were immunized with the 
CPE290-319 synthetic peptide, neutralizing antibodies were produced, adding more support for this 
region’s importance in CPE binding (132).  Further deletion mutagenesis revealed that even 
when only the last 5 amino acids of CPE are removed, toxin binding is inhibited (87). 
Several recent studies have investigated the use of C-terminal CPE (C-CPE) derivatives 
as modulators of claudins, which have given further insight into the amino acids of the C-
terminal domain essential for binding.  The first of these studies showed that treatment of Caco-2 
cells with C-CPE (CPE184-319) decreased transepithelial electrical resistance (TEER), but deletion 
of the C-terminal 16 amino acids of C-CPE reversed this decrease in TEER (193).  Alanine-
scanning mutagenesis of the three tyrosines in this 16 residue region (Y306, Y310, and Y312) 
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revealed these to be important for binding, TEER, and intestinal absorption, with Y306 being 
most crucial (68).  Upon further analysis of Y306, replacing Y with W or F had no reduced 
effects on binding, however, a Y306K mutant greatly reduced binding and TEER (41).  This 
finding indicated aromatic and hydrophobic properties, but not hydrogen bonding potential, 
influence the binding of C-CPE to claudin.  An additional L315A substitution was found to 
decrease modulation of the TJ as compared to C-CPE, and when coupled with the Y360A 
variant, the ability to bind claudin, modulate TEER, and enhance intestinal absorption was fully 
lost (192).  Collectively, these results confirm the importance of the C-terminus in CPE binding, 
and narrow down the important residues to Y306 and L315.  Information from these studies can 
aid in the development and design of claudin modulators useful for increasing drug absorption in 
the intestine (see below). 
Another recent endeavor was undertaken to solve the crystal structure of CPE (205).  A 
C-CPE fragment representing a 14 kDa peptide corresponding to residues 194-319 was used for 
crystallization.  At a resolution of 1.75 Ǻ, the solved C-terminal structure reveals a nine-stranded 
β sandwich with anti-parallel strands, as shown in Fig. 1.5.  Interestingly, a loop spanning 
residues K304-Y312 lies outside of the β sandwich, and contains the three tyrosine residues, 
described above, important for CPE binding.  As mentioned previously, CPE lacks nucleotide or 
amino acid homology with any other known proteins.  However, when this C-CPE structure is 
compared to other known protein structures, an unappreciated similarity is seen with the 
collagenase, ColG, from C. histolyticum and from members of the Cry family of insecticidal 
toxins from Bacillus thuringiensis.  In both cases, as is for CPE, these structures represent the 
regions that play a role in binding.  This CPE structure can aid in designing future mutagenesis 
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studies to determine important CPE:claudin interactions.  Current research is aimed at solving 
the full-length CPE protein, as well as the crystal structure of CPE bound to its receptor, claudin. 
        
 
Figure 1.5  Functional Domain Mapping and C-CPE194-319 Structure 
Map illustrates positions of the N-terminal Cytotoxicity Domain, Putative 
Transmembrane Stem Domain, and C-terminal Binding Domain.  Structure shows β 
sandwich with anti-parallel strands.  Binding loop (dark blue) protrudes from the β 
sandwich, exposing tyrosines previously shown to be important for binding.  Modified 
from (205). 
 
1.3.5.4 Putative Transmembrane Stem Domain 
Examination of the primary sequence of the CPE protein reveals a region (residues 81-106) with 
a striking pattern of alternating residues of side chain polarity.  This alternating pattern is 
reminiscent of the transmembrane domains of the β-barrel family of pore-forming toxins in 
which β-hairpins from toxin monomers insert into the membrane after oligomerization to form a 
functional pore (196, 200).  When amino acids 81-106 are deleted from CPE, this variant (TM1) 
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cannot form functional pores within the membrane and cannot elicit cytotoxicity of Caco-2 cells 
(184).  Interestingly, however, the TM1 mutant can still form the CH-1 complex (but not CH-2), 
but the CH-1 complex formed appears to be significantly more sensitive to proteases and 
dissociation from the membrane, suggesting it is in an unstable, exposed, and uninserted state.  
These findings suggest the TM1 domain is a putative transmembrane stem domain important for 
insertion into the membrane, and deletion of this domain results in the stalling of the CPE 
prepore on the exposed plasma membrane. 
1.3.6 Practical Applications of CPE and CPE Derivatives 
1.3.6.1 CPE as a Cancer Therapeutic 
The ability of CPE to bind certain claudins, but not others, has sparked significance interest in 
the cancer field since the observation that cldn-3 and-4 (CPE receptors) are overexpressed in a 
number of different cancers.  Specifically, claudins have been shown to be dysregulated in many 
pancreatic, prostrate, breast, ovarian, and uterine cancers (108, 111, 131, 143, 163) (see Table 
1.3 for a more extensive list).  The role of claudins and how their expression in related to cancer 
progression is an area of active research.  One study investigated the mechanism of this 
dysregulation in ovarian cancer, and found a possible link between the overexpression of cldn-4 
and a decreased methylation state of the protein (108).  Gene regulation by growth factors such 
as hepatocyte growth factor and epidermal growth factor have been implicated as additional 
mechanisms of differential claudin expression in cancer (90, 177), as well as exposure to various 
cytokines (65, 83).  Clinically speaking, aberrant expression of claudins may lead to cancer 
progression and metastasis by reducing cell adhesion and increasing tumor motility (3). 
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Table 1.3  Differential Expression of Claudins in Cancers 
Cancer Type Claudins Dysregulated Cancer Type Claudins Dysregulated
Breast 3, 4 Breast 1, 2, 4, 7
Prostate 1, 3, 4, 7 Prostrate 2, 5
Ovarian 1, 3, 4, 5, 7, 16 Head and Neck 7
Pancreatic 1, 4 Glioblastoma 1
Colon 1, 12 Colon 8
Gastric 1,3, 4, 5, 7 Gastric 4, 18
Thyroid 1, 4, 7, 10 Thyroid 1
Hepatocellular 1, 2, 7, 10 Hepatocellular 3, 4, 7
Cervical 1, 7 Melanoma 1
Renal 1, 3, 4, 7, 8 Renal 7
Lung 1, 3, 4, 5 Lung 1, 5
Claudins Upregulated in Cancers Claudins Downregulated in Cancers
 
Information compiled from (148) and (89). 
 
In 2001, Michl et al. first investigated the potential of CPE as a tumor-targeting 
therapeutic (131).  The authors demonstrated a significant overexpression of cldn-4 in many 
pancreatic and colon carcinoma tissues and a dose-dependent killing of a pancreatic cancer cell 
line when treated with CPE.  Additionally, when injected directly into a xenograft tumor in nude 
mice, it was observed that CPE caused the inhibition of tumor growth and the induction of tumor 
necrosis.  Despite claudin expression in various other tissues, it was important to note that mice 
harboring tumors that were injected with CPE did not experience any signs of toxicity.  Similar 
studies have been performed with breast and uterine cancer tissues and cell lines, as well as 
chemotherapy-resistant ovarian cancer, and in all cases, CPE was shown to either halt tumor 
growth or actually, significantly decrease tumor size (92, 163-164). 
One particularly intriguing use of CPE was a study in which CPE was used as a targeted 
therapeutic for brain metastasis (91).  By immunohistochemical analysis, it was observed that 
expression of cldn-3 and -4 were highly expressed in brain metastases originating from breast, 
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lung, and colon carcinomas.  However, cldn-3 and -4 expression was absent from the 
surrounding normal brain tissue, as well as all regions of the CNS.  Visualized by bioluminescent 
imaging, intracranial administration of CPE significantly inhibited tumor growth by 10-fold and 
increased mouse survival.  Amazingly, there was no noticeable local or systemic toxicity 
associated with the intracranial CPE delivery method. 
Recent research has focused on use of CPE fusion constructs as cancer-targeting 
molecules.  One such study fused tumor necrosis factor (TNF) to C-CPE290-319 and tested its 
effect on ovarian cancers expressing high levels of cldn-3 and -4 (224).  TNF was successfully 
delivered to the cytosol, and cytotoxicity was observed and correlated with the level of claudin 
expression, as shown by shRNA knockdown of cldn-3 or -4 which inhibited CPE-TNF killing.  
The investigators, however, did not show the delivery or cytolysis by their construct in a tumor 
experimental model.  Saeki et al. constructed a C-CPE fusion with the protein synthesis 
inhibitory factor (PSIF) from Pseudomonas aeruginosa, and demonstrated that intratumoral 
injection of C-CPE-PSIF significantly suppressed tumor growth, resulting in 36% of the tumor 
volume (161). 
These studies described illustrate the promising potential for CPE and CPE derivatives 
use in cancer therapeutics.  Most, if not all, of these studies are using a tumor model in which 
CPE is injected directly into the tumor, however.  In many cases, this would not be plausible in a 
clinical setting, and therefore, additional research is needed to develop a tumor-targeting CPE 
molecule for these purposes. 
1.3.6.2 CPE Derivatives in Drug Delivery 
As described in detail above, it is well recognized that the C-terminus of CPE is responsible for 
binding of the toxin to receptor claudins.  Additionally, numerous reports have shown that C-
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terminal CPE fragments are still capable of binding target cells, yet do not induce cytopathic 
effects.  However, C-CPE binding to cells does have some significant effects.  For one, it has 
been shown that C-CPE binding to MDCK cells results in the removal of cldn-4, but not cldn-1, 
from the TJ, and its possible internalization and degredation (187).  As a result, TEER is 
drastically reduced in MDCK cells, a result also confirmed in Caco-2 cells (193).  These results 
indicate that C-CPE has the ability to alter the overall structure and function of the TJ, loosening 
the contacts between adjacent cells and allowing larger molecules to pass from apical to 
basolateral sides of cells.  This observation has led to an exciting area of CPE research in which 
CPE derivatives are being used as methods to increase drug delivery across the epithelial barrier. 
An initial study examined the use of C-CPE as a claudin modulator allowing the 
movement of large molecules across the epithelial barrier as a means of enhanced drug 
absorption (93).  This study used an in vivo rat loop assay to study the effects of C-CPE on the 
absorption of dextrans.  In a dose-dependent manner, C-CPE was shown to enhance the 
absorption of dextrans of up to 20 kDa in size.  Importantly, C-CPE was shown to be 400 times 
more potent at enhancing dextran absorption than capric acid, a clinically used enhancer of 
absorption.  Additionally, no intestinal damaged in the rats was observed with C-CPE treatment.  
The enhanced absorption was related to the removal of claudin from the TJ and required binding 
to claudin (93), however, binding was not sufficient for this effect.  When the N-terminal 36 
amino acids of C-CPE were deleted, the enhanced dextran absorption effect was greatly reduced 
(116). 
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1.4 SPECIFIC AIMS 
1.4.1 Specific Aim 1 
The first aim of this project is to explore the role of the cholesterol/sphingolipid-rich membrane 
microdomains, known as lipid rafts, in the mechanism of action of CPE.  The role of lipid rafts 
has been well established in the action of many bacterial pore-forming toxins, as well as many 
clostridial toxins.  These membrane raft domains serve as a platform for toxin binding, 
oligomerization, and insertion of toxin complexes in target cell membranes.  Therefore, 
considering the pore-forming activity of CPE, it is hypothesized that CPE may interact with lipid 
rafts.  To test this hypothesis lipid rafts will be disrupted by perturbing cholesterol levels in cells 
and assessing the effect on CPE complex formation and cytotoxicity. 
1.4.2 Specific Aim 2 
Claudins serve as receptors for CPE; however, CPE cannot bind to all members of the claudin 
family.  Recently, it has been discovered that even non-receptor claudins can become associated 
with CPE complexes.  Through immunoprecipitation experiments, CPE has been shown to also 
interact with the tight junction protein, occludin; and occludin has also been shown to be directly 
located within the CH-2 complex.  When one considers the complex architecture of the TJ and 
the close interactions between TJ proteins, one can hypothesize that these are most likely not the 
only cellular proteins making up the toxin complexes.  It is the second aim of this project, 
therefore, to determine what cellular components, in addition to claudin and occludin, make up 
the CPE complexes.  This aim will be accomplished by isolating toxin complexes and utilizing 
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mass spectrometry to identify cellular proteins located within each complex.  Electroelution and 
immunoprecipitation will be employed to confirm identified proteins. 
1.4.3 Specific Aim 3 
Upon histological assessment of CPE damage of the intestinal epithelia in animal models, one 
can visualize the infiltration of inflammatory cells, suggesting inflammatory events are 
occurring.  Additionally, in vitro data suggests that CPE can activate cell death pathways that are 
pro-inflammatory (e.g. oncosis).  Previous studies have indicated CPE can cause the systemic 
induction of inflammatory cytokines in animal models, but the role of cytokines in the area of 
local CPE damage (i.e. in the intestine) has not been investigated.  Despite the numerous reports 
detailing the need for CPE complex formation, the formation of CPE complexes has never been 
demonstrated as a contributor to CPE action in vivo.  Moreover, recent epidemiological studies 
have implicated type A food poisoning in the deaths of a high rate of individuals in mental health 
care facilities.  It was concluded that these deaths were attributed to the ability of CPE to gain 
access to the circulation.  The goal of Aim 3, therefore, is to develop a mouse model that enables 
us to mimic CPE-induced lethality where CPE complex formation in the intestine induces 
damage that allows CPE to gain access to the circulation.  Furthermore, the development of this 
mouse model will allow us to measure the local cytokine production profile within the intestine 
during CPE challenge. 
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2.0  THE ROLE OF LIPID RAFTS IN THE ACTION OF C. PERFRINGENS 
ENTEROTOXIN 
The data presented in this Chapter has been published as original work in Caserta JA, Hale ML, 
Popoff MR, Stiles BG, McClane BA. 2008. Evidence that membrane rafts are not required for 
the action of Clostridium perfringens enterotoxin.  Infect Immun. 76:5677-85. 
2.1 INTRODUCTION AND RATIONALE 
2.1.1 Bacterial Pore-Forming Toxins 
Despite the evident lack of sequence homology of CPE with other known bacterial toxins, there 
does exist significant structural homology with the family of pore-forming toxins.  The plasma 
membrane is a dynamic and complex structure that serves multiple functions in the eukaryotic 
cell.  Thus, the plasma membrane has proven to be an attractive target for bacteria and their 
products and toxins.  Of the many toxins produced by bacteria, pore-forming toxins (PFTs) are 
the most numerous group of toxins, compromising 30% of all bacterial toxins described.  PFTs 
are classified into two groups based on the structural components responsible for causing pore 
formation (78).  The first class of PFTs, α-PFTs, employ alpha helices to span the lipid bilayer, 
and include examples such as E. coli colicins (29), actinoporins produced by sea anemones (95), 
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and the insecticidal Cry family from Bacillus (151).  The other class of PFTs is the β-barrel PFTs 
(β-PFTs) which contain amphipathic β-strands that combine in multiprotein complexes to form a 
β-barrel pore.  Well known examples of β-PFTs include Staphylococcus aureus α-toxin (185), 
aerolysin (48), protective antigen from Anthrax toxin (222), and the large family of cholesterol-
dependent cytolysins (CDCs) (200).  Despite the structural differences between various PFTs, 
most have a common mechanism of action (Fig. 2.1).  The first step is secretion of the toxin in a 
monomer form and diffusion towards the target membrane.  Step 2 involves binding of the toxin 
monomer to a specific receptor on the surface of the membrane of target cells.  Third, monomers 
associate with one another to form an oligomeric prepore on the surface of the membrane, 
commonly mediated through a latch domain.  Lastly, the prepore inserts into the membrane 
forming the functional pore. 
                         
Figure 2.1  Mode of Action by Pore-forming Toxins 
2.1.2 Lipid Rafts and Their Role in Bacterial Pathogenesis 
When one thinks about the mechanism of pore formation by PFTs, it is apparent that the key, 
rate-limiting step is that of oligomerization, or the aggregation of multiple monomers and their 
associated receptors.  Bacteria are constantly evolving in order to take advantage of eukaryotic 
 37 
cells to aid in the action of their products.  In the case of bacterial toxins, bacterial have evolved 
mechanisms to make the oligomerization process more efficient.  Many bacteria and their toxins 
have been shown to utilize host cell lipid rafts as a means to aid in their pathogenesis, relying of 
these domains for binding, internalization/invasion, and evasion (70, 98, 115, 208). 
Lipid rafts, also known as detergent-resistant membranes (DRMs), and recently redefined 
as membrane rafts, are small (10-200 nm), highly specialized and dynamic domains within the 
lipid bilayer that are rich in cholesterol, sphingolipids and serve to compartmentalize cellular 
processes (152).  Although small, these raft domains have the ability to coalesce into larger 
domains allowing for the clustering of similar proteins within the microdomain, while excluding 
other non-raft-associated proteins.  This clustering serves as a platform for compartmentalizing 
cellular processes such as signal transduction, protein sorting, and membrane trafficking (23). 
Glycerophospholipids with long, fully saturated acyl chains make up the composition of 
raft domains, allowing tight packing of these lipids.  Additionally, rafts are highly enriched in 
sphingolipids which laterally associate with one another through hydrogen bonding of head 
groups.  The large head groups of sphingolipids and glycosphingolipids results in a void that 
allows cholesterol to preferentially interdigitate within the spaces of the fatty acid chains serving 
as a glue to maintain the structure and function of these domains (175).  Enrichment of 
cholesterol within lipid rafts results in a liquid-ordered (Lo) state with decreased fluidity.  The 
result is a condensed assemblage separated from the surrounding disordered unsaturated 
glycerophospholipid environment (i.e. non-rafts).  Additionally, an early observation was made 
that membrane rafts are resistant to non-ionic (Triton X-100) detergent extraction at 4°C.  With 
this detergent insolubility and the high lipid content, which allows these domains to float on 
sucrose density gradients, a method of lipid raft isolation was established (24).  Much of the 
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criticism of the lipid raft theory argues that DRMs extracted at 4°C are just artifacts and are not 
isolations of pre-existing structures (22).  However, it has been shown recently that membranes 
have the capacity to partition into raft domains at physiologic temperature (107). 
2.1.3 Rationale 
Many pore-forming toxins hijack lipid rafts to aid in toxin binding, oligomerization, and/or pore 
insertion into membranes of target cells.  Similarly, C. perfringens toxins, such as β, ε, ι, and 
PFO (64, 137, 141-142, 209), have all been shown to require lipid rafts for their action.  Because 
CPE shares structural and functional aspects of these toxins, it is hypothesized that CPE may also 
require lipid raft domains for its action. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
CPE was purified to homogeneity from strain NCTC 8239, as described previously (127).  
Methyl-β-cyclodextrin (MβCD) was purchased from Sigma-Aldrich (St. Louis, MO).  Claudin-4 
and occludin antibodies were purchased from Invitrogen (Carlsbad, CA).  Flotillin-1 antibody 
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Na+K+-ATPase antibody 
was obtained from Affinity Bioreagents (Golden, CO). 
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2.2.2 Cell Culture 
Caco-2 cells were maintained in Eagle minimal essential medium (Sigma, St. Louis, MO) 
supplemented with 10% fetal bovine serum (Mediatech, Herndon, Va.), 1% nonessential amino 
acids (Sigma, St. Louis, MO), 100 U/ml of ampicillin, and 100 µg/ml of streptomycin. All 
cultures were grown at 37°C with 5% atmospheric CO2. 
2.2.3 Small Complex Formation 
Caco-2 cells were seeded into 100 mm dishes (Corning, Corning, NY) and grown to confluency 
(4-5 days). After treatment with CPE (2.5 μg/ml) in cold (4oC) Hanks’ Balanced Salt Solution 
without Ca2+ and Mg2+ (iHBSS) for 15 min, the toxin was removed and cells were then washed 
twice with 10 ml iHBSS.  Cells were then gently scraped and centrifuged for 3 min at 1000 x g.  
Cell pellets were resuspended in 950 μl of TX-100 extraction buffer (see below) and loaded onto 
sucrose density gradients as described later.  Visualization of the SC was acquired by 
immunoblotting with an anti-CPE antibody, as described below. 
2.2.4 CH-1 and CH-2 Complex Formation 
Caco-2 cells were seeded into 100 mm dishes (Corning, Corning, NY) at a density of 2.5 x 105 
cells/ml in 10 ml.  Those cultures were then grown to confluency (4-5 days) and treated with 2.5 
μg/ml of CPE in warm iHBSS for 60 min at 37oC.  After this treatment, cells were washed twice 
with 10 ml iHBSS, harvested by gentle scraping and centrifuged for 3 min at 1000 x g to pellet 
material.  Cell pellets were washed with 10 ml iHBSS, centrifuged, and resuspended with 950 μl 
of TX-100 extraction buffer and loaded onto sucrose gradients (see below).  Visualization of 
CH-1 and CH-2 was acquired by Western blot with an anti-CPE antibody, as described below. 
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2.2.5 Ib Treatment 
Caco-2 cells were seeded into 100 mm dishes (Corning, Corning, NY) at a density of 2.5 x 105 
cells/ml in 10 ml.  Cultures were grown to confluency (4-5 days) and treated with 2.0 µg/ml of Ib 
for 15 min at 37°C.   
2.2.6 Cholesterol Depletion 
For experiments involving cholesterol depletion, Caco-2 cells were pre-treated with 10 mM 
MβCD in  iHBSS at 3 7oC.  After 60 min of treatment, MβCD was removed and cells washed 
twice with iHBSS.   
2.2.7 Cholesterol Quantitation 
The cholesterol content of Caco-2 cells was determined before and after depletion of cholesterol 
by MβCD treatment using the Amplex Red Cholesterol Assay kit (Invitrogen, Carlsbad, CA), 
with modifications.  Briefly, Caco-2 cell monolayers with or without MβCD treatment (60 min) 
were washed 2 times, scraped and lysed in 750 μl of the Amplex Red 1X Reaction Buffer.  Cells 
were lysed for 15 min at room temperature and insoluble material was pelleted by centrifugation 
for 1 min at 13,000 x g.  A 50 μl aliquot of supernatant for each sample was transferred to wells 
of a clear 96-well microtiter plate.  A 50 μl aliquot of Amplex Red working solution (cholesterol 
esterase omitted) was then added to each sample well.  Samples were covered and incubated for 
30 min at 37oC in the dark.  Following this incubation, samples were read using Revelation 4.21 
Software (Dynax Technologies) by measuring OD absorbance at 570 nm.   
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2.2.8 TX-100 Extraction of Caco-2 cells  and Sucrose Density Gradient Centifugation 
Caco-2 cells treated under the varying conditions explained above were extracted with 950 µl of 
TX-100 extraction buffer (1% TX-100, 10mM NaF, 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 
mM EDTA, 30 mM Na-pyrophosphate, 10 mM β-glycerophosphate, 1X Complete Protease 
Inhibitor Cocktail (Roche)) for 1 h at 4°C.  Following this cold TX-100 extraction, lysates were 
overlayed with 950 µl of an 80% sucrose solution (80% sucrose in 25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 5 mM EDTA, 30 mM Na-pyrophosphate, 10 mM β-glycerophosphate).  
Subsequently, 1.9 ml of a 30% sucrose solution was overlayed on this sample, followed by 950 
µl of a 5% sucrose solution.  Samples were then spun at 200,000 x g for 18 h in a Beckman XL-
90 ultracentrifuge.  After centrifugation, twelve 400 µl fractions were collected from the top of 
the gradient.   
2.2.9 Western Blotting 
For detection of claudin-4, occludin, flotillin-1, and Na+K+-ATPase, each of the twelve gradient 
fractions were concentrated by TCA precipitation.  One-fourth volume (100 µl) of 100% TCA 
was added to each fraction and incubated on ice for 1 h.  Samples were then centrifuged (14,000 
x g) for 15 min at 4°C.  Pellets were washed twice with 200 µl of ice cold acetone.  Those pellets 
were resuspended in 50 µl of 1X Laemmli Buffer and analyzed by SDS-PAGE, using 10% (for 
occludin, NaK ATPase) or 12% (for claudin-4, flotillin-1) acrylamide gels.  Those separated 
proteins were transferred to nitrocellulose, and probed with appropriate primary (rabbit anti-
claudin-4, mouse anti-occludin, rabbit anti-flotillin-1, or mouse anti-Na+K+-ATPase) and 
secondary antibodies (mouse or rabbit) conjugated with horseradish peroxidase (HRP) (Sigma, 
St. Louis, MO). 
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For experiments determining the localization of CPE complexes on sucrose gradients, 50 
µl aliquots of each fraction were run on native 6% PAGE gels (for SC) or mixed with 10 µl of 
5X Laemmli Buffer were analyzed by SDS-PAGE using 4% acrylamide gels (for CH-1 and CH-
2).  After electrophoresis, separated proteins were transferred to nitrocellulose, and probed with a 
rabbit anti-CPE antibody followed by incubation with a goat anti-rabbit antibody conjugated to 
HRP (Sigma, St. Louis, MO).  Densitometry of Western blots was performed using the program 
Quantity One (BioRad, version 4.6.3). 
2.2.10 Trypan Blue Staining 
Caco-2 cells were seeded into 35 mm dishes at a density of 5 x 104 cells/ml in 2 ml and grown to 
confluency (4 days).  Control and MβCD-treated cells were washed and treated with CPE 
(2.5µg/ml) for various times.  After CPE treatment, cells were harvested by gentle scraping and 
centrifugation, pellets were then resuspended in 500 µl of 0.4% Trypan Blue Stain (Sigma).  
Live and dead cells were counted microscopically using a hemocytometer.  % Viability was 
calculated as expressing the number of non-blue (alive) cells over the total number of cells (blue 
and non-blue). 
2.2.11 Formation of CH-1 in Absence of CH-2 
For experiments requiring the formation of CH-1 in the absence of appreciable CH-2 complex, a 
previously described technique was used (158, 178).  Caco-2 cells were seeded at a density of 2 
x 105 cells/ml into two 75 mm Transwell permeable supports (Corning) for each experimental 
condition (Untreated or CPE-treated).  After confluency (5 days), cells were treated apically with 
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CPE (1.0 µg/ml) for 30 min.  After CPE treatment, cells were extracted and subjected to sucrose 
density gradient centrifugation as described above. 
2.3 RESULTS 
2.3.1 Detergent Solubility and Raft Localization of CPE Small Complex 
To evaluate the involvement of membrane rafts in CPE action, we first investigated whether CPE 
complexes localize within DRMs.  Since rafts are characteristically insoluble in TX-100 when 
extracted at 4°C (23), a series of sucrose density gradient experiments were performed using cold 
TX-100 extracts of Caco-2 cells treated with CPE (2.5 μg/ml) for 15 min at 4°C, conditions that 
allow formation of the ~90 kDa SC without appreciable formation of the CH-1 or CH-2 
complexes (122).  The formation of the ~90 kDa complex likely represents the interaction of 
CPE with its receptor, claudin (214, 216).  When fractions from the gradient were collected, 
subjected to Native-PAGE, and Western blotted with an anti-CPE antibody, the CPE SC was 
localized exclusively within the detergent-soluble fractions (8-12) of the gradient (Fig. 2.2A).  
The marker protein flotillin-1 was used as a control for raft-associated proteins and, as expected, 
it predominately migrated towards the top of the gradient, mostly within fractions 2-5 (Fig. 
2.2B).  In contrast, Na+K+-ATPase, a non-raft protein marker (137), was present within the 
detergent-soluble fractions at the bottom of the gradient (fractions 9-12) (Fig. 2.2B).  CPE 
treatment had no observable effect on the localization of either marker proteins (data not shown). 
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Figure 2.2  The CPE Small Complex (SC) is not localized within lipid rafts.   
A)  CPE Western blot of sucrose gradient fractions from Caco-2 cells containing SC.  After treatment 
with CPE (2.5 µg/ml) for 15 min at 4°C, Caco-2 cells were cold extracted with TX-100 and subjected to 
sucrose gradient centrifugation.  Gradient fractions were loaded on a 6% Native-PAGE gel, transferred to 
nitrocellulose, and Western blotted with an anti-CPE antibody.  Sucrose gradient fractions are numbered 
1-12 at the top of the blot, with fraction 1 being the gradient top and fraction 12 representing the gradient 
bottom.  “Raft” and “Non-Raft” labels reflect localization of raft-associated or non-raft-associated 
proteins, respectively.  Arrow depicts SC migration.  Shown is a representative blot for 3 independent 
experiments.  B) Western blotting of gradient fractions from Caco-2 cells to determine raft vs. non-raft 
fractions.  Top panel, Gradient fractions were concentrated using TCA (see Materials and Methods), 
loaded onto a 12% SDS-PAGE gel, and Western blotted with a rabbit anti-flotillin-1 antibody.  Bottom 
panel, same fractions were loaded onto a 10% SDS-PAGE gel and Western blotted with a mouse anti-
Na+K+-ATPase antibody.  Shown are representative blots from 3 independent experiments. 
 
2.3.2 Detergent Solubility and Raft Localization of CH-1 and CH-2 Complexes 
The Fig. 2.2 results indicated that SC formation, which corresponds to the initial binding of CPE 
to its receptor (214), does not occur within membrane rafts.  However, rafts might still contribute 
to CPE oligomerization.  To explore this possibility, experimental conditions were used that 
allow formation of both the CH-1 and CH-2 SDS-resistant complexes in Caco-2 cells.  In this 
case, Caco-2 monolayers were treated with CPE (2.5 μg/ml) for 60 min at 37°C, followed by a 
cold TX-100 extraction and sucrose density gradient centrifugation.  Western blot analysis (Fig. 
2.3A) of those gradient fractions indicated that the CH-1 complex localized exclusively within 
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the detergent-soluble fractions (fractions 8-12) at the bottom of the gradient.  The CH-2 complex 
also predominately localized within those detergent-soluble fractions (Fig 2.3A), although a 
small pool of CH-2 complex was detected within the detergent-insoluble fractions (fractions 3-
5). 
 
Figure 2.3  Localization of the CH-1 and CH-2 Complexes.   
A)  CPE Western blots of sucrose gradient fractions from Caco-2 cells containing CH-1 and CH-2.  After 
treatment with CPE (2.5 µg/ml ) for 60 min at 37°C, Caco-2 cells were cold extracted with TX-100 and 
subjected to sucrose gradient centrifugation.  Gradient fractions were loaded on a 4% SDS-PAGE gel, 
followed by Western blotting with a rabbit anti-CPE antibody.  Sucrose gradient fractions are numbered 
1-12 at the top of the blot, with fraction 1 representing the gradient top and fraction 12 the gradient 
bottom.  “Raft” and “Non-Raft” labels depict localization of raft-associated and non-raft-associated 
proteins, respectively.  Arrows indicate migration of the CH-1 and CH-2 complexes.  Shown is a 
representative blot for 3 independent experiments.  B) Ib Western blots of sucrose gradient fractions from 
Caco-2 cells containing Ib oligomers.  Caco-2 cells were treated with 2.0 µg/ml of Ib for 15 min at 37°C, 
followed by cold TX-100 extraction and sucrose gradient centrifugation.  Fractions were visualized by 
Western blot of a 4% SDS-PAGE gel with a rabbit anti-Ib.  Single arrow indicates 20 ng of purified free 
Ib.  Shown is a representative blot from 2 independent experiments. 
 
Since the data from Fig. 2.3 suggested that, except for a small fraction of CH-2, both the 
CH-1 and CH-2 complexes are non-raft-associated, a control was run to demonstrate that our 
methods could detect raft-associated toxin oligomers.  Caco-2 cells were treated with Ib, the 
binding subunit of C. perfringens iota toxin, whose oligomers are localized, at least partially, in 
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membrane rafts (64, 142).  In agreement with those previous findings, Ib oligomers were 
detected (Fig. 2.3B) within raft fractions. 
2.3.3 Effect of Cholesterol Depletion on CPE Complexes 
To evaluate whether membrane rafts are needed for CPE complex formation, these 
microdomains were disrupted by depleting cells of cholesterol using the compound methyl-β-
cyclodextrin (MβCD), which extracts cholesterol directly from the plasma membrane of cells.  
When the total cholesterol content of Caco-2 cells was measured before and after MβCD 
treatment, MβCD had removed ~70% of the cholesterol from Caco-2 cell monolayers (see 
Materials and Methods). 
Depletion of cholesterol in Caco-2 cells by MβCD pre-treatment prior to the addition of 
CPE had no major effect on CH-1 complex formation (Fig. 2.4A).  Additionally, MβCD pre-
treatment did not affect localization of the CH-1 complex in detergent-soluble fractions.  
Similarly, MβCD pre-treatment had little or no effect on the formation or localization of the CH-
2 complex pool that is non-raft-associated (Fig. 2.4A).  However, the small raft-associated pool 
of CH-2 complex (Fig. 2.3A) in CPE-treated Caco-2 cells was absent from cells depleted of 
cholesterol with MβCD treatment prior to CPE treatment, thus, confirming that this small pool is 
in fact raft-associated as it is sensitive to cholesterol depletion. 
As a control to show the effectiveness of MβCD in disrupting the localization of 
normally raft-associated oligomers, Caco-2 cells were pre-treated with MβCD prior to treatment 
with Ib.  Fig. 2.4B shows that cholesterol depletion effectively prevented the ability of Ib 
oligomers to form in raft domains, confirming that MβCD treatment affects the presence of toxin 
complexes in membrane microdomains. 
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Figure 2.4  Effect of Cholesterol Depletion on CH-1 and CH-2 Formation.   
A)  CPE Western blot of sucrose gradient fractions from CPE-treated Caco-2 cells with reduced 
cholesterol levels.  Caco-2 cells were pretreated with 10 mM MβCD for 60 min, followed by treatment 
with CPE (2.5 µg/ml) for 60 min.  Those Caco-2 cells were then cold extracted with TX-100 and 
subjected to sucrose gradient centrifugation.  Gradient fractions were loaded on a 4% SDS-PAGE gel and 
Western blotted with a rabbit anti-CPE antibody.  Arrows indicate migration of the CH-1 and CH-2 
complexes.  Shown is a representative blot from 3 independent experiments.  B) Ib Western blots of 
sucrose gradient fraction from Ib-treated Caco-2 cells with reduced cholesterol levels.  Caco-2 cells were 
pretreated with 10 mM MβCD for 60 min followed by treatment with 2.0 µg/ml Ib for 15 min at 37°C.  
Fractions were visualized by Western blotting of a 4% SDS-PAGE gel with a rabbit anti-Ib antibody.  
Arrow indicates migration of 20 ng free purified Ib.  Shown is a representative blot from 2 independent 
experiments.   
 
2.3.4 Effect of Cholesterol Depletion on CPE Cytotoxicity 
Since the CH-1 complex is sufficient to obtain CPE-induced cytotoxicity (122), Fig. 2.4 results 
suggested that membrane rafts do not play a major role in the cytotoxic effect of CPE action.  To 
further address this question, we directly examined whether MβCD pre-treatment can protect 
Caco-2 cell cultures from CPE by quantitatively measuring cell viability using trypan blue 
staining. 
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In these studies, Caco-2 cell monolayers were pre-treated with 10 mM MβCD for 60 min, 
or left untreated, followed by treatment with CPE (2.5 µg/ml) for varying times (10, 20, 30, and 
45 min).  Fig. 2.5 shows no significant effect of cholesterol depletion on the viability of Caco-2 
cells in the absence of CPE (see time 0).  Likewise, there was no inhibition of CPE-induced 
cytotoxicity with pre-treatment of Caco-2 cells with MβCD.  There was, in fact, a slight increase 
in Caco-2 cell sensitivity to CPE after MβCD pre-treatment.  These data are consistent with the 
above Western blot analysis of CPE complex formation in which membrane rafts are not 
required for formation of the CH-1 complex that triggers cytotoxicity. 
      
Figure 2.5  Effect of Cholesterol Depletion on CPE-induced Cytotoxicty.   
Caco-2 monolayers were left untreated (♦) or pre-treated for 60 min  with  10 mM MβCD (■).  
Cells were then treated for varying times (10, 20, 30, or 45 min) with 2.5 µg/ml of CPE, or left 
untreated (time 0).  Trypan blue staining was performed as described in Material and Methods to 
obtain % Viability at each time point.  Data points (♦) and (■) represent % viability of untreated 
or MβCD-treated, respectively, with buffer only during the course of 45 min.  Error bars 
represent standard deviation of the mean of 3 independent experiments performed in triplicate. 
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2.3.5 Detergent Solubility and Raft Localization of Claudin-4 
One possible contributor to CPE complexes not being associated with membrane rafts would be 
for the toxin receptor to reside outside of raft domains in control (no CPE treatment) Caco-2 
cells.  The presence of claudins within raft domains has been somewhat controversial (99-100, 
114); therefore, we investigated whether the CPE receptor, claudin-4, is associated with DRMs 
in our experimental system.  Sucrose density gradient experiments followed by claudin-4 
Western blots (Fig. 2.6A) showed that, when extracted from control Caco-2 cell monolayers, 
claudin-4 is normally localized to the detergent-soluble, non-raft fractions at the bottom of the 
gradient.  CPE-treatment of Caco-2 cell monolayers did not affect localization of claudin-4 into 
non-raft domains (Fig. 2.6B).  Similarly, MβCD-treatment had no significant effect on the 
detergent solubility of claudin-4 in Caco-2 cells (Fig. 2.6C). 
                                        
Figure 2.6  Raft Localization of Claudin-4.   
Caco-2 cells were untreated (A), treated with 2.5 µg/ml of CPE for 60 min (B), or treated for 60 min with 
10 mM MβCD (C) followed by cold TX-100 extraction and sucrose density gradient centrifugation.  Each 
fraction was concentrated using TCA (see Materials and Methods) and loaded onto a 12% SDS-PAGE 
gel.  Those gels were then Western blotted with a rabbit anti-claudin-4 primary antibody. 
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2.3.6 Detergent Solubility and Raft Localization of Occludin  
In addition to claudins, a second TJ protein named occludin is also present within the CH-2 
complex (179).  Existing literature is contradictory concerning the presence of occludin in 
membrane rafts, so we similarly assessed occludin localization in our experimental system.  
After sucrose gradient centrifugation of control Caco-2 cell TX-100 extracts and Western blot 
analysis using an anti-occludin antibody, occludin localized mostly in gradient fractions 3-5, 
suggesting that this TJ protein is mainly raft-associated (Fig. 2.7A).  In contrast, similar analysis 
of Caco-2 cells treated with CPE for 60 min revealed that most of the raft-associated occludin 
extracted from those cells had shifted to non-raft fractions in the sucrose gradient (Fig. 2.7B).  
However, a small pool of occludin remained raft-associated in CPE-treated cells.  This CPE-
induced shift in occludin to non-raft fractions was similar to that observed when Caco-2 cells 
were treated with MβCD alone, i.e. without CPE treatment (Fig. 2.7C).  The CPE-induced shift 
of occludin to non-raft fraction was not a consequence of generalized membrane raft dissolution 
since flotillin-1 remained raft-associated in these cells (data not shown). 
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Figure 2.7  Raft Localization of Occludin.   
Caco-2 cells were untreated (A), treated with CPE (2.5 µg/ml) for 60 min (B), or treated for 60 min with 
10 mM MβCD (C) followed by cold TX-100 extraction and sucrose density gradient centrifugation.  Each 
fraction was concentrated using TCA (see Materials and Methods) and loaded onto a 10% SDS-PAGE 
gel.  Those gels were then Western blotted with a mouse anti-occludin primary antibody. 
 
2.3.7 Kinetics of CPE-induced Occludin Redistribution 
The CPE-induced shift of occludin from raft to non-raft fractions was further investigated by 
kinetic analysis.  Densitometric scanning of occludin Western blots of pooled raft fractions 
(gradient fractions 2-4) or non-raft fractions (gradient fractions 9-12) from Caco-2 cells treated 
with CPE for varying times showed that the shift of occludin from insoluble to soluble gradient 
fractions begins relatively quickly upon CPE treatment and increases with time thereafter up to 
30 min (Fig. 2.8A).  Specifically, after only 10 min of CPE treatment, most occludin remained 
raft-associated, as in untreated Caco-2 cells (Fig. 2.7A).  However, by 30 min of CPE treatment 
the majority of occludin had shifted to non-raft fractions (Fig. 2.8A).  Additionally, CPE 
treatment caused an apparent decrease in the total cellular levels of occludin, similar to that 
observed with MβCD treatment alone (Fig. 2.7C). 
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Figure 2.8  Kinetics of CPE Complex Formation and Occludin Distribution.   
A)  Caco-2 monolayers were treated with 2.5 µg/ml of CPE for the indicated times (10, 30, and 45 min) 
and sucrose gradients were then performed for TX-100 lysates of each time.  Gradient fractions 2-5 were 
pooled and concentrated for each time point to give detergent-insoluble raft fractions (I).  Gradient 
fractions 9-12 were pooled and concentrated to give detergent-soluble non-raft fractions (S).  Pooled 
samples were run on a 10% SDS-PAGE gel and Western blotted using a rabbit anti-occludin antibody.  
Caco-2 monolayers were treated with 2.5 µg/ml of CPE for the indicated times (10, 20, 30, and 45 min), 
lysed in SDS buffer and subject to SDS-PAGE and Western blotted with B) rabbit anti-CPE antibody or 
C) rabbit anti-occludin antibody.  D)  Densitometry analysis of Western blot data from A-C) (▲) 
depicting % occludin within detergent-insoluble rafts at each time point.  Data were calculated by 
comparing band intensity of raft-associated occludin over non-raft-associated occludin.  Data points (♦) 
and (■) represent densitometry analysis of Western blots of % CH-2 formation and % occludin 
incorporation into CH-2, respectively.  To calculate the % CH-2 formation and % occludin incorporation 
into CH-2, each time point was taken as a percentage of 100% normalized to highest band intensity at 30 
min of CPE treatment.  Error bars represent the standard deviation of the mean for 3 independent 
experiments. 
 
Since occludin is associated with the CH-2 complex (179), which mainly forms outside 
of raft microdomains (Fig. 2.3), densitometry analysis was performed on Western blots data to 
quantitatively determine the fold increase in CH-2 formation over time in order to test whether 
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the kinetics of CH-2 complex formation could be a contributor to the CPE-induced shift of 
occludin from membrane rafts.  As reported previously (179), this kinetic experiment 
demonstrated (Fig. 2.8B and 2.8D, diamonds) CH-2 complex formation begins within 10 min of 
CPE toxin challenge.  By 30 min of toxin treatment, significant amounts of the CH-2 had formed 
in Caco-2 cells under the experimental condition used in these studies.  Densitometry of occludin 
Western blots also revealed (Fig. 2.8C and 2.8D, squares) a time-dependent incorporation of 
occludin into the CH-2 complex, as reported previously (179).  However, these analyses also 
suggested that not all occludin within Caco-2 cells may be associated with the CH-2 complex 
since considerable amounts of occludin was present at the gel dye front (Fig. 2.8C).  Coincident 
with CH-2 formation, the amount of occludin present at the gel dye front decreased with time of 
CPE treatment under the experimental conditions used.  These CPE blots showing the presence 
CH-2 were stripped and reprobed with an occludin antibody to confirm the presence of occludin 
within CH-2 (data not shown).  The data presented in Fig. 2.8D are consistent with a relationship 
between CH-2 formation, occludin incorporation into CH-2, and removal of occludin from lipid 
rafts (Fig 2.8A-D, triangles).  
To distinguish whether the shift of occludin from raft to non-raft domains seen in Figs. 
2.7 and 2.8 is correlated with CH-2 complex formation or is merely a by-product of CPE 
challenge, additional experiments were performed that investigated the effects of SC and CH-1 
on occludin distribution.  To assess the effect of SC formation on occludin distribution, the 
gradient fractions from Fig. 2.2 were pooled, concentrated into raft and non-raft fractions, and 
Western blot analysis was performed using an anti-occludin antibody.  When compared to 
untreated Caco-2 cells, results from this experiment (Fig. 2.9A) showed that occludin remains in 
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the insoluble raft fractions upon CPE treatment at 4°C, strongly suggesting that SC formation has 
no major effect on the localization of occludin in raft domains.  
A second experiment was then performed to address whether CH-1 complex formation is 
sufficient to cause the redistribution of occludin observed after CPE treatment (Figs. 2.7 and 
2.8).  This experiment used Caco-2 cells grown on Transwell supports, which produces polarized 
monolayers (158, 178) with fully formed tight junctions, e.g. 4-70 kDa fluorescently-labeled 
dextrans are impermeable to these monolayers (data not shown).  As described previously (158, 
178), formation of the CH-1 complex in the absence of any CH-2 formation was obtained by 
treating these cells apically with CPE (1.0 µg/ml) for 30 min. 
                                      
Figure 2.9  Effects of SC and CH-1 on Occludin Distribution.   
A)  After treatment with CPE (2.5 µg/ml) for 15 min at 4°C, Caco-2 cells were extracted with cold TX-
100 and subjected to sucrose gradient centrifugation.  Gradient fractions 2-5 and 9-12 were pooled and 
concentrated to give detergent-insoluble raft fractions (I) or detergent-soluble non-raft fractions (S), 
respectively.  Pooled samples were run on a 10% SDS-PAGE gel and Western blotted using a rabbit anti-
occludin antibody.  B)  Caco-2 cells were grown in Transwell permeable supports until confluency to 
form CH-1 in the absence of CH-2, and either left untreated or treated with CPE (1.0 µg/ml) for 30 min at 
37°C.  TX-100 extraction and sucrose gradients were performed as before, followed by pooling of 
fractions to obtain detergent-insoluble (I) and detergent-soluble (S) samples.  Pooled samples were run on 
a 10% SDS-PAGE gel and Western blotted using a rabbit anti-occludin antibody.  C)  CPE Western blot 
of CPE-treated Caco-2 TX-100 extractions from B) confirming the presence of CH-1 without CH-2.  
Arrow indicates CH-1 complex formation, in the absence of CH-2 complex.  Representative blots are 
shown for 2 independent experiments. 
 
Sucrose gradients and CPE Western blots were performed as above, which confirmed the 
presence of CH-1 in non-raft fractions (data not shown), along with the absence of the CH-2 
complex from these cells (Fig. 2.9C).  Western blots of these polarized Transwell cultures 
 55 
containing tight junctions also confirmed the data in Fig. 2.6 with the presence of claudin-4 in 
non-raft fractions (data not shown).  Additionally, occludin Western blots (Fig. 2.9B) of those 
same gradient samples revealed that, with or without CPE treatment, occludin remains raft-
associated in these CH-1-containing Transwell cultures, indicating that CH-1 formation and CPE 
cytotoxicity from pore formation are not sufficient for the redistribution of occludin to non-raft 
fractions observed in the presence of CH-2. 
2.4 DISCUSSION 
Membrane rafts are now well-established in contributing to the action of many bacterial toxins.  
With respect to PFTs, raft domains can promote toxin receptor binding, oligomerization, and 
oligomer insertion into membranes for pore formation.  The involvement of membrane rafts in 
PFT oligomerization is largely attributable to their dynamic ability to coalesce into larger 
domains, serving as platforms that allow for protein clustering. 
Since membrane rafts are involved in the action of many PFTs, the current study 
investigated whether these microdomains also contribute to the action of CPE, another PFT, 
whose action involves sequential formation of three CPE-containing complexes, i.e. SC, CH-1, 
and CH-2 (158, 179, 214).  Experiments assessing whether each of those CPE complexes is 
localized within membrane rafts showed that both the SC and CH-1 are found exclusively 
outside rafts in non-polarized and polarized Caco-2 cells.  In our Caco-2 model, we were capable 
of detecting toxin oligomers localized to membrane rafts since Ib oligomers were, as reported 
previously (64, 142), detected in raft fractions. 
 56 
Localization of the CH-1 complex outside lipid rafts of polarized and non-polarized cells 
was interesting since formation of this complex, which appears to be sufficient for causing CPE-
induced cytotoxicity, is thought to correspond to the CPE pore (118, 158, 178).  Therefore, Caco-
2 cells were pre-treated with MβCD to deplete cells of their cholesterol and disrupt rafts to 
determine if these domains are required for CH-1 formation.  This pre-treatment had no 
detectable effect on the formation of CH-1 (Fig. 2.4) or on its presence within non-raft fractions.  
In contrast, MβCD pre-treatment effectively shifted raft-associated Ib oligomers from raft into 
non-raft membrane domains in Caco-2 cells, confirming that this pre-treatment was sufficient to 
disrupt membrane rafts in Caco-2 cells.   
The inability of cholesterol depletion to affect CH-1 formation suggested that rafts are 
not required for CPE action.  Further support for this suggestion was then provided by the 
inability of MβCD treatment to delay the onset of CPE-induced cytotoxicity in Caco-2 cells (Fig. 
2.5).  In fact, pre-treatment of cells with MβCD before CPE addition slightly increased CPE-
induced damage to Caco-2 cell monolayers even though MβCD itself caused no cytotoxic effects 
in our system.  One possible explanation for this increased CPE sensitivity is that cholesterol 
depletion might loosen the TJ, so that CPE gains access to the basolateral side of the cell, where 
more CPE receptors are located (178).  This possibility is supported by previous studies showing 
that MβCD treatment decreases transepithelial resistance in Caco-2 and MDCK cells (50, 99).  It 
is also possible that removing an important structural component of the plasma membrane (i.e. 
cholesterol) compromises the overall integrity of the plasma membrane, increasing susceptibility 
of the cell to CPE. 
While there is less certainty regarding its contribution to CPE action, the CH-2 complex 
is clearly not required for CPE-induced cytotoxicity and only forms in damaged, dying cells 
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(179).  CH-2 may represent a second CPE pore that further contributes to increased membrane 
permeabilty alterations; it also appears to facilitate the observed removal of occludin from TJs of 
CPE-treated cells, with subsequent internalization into the cytoplasm (178).  In the current study, 
most of the CH-2 complex formed by CPE-treated Caco-2 cells localized outside rafts, although 
a small pool of CH-2 in Caco-2 cells was raft-associated (Fig. 2.2).  MβCD-pre-treated cells did 
not contain this small pool of raft-associated CH-2 (Fig. 2.4), supporting its association with raft 
microdomains. 
CPE is an unusual PFT in that eukaryotic proteins are closely associated with the CPE 
oligomer (158).  Therefore, we investigated whether the observed CPE oligomerization outside 
membrane rafts might involve CPE complex-associated eukaryotic proteins (especially receptor 
claudins) residing in non-raft membrane domains prior to CPE treatment.  We first determined 
whether a TJ protein, claudin-4, is raft-associated in our cell culture model system since i) this 
CPE receptor is present in SC, CH-1 and CH-2 (158), and ii) there are conflicting reports 
regarding the association of claudins with lipid rafts (99-100, 114).  The methods used in our 
study localized claudin-4 of Caco-2 cells exclusively within non-raft-associated fractions.  Since 
claudin-4 is a CPE receptor and the SC forms immediately upon CPE binding, the presence of 
claudin-4 CPE receptors in non-raft lipid domains offers an explanation for the localization of 
SC to non-raft fractions.   
The exclusive localization of CH-1 and claudin-4 in non-raft fractions of non-polarized or 
polarized Caco-2 cells and the formation of CH-1 in MβCD-treated cells also indicates that, 
unlike most PFTs, CPE does not require rafts to promote its oligomerization.  For CPE, raft-
mediated clustering of receptors may be unnecessary since claudins already lie in close 
proximity to one another due to their presence in TJs as polymerized strands (53, 199).  
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Furthermore, those strands also closely associate with similar claudin strands in the same and on 
apposing cells.  However, membrane fluidity does appear to play some role in CH-1 formation 
since CPE binds and forms SC at 4°C, yet CH-1 and CH-2 formation are inhibited at this low 
temperature (179).   
Although most PFTs oligomerize within rafts, CPE in not a unique PFT with respect to 
its ability to bind and oligomerize outside lipid rafts.  Protective antigen (PA) of anthrax toxin 
also binds to receptors and oligomerizes outside of a raft.  However, unlike CPE, oligomerization 
triggers the association of the PA pre-pore with membrane rafts (1).  The presence of PA 
oligomers in rafts appears important for the eventual translocation of lethal and edema factors 
through the PA pore (222), i.e. for cytotoxicity, since MβCD inhibits this process.  Thus, our 
results distinguish CPE from PA (and other PFTs) in that CPE not only binds and oligomerizes 
independently of raft domains, but also forms active pores outside of these microdomains.  The 
lack of movement of CPE oligomers into rafts might be attributable to claudin CPE receptors 
being localized in strands where movement is relatively restricted inside TJs. 
The association of occludin with membrane rafts has also been controversial (40, 85, 100, 
145).  In contrast to the exclusive association of claudin-4 with non-raft fractions, our study 
found that most occludin localizes in raft fractions of control (no CPE treatment) non-polarized 
or polarized Caco-2 cells.  As expected, MβCD treatment of Caco-2 cells completely shifted 
occludin to non-raft membrane fractions.  CPE treatment similarly shifted most of the occludin 
in polarized or non-polarized Caco-2 cells from raft to non-raft membrane domains.  This effect 
was time-dependent (Fig. 2.8) and paralleled the appearance of most occludin-containing CH-2 
in non-raft microdomains of CPE-treated Caco-2 cells.  Establishing this correlation is consistent 
with the possibility that occludin is pulled from lipid rafts as it becomes associated with CH-2.  
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Also consistent with CH-2 complex formation specifically contributing to the redistribution of 
occludin into non-raft domains, our results showed that the presence of the SC or CH-1 
complexes (in the absence of CH-2) is not sufficient to shift occludin from rafts.  This result also 
indicates that removal of occludin from rafts is not merely a nonspecific consequence of CPE-
induced cytotoxicity.  Nor is removal of occludin from rafts due to nonspecific occludin 
internalization since our previous studies showed occludin internalization only occurs in the 
presence of CH-2 (178).  Additionally, the CPE-associated removal of occludin from raft 
domains is not a non-specific consquence of raft breakdown as we observed that CPE treatment 
does not remove the raft marker, flotillin-1, from rafts.   
However, sequestration of occludin in CH-2 may not fully explain CPE effects on 
occludin membrane distribution since not all occludin present in CPE-treated Caco-2 cells is 
localized in the CH-2 complex, at least as assessed by Western blotting.  CPE treatment also had 
other effects on occludin in Caco-2 cells.  In particular, total occludin levels appeared to slightly 
decrease in CPE-treated cells.  This effect was noticed in cells containing CH-1 in the absence of 
CH-2, but appeared to be stronger when both CH-1 and CH-2 complexes were present, possibly 
because cells containing both complexes together enhance cell death.  The observed CPE-
induced decrease in occludin could be a general response to cell death and also might involve, at 
least in part, the previously described CPE-induced removal of occludin from the TJ into the 
cytoplasm of Caco-2 cells, an effect that seemingly correlates with CH-2 formation (178).  A 
recent study (13) has shown that removal of occludin from the tight junction by addition of an 
exogenous peptide activates the extrinsic pathway of apoptosis which is mediated by the 
formation of a complex between occludin and Fas and FADD, a death receptor adaptor molecule 
of the death inducing signaling complex (DISC).  It is plausible that CPE-dependent removal of 
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occludin from the tight junction may be triggering apoptosis, a process that has been previously 
described in CPE-treated cells (32).  Experiments are needed to examine whether CPE treatment 
results in the interaction of occludin with FADD and the DISC, and is activating apoptosis 
through the extrinsic pathway.  In addition to the gate and fence functions of the tight junction, 
this junctional complex of the cell can serve as an intracellular signaling platform (60) and 
occludin has been shown to serve as a signaling molecule (223).  This opens many pursuable 
avenues for signaling studies investigating the intracellular signaling effects of CPE treatment in 
the context of tight junction disruption.  
It is also notable that even CPE-treated Caco-2 cells still contained a small pool of raft-
associated CH-2 and occludin.  This small amount of raft-associated CH-2 could represent 
interactions between SC or CH-1 with a distinct occludin pool.  Different occludin pools could 
correspond to differences in occludin phosphorylation (114, 145, 219), polymerization (53), 
internalization (178), or an occludin splice variant (61).  Further studies will be needed to clarify 
the complicated relationship between occludin, rafts, and CH-2 formation. 
In summary, the current study strongly suggests that CPE is a novel PFT that does not 
require lipid rafts for binding, oligomerization, or cytotoxicity.  The presence of claudin 
receptors in polymerized strands may restrict the subsequent movement of receptor-bound CPE 
or CPE oligmers into rafts.  Furthermore, CPE treatment causes a dramatic shift of most occludin 
in Caco-2 cells, from raft to non-raft domains.  This effect may be mediated, at least in part, by 
the sequestration of occludin in the CH-2 complex. 
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3.0  DEVELOPMENT OF A CPE COMPLEX ISOLATION METHOD FOR 
COMPOSITIONAL ANALYSIS BY MASS SPECTROMETRY 
3.1 INTRODUCTION AND RATIONALE 
3.1.1 CPE Complex Formation 
Oligomerization of pore-forming toxins results in the formation of high molecular weight 
complexes on target cell membranes (56, 136, 228).  The formation of CPE-containing protein 
complexes on the surface of target cell membranes is crucial to the pore-forming action of the 
toxin.  For example, CPE-induced pore-formation and cytotoxicity requires, and occurs 
concomitantly, with the formation of the CH-1 complex (86, 122).  Additionally, formation of 
the CPE Small Complex (SC), although not sufficient for cytotoxicity, is still a necessary first 
step prior to observing CPE-induced pore-formation (122).   
Recent studies have reassessed both the size and composition of the three CPE complexes 
(SC, CH-1, and CH-2) (158).  When the CPE receptor, claudin-4, was first identified, it was 
suggested this protein is present within the high molecular weight CPE complexes (82).  
However, it was not until recently that direct evidence for the presence of receptor claudins 
within the CPE complexes was available (158).  Analysis by electroelution of the three CPE 
complexes directly revealed the presence of claudin-4, as well as another functional CPE 
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receptor, claudin-3, within these complexes.  This was the first report of the presence of a toxin 
receptor within a high molecular weight toxin complex.  Interestingly, however, 
immunoprecipitation showed that despite lacking the ability to bind to CPE, claudin-1 was found 
to interact with CPE.  Furthermore, electroelution of the SC, CH-1, and CH-2 complexes 
revealed the presence of claudin-1 within these complexes.  These studies showed that not only 
do receptor claudins become associated with the CPE-containing complexes, but non-receptor 
claudins can also associate with these complexes. 
Additionally, it was not until recently that the stoichiometry of the CPE complexes was 
addressed.  Before the identification of claudin as the CPE receptor, it was originally 
hypothesized that one CPE monomer bound to one ~50 kDa unidentified protein and one ~70 
kDa unidentified protein to make up the “~155 kDa Large Complex” (122).  The identification of 
the presence of the 65 kDa protein, occludin, in a second large CPE complexes led to the naming 
of the “~200 kDa Large Complex” (179).  Knowledge of claudin, a protein of only ~20 kDa, as 
the CPE receptor led to the questioning of the original model of the composition of CPE 
complexes.  Therefore, the number of CPE molecules within the Large Complexes was assessed 
by molecular weight variants of CPE and heteromeric gel shift analysis, which revealed the 
presence of six copies of CPE (158).  In turn, now knowing that six copies of CPE and both 
receptor and non-receptor claudins can be present in the complexes, the sizes of the CH-1 and 
CH-2 complexes were reassessed by gel filtration and Ferguson plot analysis (158).  The 
molecular weights of the CH-1 and CH-2 complexes were resized to be ~450 kDa and ~600 kDa, 
respectively.  Taking into consideration i) the presence of both receptor and non-receptor 
claudins, ii) the stoichiometry of 6 CPE molecules, and iii) the larger molecular weights, the 
composition of the CPE complexes are is more heterogeneous than originally thought. 
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3.1.2 The Complexity of the Tight Junction 
As described, the tight junction (TJ) is an important structure of epithelial cells for forming a 
continuous intercellular barrier between adjacent cells, separating apical vs. basolateral 
compartments, and regulating the transport of solutes across the epithelium (6).  The claudin 
family of proteins has emerged as the most critical TJ proteins for maintaining TJ functions such 
as regulating permeability selectivity (6).  Although claudins are likely the most important TJ 
proteins for function, they are far from the only TJ-associated proteins.  Proteomic analysis of 
enriched junctional membrane proteins identified >40 proteins that are associated with this 
membrane fraction (221).  The schematic in Figure 3.1 illustrates the complexity of the TJ, 
highlighting both the transmembrane and cytosolic structural components, as well as the 
intracellular signaling elements that are transiently associated with the TJ. 
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Figure 3.1  Schematic Representation of the Tight Junction and its Associated Proteins.   
This diagram illustrates the structural transmembrane components of the TJ, such as Claudin, Occludin, 
and JAM, which traverse the plasma membrane to interact with adjacent cells.  Intracellular scaffolding 
proteins, such as ZO-1, -2, and -3, PAR-3, PAR-6, MUPP1, MAGIs and AF-6, contain PDZ domains that 
serve to link the TJ to the actin cytoskeleton.  Kinases (aPKC, ZAK, c-Yes), GEFs (Tiam1, GEF-H1, 
Tuba, Rap1GEF), membrane traffic regulators (Rab3B and Rab13), and signaling proteins (Cdc42, RhoA 
and Rac1) transiently associate with the TJ plaque and serving functions necessary for assembly, 
stabilization, and maintenance of the junction, and regulating proliferation and differentiation.  Taken 
from (62). 
 
3.1.3 Rationale 
Considering the recent findings of the large CPE-containing complexes containing both claudin 
receptors and non-receptors, it seems that the CPE complexes on the membrane have the ability 
to associate with proteins that may not necessarily have the ability to directly bind to CPE.  
Therefore, it is plausible that the CPE complexes are capable of pulling proteins that associate 
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with receptor claudins into the protein complex.  When one considers the complex architecture 
of the TJ and the numerous proteins that are closely or transiently associated with claudin, many 
other TJ proteins besides claudin and occludin could be present within the CH-1 and CH-2 
complexes.  Antibody studies aimed at identifying likely constituents of the complexes would be 
nothing less than a fishing expedition, and would not be an economical strategy.  We, therefore, 
wish to develop a method to isolate the CPE complexes individually to analyze their protein 
components by mass spectrometry. 
3.2 MATERIALS AND METHODS 
3.2.1 Affinity Purification of rCPE 
E. coli strain pJK9 (full length wild type CPE cloned into the pTrcHisA vector) was inoculated 
into 50 ml of LB Broth containing 100 μg/ml ampicillin (LB Amp), and grown overnight by 
shaking at 37°C.  The following day, 20 ml of the overnight culture was inoculated into 1L of 
LB Amp and shaken for 3 h.  The production of rCPE was induced by the addition of IPTG (final 
concentration of 1 mM) with shaking for 4 more hours.  Cultures were harvested by 
centrifugation for 15 min at 7500 rpm in a GS-3 rotor.  Pelleted cells were frozen overnight at  
-20°C.  After thawing, pellets were resuspended in 20 ml of HisTrap Binding Buffer (20 mM 
sodium phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4).  Cells were lysed by 8 X 1 min 
blasts of sonication using the Misonix Sonicator 3000 (output of 7.0).  Cell debris was removed 
by centrifugation for 15 min at 7500 rpm in a SS-34 rotor.   Supernatant was then filtered using a 
0.45 μm syringe filter. 
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A 1 ml HisTrap Fast Flow Ni2+-affinity column (GE Lifesciences) was prepared by 
manually equilibrating the column with 10 column volumes (10 ml) of Binding Buffer using a 
Luer-Lok syringe system.  The filtered supernatant was added to the column using a syringe at a 
flow rate of 1 ml/min.  The column was washed twice with 5 ml of Binding Buffer.  Elution was 
performed by adding 5 ml of HisTrap Binding Buffer (20 mM sodium phosphate, 0.5 M NaCl, 
500 mM imidazole, pH 7.4) to the column and collected 5 X 1 ml fractions.  Column flow-
throughs were collected for each step for analysis by SDS-PAGE, where 10 μl of each fraction 
was loaded onto a 12% SDS-PAGE gel followed by staining with Coomassie blue.  Purified 
fractions were combined (Fractions 2 and 3) and a Lowry was performed to determine the 
protein concentration. 
3.2.2 Affinity Purification of rCPE Complexes 
Ten 100 mm cell culture plates were seeded with Caco-2 cells at a density of 1 x 105 cells/ml.  
When confluent (4-5 days), monolayers were treated with 2.5 μg/ml of rCPE for 45 min.  Cells 
were harvested by gentle scrapping and centrifugation.  Pellets were washed and lysed in 1% 
TX-100.  Lysates were spun down and filtered with a 0.45 μm syringe filter and added to the 
HisTrap column.  Purification was performed similar to that for purification of rCPE (above).  25 
μl aliquots of each fraction were run on 4% SDS-PAGE, transferred to nitrocellulose and 
Western blotted with a rabbit anti-CPE antibody.  
3.2.3 AlexaFluor488 Labeling 
Alexa labeling was performed as described by the manufacturer for the AlexaFluor 488 Protein 
Labeling Kit (Invitrogen).  Native CPE (nCPE) was reconstituted in PBS to a final concentration 
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of 2 mg/ml.  500 μl of nCPE (2 mg/ml) was used for labeling; 50 μl of 1M Sodium Bicarbonate 
was added to the 500 μl of CPE.  This solution was added to a vial of reactive dye and stirred for 
1 h at RT.  After the labeling reaction, the solution was added to a gel filtration column (supplied 
with kit) and 1 ml fractions were collected after eluting with Elution Buffer (10 mM potassium 
phosphate, 150 mM NaCl, 0.2 mM sodium azide, pH 7.2).  Ten μl of each fraction was analyzed 
by running on 12% SDS-PAGE and visualizing bands by scanning on a Typhoon 9400 Scanner 
(Amersham). 
3.2.4 Affinity Purification of Rabbit α-CPE Antibody 
     Serum from rabbits immunized with purified nCPE was affinity purified by using a 
Protein A-agarose column (Pierce).  Five milliliters of rabbit serum was diluted 1:1 with Binding 
Buffer (100 mM sodium phosphate, 150 mM NaCl, pH 7.2).  To avoid clogging of the 
purification column, diluted serum was filtered using 0.45 μm syringe filters.  Using the Luer-
Lok adapter system, a syringe filled with 10 column volumes (10 ml) of Binding Buffer was 
attached to the column, and to equilibrate the column Binding Buffer was flowed through the 
column at a rate of ~1 ml/min.  After equilibration, diluted serum was added through the column 
at a rate of ~1 ml/min.  The column was then washed with 10 ml of Binding Buffer.  Bound 
antibody was eluted from the column using 5 ml of Elution Buffer (0.1M Glycine, pH 2.0).  Prior 
to elution, 500 μl of 1M Tris, pH 8.0 was added to the collection tube to neutralize the low pH of 
the Elution Buffer. 
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3.2.5 Electroelution 
Thirty 150 mm cell culture dishes of Caco-2 cell monolayers (~107 cells) were each treated with 
2.5 μg/ml nCPE in 15 ml of complete HBSS (with Ca2+, cHBSS) for 45 min.  Two plates were 
treated with 2.5μg/ml of Alexa-CPE for 45 min.  Cells were harvested by gentle scraping and 
washed twice with cHBSS.  Combined cell pellets were resuspended in 2 ml of cHBSS and 
incubated for 10 min with the addition of 20 μl of benzonase (Novagene, EMD).  Cells were 
lysed by the addition of 2 ml of 2X Laemmli buffer.  Lysates were loaded onto a single-well 4% 
SDS-PAGE preparative gel and electrophoresed at 40 mA for 4 h in the dark.  Bands were 
visualized by fluorescence imaging using Typhoon scanning and the location of the bands was 
marked by a fluorescent ruler.  CH-1 and CH-2 bands were excised from the gel and cut into 6 
smaller gel pieces each.  Two gel pieces were placed into dialysis tubing (MWCO 6-8000) 
containing 2 ml of Electroelution (EE) Buffer (25 mM Tris, 0.192 M glycine, 0.1% (w/v) SDS, 
pH 8.3). These dialysis sacks were sealed and electrophoresed at 50 mA for 5 h at 4°C in the 
dark.  After EE, fluid was collected and combined for each CH-1 and CH-2 and concentrated 
using Amicon centrifuge concentrators to a final volume of ~500 μl.  To eliminate SDS in 
samples which was found to prohibit successful immunoprecipitation, concentrated samples 
were washed with 5 ml of PBS and reconcentrated to 500 μl.  This wash step was repeated for a 
total of 2 washes. 
3.2.6 Immunoprecipitation 
Concentrated EE samples were immunoprecipitated by the addition of 25 μl of affinity-purified 
rabbit anti-CPE antibody (see above).  This solution was incubated overnight at 4°C with gentle 
rotation.  The next day, 20 μl of Protein A-acrylic beads (Sigma) were incubated with the IP 
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reaction with gentle rotation for 1 h at 4°C.  Immunoprecipitated material was pulled down by 
centrifugation.  Pellets were washed 3 times with 0.1% TX-100/PBS buffer.  To dissociate 
antibody and IPed material from the beads, 50 μl of 2X Laemmli was added to resuspend the 
beads and boiled for 5 min.  Samples were centrifuged and supernatants were collected.  One-
tenth of the sample was run on 4% SDS-PAGE along with a samples of purified nCPE to act as a 
standard curve.  The gel was transferred and Western blotted with a monoclonal mouse anti-CPE 
antibody (Mab3).  Densitometry (using Quantity One Software, Biorad) was used to construct a 
standard curve to extrapolate the amount of CPE present in the EE/IP sample. 
3.2.7 In-gel Digestions 
After determining the amount of CPE present in the sample, the remaining sample was run on 
SDS-PAGE and the CH-1 and CH-2 bands were visualized by Typhoon scanning.  
Corresponding bands were excised from the gel and cut into 1.5 mm pieces.  Gel pieces were 
rinsed 3X in 500 µL 50% Acetonitrile in 25 mM Ammonium bicarbonate with vigorous shaking 
for 15 min at RT.  Gel slices were dehydrated by the addition of 500 µL  of 100% Acetonitrile 
with 15 min shaking at RT.  Fluid was evaporated by spinning samples in a Speed Vac for 15 
min with low heat.   
For trypsin digestions, 40 μl of trypsin (Sigma, proteomics grade) (20 μg/ml in 25 mM 
ammonium bicarbonate/0.9% acetonitrile) was added and let absorbed into gel slices.  An 
additional 40 μl of trypsin was added and was allowed to absorb until gel pieces turned clear.  
Gel slices were overlayed with 100 μl of 25 mM ammonium bicarbonate and incubated at 37°C 
overnight.  Liquid was transferred to a new tube.  Peptides were extracted by adding 100 μl of 
50% acetonitrile/2.5% Trifluoroacetic Acid (TFA) and shaken vigorously at RT for 15 min.  
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Extraction liquid was added to collection tube.  The extraction was repeated twice.  Peptides 
were dried by spinning in a Speed Vac (~1.5 h) with low heat. 
For chymotrysin digestions, the same procedure was followed as for trypsin digestions, 
however, 1 μg/ml of chymotrypsin (Pierce, proteomics grade) was used. 
3.2.8 LC-ESI MS/MS 
After enzymatic digestion, the mixture of peptides were separated by capillary C18 HPLC 
(ThermoElectron Surveyor liquid chromatograph with a Micro AS autosampler) and direct 
analysis of the effluent on  a ThermoElectron LCQ Deca XP Plus quadrupolar ion trap mass 
spectrometer utilizing a nanospray ionization source. The mass spectrometer was set up to 
perform both MS and MS/MS experiments. The computer algorithm controlling these 
experiments selected the three largest ions from a MS spectrum, then instructed the mass 
spectrometer to perform three separate MS/MS experiments on those three ions.  This process 
was repeated every few seconds throughout the LC separation.  The data was analyzed and 
searched against human and/or C. perfringens databases using the SEQUEST search engine in 
the BioWorks Browser (Thermo Fisher Scientific).  MS analysis was performed by the 
Proteomics Core Facility at the University of Pittsburgh. 
Liquid Chromatography 
Instrument:  Surveyor Dual Pump LC (Thermo Fisher Scientific Corp., San Jose, CA) 
Column:  BioBasic C18 , 75μm ID x 100mm, PicoFrit Column (New Objective, Inc., Woburn, 
MA) 
Trap:  Peptide Cap Trap, (Michrom BioResources, Inc., Auburn CA) 
Trapping Conditions:  Flow rate: 10μl/min. @ 100% H2O/0.1% formic acid 
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LC Conditions: 
  Flow rate: 160nl/min. 
  Ramp from 5% ACN up to 50% ACN in 25 min. 
  Ramp from 50% ACN up to 98% ACN in 5 min. 
  Hold for 5 min. @ 98% ACN/2% H2O/0.1% formic acid 
  Ramp from 98% ACN down to 5% ACN in 5 min. 
  Hold for 10 min. @ 95% H2O/5% ACN/0.1% formic acid     
Mass Spectrometry 
Instrument:  LCQ DECA XP Plus (Thermo Fisher Scientific Corp., San Jose, CA) 
Spray Source:  Nanospray (Thermo Fisher Scientific Corp., San Jose, CA) 
Source Conditions:  Spray voltage: 1800 volts; Capillary Tube Temperature: 180oC 
Mass Spectrometer Method:  MS scan followed by three MS/MS scans of the three most intense 
ions from the MS scan with dynamic exclusion. 
MS Scan Acquisition:  Scan type: Positive mode; Masses: 300 - 2000 Da 
Data Dependent Acquisition: 
  Top three most intense peaks 
  Exclusion mass width (amu):  1.50 
  Dynamic exclusion enabled 
   Repeat Count:  2 
   Repeat Duration (min.):  0.50 
   Exclusion Duration (min.):  1.50 
   Exclusion Mass width (amu):  1.50 
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3.3 RESULTS 
3.3.1 Purification of CPE Complexes 
The first step in identifying the protein composition of CPE complexes is to purify each complex 
(CH-1 and CH-2) to homogeneity prior to analysis by mass spectrometry.  Multiple strategies of 
purification were employed to determine the best method for this purpose.  These methods 
include affinity purification, 2D-PAGE, and a combination of electroelution and 
immunoprecipitation.  The results of each method will be discussed individually in this Section. 
3.3.1.1 Affinity Purification 
The first strategy used to purify the CH-1 and CH-2 complex was to affinity purify the 
complexes from Caco-2 cells that had been treated with a recombinant, his6X-tagged CPE 
(rCPE).  It was necessary then to first purify rCPE to homogeneity for treatment of Caco-2 cells.  
After induction of toxin expression in E. coli by addition of IPTG, a Ni2+-affinity column was 
used to purify rCPE from bacterial lysates.  Fig. 3.2A is a Coomassie stained gel which shows 
the collected fractions from the affinity column.  Elutions 2 and 3 (lanes 6 and 7) shows the 
presence of highly purified rCPE which was used for treatment of Caco-2 cells.   
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Figure 3.2  Affinity Purification of rCPE and rCPE-associated Complexes.   
A) rCPE-expression E. coli lysates were added to a Ni2+-affinity column and the flow through was 
collected (lane 2).  Lanes 3 and 4:  two washes with binding buffer.  Lanes 5-8:  Elution fractions 1-4.  10 
μl of each fraction was loaded on a 12% SDS-PAGE gel followed by staining with Coomassie blue.  
Molecular weight marker was run in Lane 1.  Arrow indicates migration of purified rCPE.  B) anti-CPE 
Western blot of fractions from Ni2+-affinity column in which TX-100 lysates of Caco-2 cells treated with 
rCPE were purified.  “I” is the Input (Caco-2 treated cells) prior to addition to column.  “FT” is the flow 
through from the column after addition of the Caco-2 cell lysate.  “W” is a collected wash fraction.  E1-4 
are elutions from the column.  Numbers on the left are molecular weight markers in kDa.  d.f. is the 
migration of the dye front. 
 
After successfully purifying his-tagged CPE, Caco-2 cells were treated with rCPE.  CPE-
treated Caco-2 cell lysates were then run through the Ni2+-affinity column with the goal of 
binding his-tagged rCPE and any associated protein complexes that may be interacting with CPE 
on the membrane of cells.  Western blot analysis (Fig. 3.2B) of fractions eluted from the affinity 
column shows the presence of CPE-immunoreactive high molecular weight complexes (E1 and 
E2).  However, the sizes of these complexes are somewhat different than the sizes usually 
observed for the CH-1 and CH-2 complexes (Fig. 2.7).  Additionally, there is a third complex of 
~100 kDa that is not normally seen with nCPE treatment.  When rCPE-treated Caco-2 TX-100 
lysates are probed for CPE, the distinct CH-1 and CH-2 complexes are not observed (Fig. 3.2B, 
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“I”).  A probable explanation for this is the inability of TX-100 to sufficiently extract the 
complexes from the membrane. 
3.3.1.2 Electroelution and Immunoprecipiation 
A common theme deduced from above is the poor extraction of CPE complexes using TX-100.  
Therefore, using SDS-PAGE as a first step of solubilization and separation was decided upon.  
Electroelution (EE) was used to accomplish this first step of this purification strategy.  After CPE 
treatment of Caco-2 cells, lysates were run on SDS-PAGE and a small vertical slice of gel was 
then transferred and Western blotted to determine the migration of the CH-1 and CH-2.  After 
lining up the Western blot with the preparative gel, the corresponding areas of the gel were 
excised and electroeluted.  Electroeluted samples were concentrated and rerun on SDS-PAGE 
and Western blotted with an anti-CPE antibody (Fig. 3.3).  The distinct separation of the CH-1 
and CH-2 complexes is clearly seen after EE.  It is also apparent that concentration of the 
samples is necessary. 
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Figure 3.3  Electroelution of CH-1 and CH-2.   
Ten 100 mm cell culture plates of Caco-2 cell monolayers were treated with 2.5 μg/ml of 
CPE for 45 min.  After harvesting cells, lysates were run on a single-lane preparative 4% 
SDS-PAGE gel.  After Western blotting to determine location of CH-1 and CH-2 bands, 
gel slices were electroeluted  fo r 5  h .   25  μl of each  CH-1 and CH-2 EE samples were 
collected (CH-1 unconc and CH-2 unconc).  Samples were then concentrated using 
Amicon spin filters (~100X).  25μl of each sample (CH-1 conc and CH-2 conc) was run, 
along with unconcentrated samples, on 4% SDS-PAGE and Western blotted with a rabbit 
anti-CPE antibody. 
 
To eliminate the need to perform Western blotting to determine the locations of the CH-1 
and CH-2 bands, which can add significant time to the procedure, a fluorescently-labeled CPE 
was prepared to directly visualize the CH-1 and CH-2 bands on the preparative gel.  CPE was 
labeled with the AlexaFluor488 dye (referred from now on as Alexa-CPE), which labels free 
amines.  Gel filtration chromatography was performed to separate labeled protein from free label 
(Fig. 3.4A).  Labeled CPE clearly elutes from the column in fraction #3, with nearly a 100% 
yield.  This is distinct from free label which is only starting to come off the column at fractions 7 
and 8.  To test whether the toxin retains activity with the added label, Alexa-CPE was added to 
Caco-2 cells, and upon morphological analysis, labeled toxin was similarly cytotoxic as 
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compared to unlabeled CPE (data not shown).  Caco-2 cells treated with Alexa-CPE were then 
lysed and run on SDS-PAGE to determine if CH-1 and CH-2 complexes are formed.  Fig. 3.4B 
clearly shows the formation of both the CH-1 and CH-2 complexes (arrows).  This was 
confirmed by performing Western blot analysis on the same Alexa-CPE-treated Caco-2 lysates 
with an anti-CPE antibody (Fig. 3.4C). 
          
Figure 3.4  Purification and Complex Formation of AlexaFluor488-CPE.   
A) Equal volumes of each fraction (#1-8) were loaded on a 12% SDS-PAGE gel.  Gel was scanned using 
a Typhoon 9400 scanner.  B) Caco-2 monolayers were treated with 2.5 μg/ml of Alexa-CPE for 45 min.  
The lysate was run on a 4% SDS-PAGE gel and scanned with a Typhoon 9400 scanner.  Arrows indicate 
migration of the CH-1 and CH-2 complexes.  C)  Duplicate Alexa-CPE-treated Caco-2 cell lysates were 
run on 4% SDS-PAGE and Western blotted using a rabbit anti-CPE antibody.  Numbers indicate 
molecular weight markers in kDa.  d.f. is the migration of the dye front. 
 
After establishing that the fluorescently-labeled CPE retains full cytotoxicity and the 
ability to form complexes, we proceeded with a full scale EE in which 30 150 mm plates of 
Caco-2 cells were treated with CPE and “spiked” with Alexa-CPE (the amount of unlabeled to 
labeled CPE was ~100:1).  Caco-2 lysates were loaded onto a single-lane preparative gel and 
electrophoresed (Fig. 3.5) followed by Typhoon scanning.  Corresponding bands for the CH-1 
and CH-2 complexes were excised and were electroeluted and concentrated (data not shown).   
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Figure 3.5  Large Scale Preparative Gel for Electroelution.   
Lysates Caco-2 cells treated with 2.5 μg/ml of Alexa-CPE for 45 min were run on a single-lane 
4% SDS-PAGE gel.  The gel was then scanned using a Typhoon 9400 scanner.  Arrow specifies 
migration of CH-1.  Arrowhead indicates migration of the CH-2 complex.   
 
Concentrated EE samples for each CH-1 and CH-2 were immunoprecipitated with an 
affinity-purified rabbit anti-CPE antibody (see Materials and Methods) and Protein A-agarose 
beads.  Immunoprecipitated material was then run on SDS-PAGE and visualized by Typhoon 
scanning (Fig. 3.6A).  Fluorescent complexes are visualized for both the CH-1 and CH-2 
electroeluted samples.  Peculiarly, the material immunoprecipitated from the CH-1 EE was at the 
same size as the material immunoprecipitated from the CH-2 EE.  A possible explanation for this 
increase in size was due to the boiling of the samples that was necessary to dissociated 
immunoprecipitated material from the Protein A beads.  Boiling has been known for some time 
to induce aggregation of purified CPE.  Therefore, boiling might be inducing aggregation of the 
CPE-containing complexes as well.  This was tested by simply taking CPE-treated Caco-2 cell 
lysates and boiling them, followed by SDS-PAGE and Western blot analysis.  Fig. 3.6B shows 
that by simply boiling CPE complexes, only one band is present at a size that is similar to the 
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CH-2 band.  In an IP experiment where only the CH-1 complex is present was used as the 
starting material (Fig. 3.6C, Input), after boiling there is an increase in its molecular weight (Fig. 
3.6C, α-CPE IP).  Boiling with DTT had no effect on the aggregated material.  This suggests that 
boiling is causing aggregation of the CH-1 complex.   
            
Figure 3.6  Immunoprecipitation of EE Samples.   
A)  Electroeluted CH-1 and CH-2 samples were immunoprecipitated with an affinity purified 
anti-CPE antibody.  CPE-antibody complexes were pulled down with Protein A-agarose beads 
followed by boiling to dissociate CPE and associated proteins.  Immunoprecipitated material 
was then loaded on a 4% SDS-PAGE gel and visualized by Typhoon scanning.  B)  Caco-2 
cells were treated with nCPE and lysates were either boiled or not (Input).  4% SDS-PAGE 
and Western blotting was performed using a rabbit anti-CPE antibody.  C)  CPE-treated Caco-
2 cells were lysed with RIPA buffer and either immunoprecipitated with rabbit IgG or affinity 
purified anti-CPE.  IPs and supernatants were run on SDS-PAGE and Western blotted with a 
monoclonal anti-CPE antibody. 
 
The two-step strategy of EE and IP established here appears to be a successful method of 
isolation and separation of the CH-1 and CH-2 complexes.  Before analysis by mass 
spectrometry, we wished to quantify the amount of protein that was recovered by this method.  
To this end, a semi-quantitative Western blot was performed where a standard curve of known 
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CPE concentrations was generated to extrapolate and quantify the amount of CPE-
immunoreactive protein in the recovered samples after EE and IP.  From this analysis, it was 
calculated that we recovered ~700 ng of CPE protein, which equates to ~20 pmol of CPE.    
3.3.2 Proteomic Analysis 
The two-step strategy of EE/IP appears to be a useful method for the purification of the CH-1 
and CH-2 complexes for analysis by MS.  After running the CH-1 immunoprecipitated material 
on SDS-PAGE and determining its migration by fluorescence scanning, the CH-1 band was 
excised and in-gel trypsin digestion was performed as described in Materials and Methods.  
Tryptic peptides were then analyzed by LC-ESI MS/MS.  Only one host protein was identified in 
the analysis (Appendix I, Table 1), and that was ribosome-binding protein 1 (RRBP1).  As this 
protein in an ER-membrane bound protein (147), it is unlikely to associate with the CH-1 
complex.  Therefore, RRBP1 was not pursued further.  Also of note is that when sequences were 
run through a C. perfringens database, CPE was identified in the analysis but with a low 
probability score of 1.0 (Appendix I, Table 2).  As a control for the trypsin digestion procedure, 
1 μg of each BSA and purified nCPE were digested by trypsin after SDS-PAGE and analyzed by 
MS.  Results show protein good coverage and identification of both BSA and CPE (Appendix I, 
Table 3 and 4).   
One of the possible explanations for the lack of meaningful data obtained from MS 
analysis was inefficient enzymatic digestion.  Tryspin was initially used to produce peptides for 
analysis.  A simple experiment was performed to determine how well trypsin dissociates the CPE 
complexes (Fig. 3.7A).  CPE-treated Caco-2 lysates were digested with trypsin in a similar 
manner as performed prior to MS analysis.  After trypsin treatment, lysates were run on SDS-
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PAGE and Western blotted for CPE.  The results in Fig. 3.7A show that the CH-1, and to some 
extent, the CH-2, are extremely resistant to trypsin digestion.  There is some digestion as 
evidenced by significant smearing of the complexes.  However, the majority of the complex 
formation remains intact.  This could be a possible explanation, then, for the inability to obtain 
MS data from our EE/IP samples. 
                                   
Figure 3.7  Sensitivity of CPE Complexes to Enzymatic Digestion.   
A)  Caco-2 monolayers were treated with 2.5 μg/ml of CPE for 45 min, 
harvested, and either mock treated (Lane 1) or treated (Lane 2) overnight with 
1 μg/ml of trypsin at 37°C.  SDS-PAGE and Western blotting was performed 
on treated samples.  B)  Caco-2 cells were treated with CPE as in A, and were 
either mock treated (Lane 1) or treated (Lane 2) overnight with 25 μg/ml of 
chymotrypsin at 37°C.  
 
From the data in Fig. 3.7A it was apparent that trypsin digestion was not going to be 
useful for our MS studies.  Therefore, we wanted to determine if another commonly used 
enzyme, chymotrypsin, is able to successfully digest the CPE complexes.  In a similar 
experiment as performed in Fig. 3.7A, CPE-treated Caco-2 cells were treated with chymotrypsin, 
and the degree of complex digestion was measured by SDS-PAGE and Western blotting (Fig. 
3.7B).  The results from this experiment clearly indicate that complete digestion of the CH-1 and 
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CH-2 complexes is accomplished by chymotrypsin treatment (Fig. 3.7B, lane 2).  This is in stark 
contrast to the ability of trypsin to digest the CPE complexes.  After learning of the potential for 
chymotrypsin, the EE/IP procedure was repeated, however, in-gel digestion was performed with 
chymotrypsin as opposed to trypsin.  Peptides were subsequently analyzed by LC-ESI MS/MS.  
Results from this analysis showed a number of potential proteins, however, all had very poor 
probability scores. 
3.3.3 Tight Junction Protein Analysis 
The hope in using MS analysis to identify proteins that associate with the CPE complexes was to 
avoid going on an “antibody fishing expedition” where antibody studies were performed for 
whichever proteins we decided to look for.  However, with the minimal success we had with the 
MS studies, we decided to look specifically for a select few proteins in the tight junction that 
may be interacting with CPE and/or the CPE complexes.  The first protein we investigated was 
JAM-A.  Junctional Adhesion Molecule-A, or JAM-A, is a tight junction protein which serves to 
modulate many cellular functions including migration, polarity, paracellular permeability, and 
proliferation (171).  These functions are mediated by the structural elements of JAM-A, such as 
the Ig-like folds and PDZ-binding domains, which serve to mediate intracellular signaling 
events.  Immunoprecipitation and electroelution experiments were performed to determine 
whether JAM-A interacts with CPE and associates with the CH-1 and CH-2 complexes.  Lysates 
of CPE-treated Caco-2 cells were immunoprecipitated with an affinity-purified anti-CPE 
antibody.  Immunoprecipitated material was then probed for the presence of JAM-A which 
would indicate an association between CPE and JAM-A.  Unfortunately, IP with CPE antibody 
did not pull-down JAM-A protein (data not shown).  This was further shown and confirmed by 
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electroelution (Fig. 3.8).  Caco-2 cells that were treated with CPE were lysed and run on SDS-
PAGE, and after Western blotting to locate the migration of the CH-1 and CH-2 bands, 
corresponding gel slices were excised for the CH-1, CH-2, and dye front.  These gel slices were 
then elecroeluted and concentrated.  The concentrated EE samples were then treated with urea 
and boiled to dissociate protein complexes and run on 12% SDS-PAGE followed by Western 
blotting for CPE (Fig. 3.8A) or JAM-A (Fig. 3.8B).  Fig. 3.8A shows the presence of CPE in all 
three EE samples (dye front, CH-1, and CH-2) as evidenced by the signal at ~35 kDa.  
Conversely, Western blot analysis of the EE samples for the presence of JAM-A reveals that 
there is no JAM-A present in either the CH-1 or CH-2 complexes (Fig. 3.8B).  Caco-2 cells do 
express JAM-A as is evidenced by the presence of JAM-A in the dye front of EE samples (Fig. 
3.8B).  These experiments suggest that JAM-A does not interact with CPE or associate with the 
CPE complexes.  Furthermore, similar IP and EE experiments were performed for another tight 
junction protein, MUPP1.  The results from these experiments were similar to that of JAM-A and 
also suggested that CPE does not interact with or incorporate this protein into the CH-1 or CH-2 
complexes (data not shown). 
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Figure 3.8  Electroelution of JAM-A.   
Dye front (d.f.), CH-1, and CH-2 bands were electroeluted from gel slices of lysates of 
Caco-2 monolayers treated with 2. 5  μg/ml o f CPE fo r 4 5  min .   After EE an d 
concentration, each sample was treated with 10% SDS and 6 M urea, and boiled for 5 
min to dissociate the complexes.  Samples were run on a 12% SDS-PAGE gel in 
duplicate and transferred for Western blotting for CPE (A) or JAM-A (B).  
 
The basis for this study partly stems from previous experiments that identified that both 
receptor and non-receptor claudins can be present in the CPE complexes (158).  From this study 
by Robertson et al., it was determined that both claudin-3 and -4 (CPE receptors) and claudin-1 
(a non-receptor) can be associated with the SC, CH-1 and CH-2.  Because we were unable to 
detect the presence of other tight junction proteins (JAM-A or MUPP1) in these complexes, we 
wished to further the previous study by examining the association of other claudins with the CH-
1 and CH-2.  Electroelution was performed, as described above, for CPE-treated Caco-2 cells to 
determine if claudin-8 (a CPE binding capable claudin) is associated with CH-1 and/or CH-2.  
The results from Fig. 3.9 show that claudin-8 is expressed by Caco-2 cells as shown by 
immunoreactivity in the EE of dye front.  Because of the intrinsic property of claudins to 
aggregate (133), immunoreactive bands are seen higher than the predicted molecular weight of 
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cldn-8 (~25 kDa).  Furthermore, it is clear that cldn-8 is associated with the CH-1 complex.  
Additionally, there is a very small amount of cldn-8 that is present in the CH-2 complex (the 
band is very faint, but is present).  The data presented in Fig. 3.9 show that, in addition to cldn-1, 
-3, and -4, cldn-8 can also be associated with the CPE complexes. 
                                               
Figure 3.9  Electroelution of Claudin-8.   
CPE treated Caco-2 lysates were electrophoresed on 4% SDS-PAGE and corresponding 
dye front (d.f.), CH-1, and CH-2 bands were excised and electroeluted and concentrated.  
Concentrated samples were run on 12% SDS-PAGE and Western blotted with a rabbit 
anti-Cldn-8 antibody.  Numbers on the left are molecular weight markers in kDa. 
 
3.4 DISCUSSION 
Pore formation by CPE is mediated through large toxin-containing protein complexes on the 
membrane of target cells.  These complexes represent the functional pore and induce ion 
permeability alterations in host cells.  Much effort has been devoted to characterizing the 
biochemical interactions between CPE and host proteins and how the resultant complexes 
function on the membrane surface.  Two large CPE-containing complexes were originally 
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identified, the ~155 kDa complex and the ~200 kDa complex, names based on the apparent size 
assessed by migration on SDS-PAGE (179).  Under native conditions, however, the sizes of 
these complexes were reassessed to be ~450 kDa and ~600 kDa, respectively (158).  
Additionally, six copies of CPE were discovered to be present in each of these two large 
complexes, and therefore, the ~450 kDa complex was renamed as the CPE Hexamer-1 (CH-1), 
and the ~600 kDa complex was renamed CH-2.  In addition to the six CPE molecules in each 
complex, both receptor and non-receptor claudins were found to be associated with the CH-1 and 
CH-2 (158), as well as the Small Complex.  The observation that claudins can be present in all 
three CPE complexes suggests other TJ proteins may be associating with CPE.  When one 
considers the complexity of the TJ (62), this is not an improbable presumption.  Moreover, the 
TJ is increasingly being recognized as a target for pathogens and their products, such as bacterial 
toxins (63).  We wished to develop a method for purification of CPE complexes for analysis by 
mass spectrometry to identify additional proteins that may compose the CPE complexes. 
Multiple strategies were attempted to develop a useful method for CPE complex 
purification, and two of them have been discussed here (other methods included 2D-PAGE using 
Rotofor or IPG strips for isoelectric focusing).  The first strategy employed was affinity 
purification using rCPE with a his-tag.  A similar strategy has recently been used, except a GST 
tag was utilized (110).  However, this study was not examining the composition of the CPE 
complexes, but rather was simply attempting to pull down claudins that were interacting with 
CPE and identify them by MS.  This was partly the problem with the his-tagged rCPE method.  
We were unable to sufficiently extract CPE complexes from Caco-2 membranes that would 
allow for binding to the Ni2+ column.  Another possible explanation for the inefficient 
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purification is that the his-tag is not sufficiently exposed to bind to the column after 
oligomerization into the large CPE complexes. 
Our next purification method involved a two-step approach where CPE complexes were 
first isolated from treated Caco-2 cells by electroelution.  The second step involved 
immunoprecipitation of CPE and associated complex proteins.  With the addition of a 
fluorescently labeled CPE molecule, this procedure proved to be a very successful method for 
purification of the CH-1 and CH-2 complexes.  Of particular importance, this method not only 
allows for purification of the complexes, but allows for purification of the complexes 
individually.  This allows us to analyze the composition of each complex as opposed to simply 
determining what proteins are interacting with CPE.  Although not attempted here, this 
procedure could also be utilized for the purification of the SC with the only major change being 
CPE treatment at 4°C.  One possible drawback with this method is the amount of starting 
material required to get a yield that is compatible with the downstream MS analysis.  The 
number of Caco-2 cells that was started with was ~107.  This may be low for MS analysis, 
however, ~75 μg of CPE was used to treat these cells.  The problem arises in that only ~1% of 
CPE binds to cells, which would be less than 1 μg of CPE to begin with.  Perhaps increasing the 
input (number of cells) by at least 10-fold may increase level of material needed for MS. 
Another hindrance that we encountered was the apparent resistance of the CH-1 and CH-
2 complexes to digestion by trypsin.  Although unfortunate, this finding was not totally 
surprising because we have found that to break apart these complexes it requires the addition of 
10% SDS, 6M urea, and boiling (data not shown).  It was shown, however, that CH-1 and CH-2 
complexes are quite sensitive to chymotrypsin digestion.  It may be that these complexes are too 
sensitive to chymotrypsin and overdigestion was accomplished.  Limited chymotrypsin digestion 
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could be attempted to avoid this, as well as use of other digestion conditions such as using 
cyanogen bromide.   
In lieu of MS, we performed some TJ protein antibody studies to examine the presence of 
these proteins in the CPE complexes.  We found that neither JAM-A nor MUPP1 were present in 
the CH-1 or CH-2 complexes.  Claudin-8, however, was found to be associated with CPE and the 
complexes.  Cldn-8 was previously shown to be a somewhat weak CPE binder (100 times less 
binding affinity than cldn-3 or -4) (52).  Although we were able to pull down cldn-8 with CPE by 
IP, it is not clear if this claudin is directly binding to CPE or is just loosely associated, as is the 
case with non-receptor claudins such as cldn-1 (158).  Transfection of rat fibroblasts, which do 
not produce any claudins and are therefore CPE-insenstive, with just one claudin receptor 
become fully sensitive to CPE treatment (82, 157).  Similar experiments are required, and are 
underway, for cldn-8 to determine if it is a functional receptor in the sense that it can mediate 
cytotoxicity when transfected into a naturally insensitive cell line.  Up to this point, the claudin 
expression profile in Caco-2 cells has not been extensively studied.  Currently, we know that 
cldn-1, -2, -3, -4, -6, -7, -8, and -14 are expressed in Caco-2 cells ((110, 158), Fig. 3.9, and 
unpublished results).  Western blot and RT-PCR analyses are now being performed for all 
claudin family members to determine the full expression profile in Caco-2 cells.  This is 
pertinent because from this study it now appears that claudins might be the only proteins 
associated with the CPE complexes.  Any of the many claudins that may be expressed by Caco-2 
cells may be associated with CPE. 
CPE treatment by both non-toxic fragments and fully functional derivatives can result in 
the removal of proteins from the TJ (179, 187), an observation that has been exploited by 
researchers examining the use of CPE in drug delivery (42, 93).  Another interesting question 
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regarding the claudin composition of CPE complexes is whether CPE treatment causes the 
incorporation of claudins from apposing cells as there is close interaction between neighboring 
claudin strands (Fig. 1.2).  A co-culture experiment involving CPE treatment of transfectants 
expressing two different claudins would help to determine if CPE can pull claudins from 
neighboring cells.  Rat fibroblasts do not express occludin, and therefore, do not form the CH-2 
complexes upon CPE treatment, even when transfected to express receptor claudins.  A similar 
co-culture experiment where one cell is expressing claudin and the other is expressing occludin 
would also be interesting to assess whether CPE also pulls occludin from adjacent cells. 
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4.0  DEVELOPMENT AND CHARACTERIZATION OF A MOUSE MODEL OF 
CPE-INDUCED INFLAMMATION AND DISEASE 
4.1 INTRODUCTION AND RATIONALE 
4.1.1 Cell Death Pathways Activated by CPE 
As described above, in an in vitro Caco-2 cell model, CPE treatment can result in either 
apoptosis or oncosis depending on the toxin dose administered (32).  A low CPE dose (1 μg/ml) 
results in the activation of the apoptotic pathway, while a high CPE dose (10 μg/ml) activates 
oncosis.  Cell death at low doses, but not the high dose, could be inhibited by pre-treatment with 
caspase 3/7 inhibitors, confirming the activation of the classical apopotic pathway.  However, the 
oncosis inhibitor, glycine, had the ability to inhibit cell death associated with the high CPE dose.  
This relationship is attributed to the levels of Ca2+ influx as a result of pore-formation, such that 
low toxin doses lead to a mild Ca2+ influx, whereas strong Ca2+ influx is a result of high toxin 
doses (31).  An important distinction between apoptosis and oncosis is that inflammation is 
associated with oncosis while apoptosis is viewed as a non-inflammatory event (46).  
Epidemiological studies of human type A food poisoning outbreaks indicate that CPE can be 
present at concentrations ranging from <10 ng/ml to >100 μg/ml in the feces of patients (12, 15).  
This range of CPE concentration indicates that both apoptosis (non-inflammatory) and oncosis 
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(inflammatory) may be occurring during CPE-induced food poisoning.  When histopathological 
damage is assessed in rabbit ileal loop models of CPE challenge, inflammatory infiltrates such as 
polymorphonuclear leukocytes are observed (125, 165). 
4.1.2 Rationale 
Despite the histological evidence for inflammation, the contribution of inflammatory cytokines 
to the local (intestinal) pathology in CPE-induced disease has not yet been examined.  Generally 
speaking, inflammatory cytokines, such as TNFα, IL-1, IL-6, etc., have major effects on tight 
junction permeability by modulating expression patterns of various tight junction proteins and 
associated signaling molecules (5, 27).  C. difficile, a close relative of C. perfringens, produces 
potent exotoxins in the gut (TcdA and TcdB) which are extremely pro-inflammatory.  Therefore, 
it is plausible that CPE treatment results in the induction of inflammatory cytokines within the 
intestine.  And it is the aim of this study to determine if cytokines are produced in response to 
CPE treatment in a novel mouse ileal loop model.  Additionally, recent reports have indicated 
CPE in lethal cases of type A food poisoning (19, 155).  Therefore, we wished to establish a 
mouse model of CPE action that mimics the lethality associated with CPE-associated disease.  
Finally, despite significant evidence for the role of CPE complex formation in vitro for CPE-
induced cytotoxicity, this has not been demonstrated in vivo.  The establishment of this mouse 
model also enables us to assess the ability of CPE to form toxin-containing complexes in vivo. 
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4.2 MATERIALS AND METHODS 
4.2.1 Purification of CPE 
Native enterotoxin was purified from C. perfringens strain NCTC 8239 as previously 
described (127).  Briefly, strain NCTC 8239 is grown overnight in 20 L of Duncan-Strong Media 
to induce sporulation and production of CPE.  Prior to the completion of sporulation, sporulating 
cultures are spun down to harvest CPE-producing bacteria.  Pellets are resuspended in S200 
Buffer (75 mM potassium phosphate, pH 6.8) and sonicated to release CPE.  Precipitation of 
CPE is accomplished by addition of ammonium sulfate, and precipitated protein is run on a S200 
gel filtration column.  After chromatography, fractions are analyzed for the presence of CPE and 
CPE-containing fractions are combined and dialyzed against ddH2O (pH 7.0).  Following 
dialysis, purified toxin is lyophilized and stored. 
4.2.2 Purification of Neutralizing Monoclonal Antibody 
The monoclonal antibody (Mab2) used for loop neutralization and passive immunization 
experiments was purified from mouse ascites fluid, previously produced and characterized (218).  
Purification was performed using a pre-poured 1 ml Protein G chromatography column 
crosslinked to 6% agarose beads (Pierce) according to the manufacturer’s instructions.  Five 
milliliters of acites fluid was diluted 1:1 with Binding Buffer (50 mM sodium acetate, pH 5.0).  
To avoid clogging of the purification column, diluted fluid was filtered using 0.45 μm syringe 
filters.  Using the Luer-Lok adapter system, a syringe filled with 10 column volumes (10 ml) of 
Binding Buffer was attached to the column, and to equilibrate the column Binding Buffer was 
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flowed through the column at a rate of ~1 ml/min.  After equilibration, diluted ascites fluid was 
added through the column at a rate of ~1 ml/min.  The column was then washed with 10 ml of 
Binding Buffer.  Bound antibody was eluted from the column using 5 ml of Elution Buffer (0.1M 
Glycine, pH 2.0).  Prior to elution, 500 μl of 1M Tris, pH 8.0 was added to the collection tube to 
neutralize the low pH of the Elution Buffer.   
4.2.3 Animals and Ileal Loop Challenge 
Male or female, 20 to 25 g Balb C mice were used. Mice were fasted 24 h before inoculation, but 
allowed access to water up to 1 h before the start of the experiments. Their abdomens were 
disinfected with iodine solution (Betadine, Purdue Pharma LP, Connecticut) immediately before 
surgery. The animals were anesthetized by intraperitoneal administration of Avertine (Winthrop 
Laboratories, New York). A midline laparotomy was performed and A ~ 5 cm long intestinal 
loop was prepared in the jejunum of each animal by double ligation of the intestine. Care was 
taken to avoid interfering with the blood supply. CPE or buffer was injected into each loop. 
Controls included in this assay consisted of replacement of CPE by buffer. The injections were 
performed by insertion of a 0.5-in., 27-gauge needle oblique to the intestinal lumen in a direction 
away from the stomach. After inoculation, the incision in the peritoneum, abdominal muscles 
and skin was sutured in one plane using super glue (Henkel Corporation, Avon, Ohio). The 
surgical procedure lasted approximately 3 min per animal.  
The animals were kept anesthetized until they were euthanized at 2, 3 or 4 hrs after 
surgery, or until they died spontaneously. In those mice that survived until the end of the 
experiment, a blood sample was collected by cardiac punction. The serum was separated by 
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centrifugation and used for a trace element screen including potassium, sodium, as described 
below. 
Euthanasia was performed by neck dislocation. The intestinal loops were removed; the 
length was measured and the content weighed. A weight/length ratio was calculated. The content 
of the loops plus specimens of intestinal loop tissue, liver and kidney were collected and frozen 
at -80 C until processing for analysis for ELISA and Complex formation.  
Also, the gastrointestinal tract, brain, kidneys, lungs, heart, spleen and liver were 
collected and fixed by immersion in 10% formalin at pH 7.2 for a minimum of 24 h, before being 
processed routinely to obtain 4 μm thick sections which were stained with hematoxylin and 
eosin. 
All procedures involving animals were reviewed and approved by the University of 
California, Davis Committee for Animal Care and Use (permit 04-11593).  All animal surgeries 
were performed by Dr. Francisco Uzal and Juliann Saputo at the California Animal Health and 
Food Safety Laboratory. 
4.2.4 Measurement of Cytokine Production 
Cytokine production was measured from homogenized intestinal tissue supernatants.  Intestinal 
tissue (0.07 g) from control mice, 50 μg, 100 μg, and 200 μg dose groups was homogenized by 
sonication (Misonix Sonicator 3000, output 2.5) with 3 10 second pulses in 0.5 ml 
Homogenization Buffer (Phosphate Buffered Saline containing:  0.4 M NaCl, 0.05% Tween-20, 
0.5% BSA, 10 mM EDTA, and Protease Inhibitor Cocktail (GE)).  Insoluble material was spun 
down by centrifugation at 1000 x g for 3 min.  Supernatants were then used for detection of 
mouse IL-1β and IL-6 by ELISA using commercially available kits (CytoSet, Invitrogen) 
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according to manufacturer’s instructions with some modifications.  Immulon 1B plates (VWR) 
were coated overnight at 4°C with 100 μl of coating antibody at a final concentration of 1.25 
μg/ml in Coating Buffer (50 mM sodium carbonate/bicarbonate, pH 9.4).  After coating, wells 
were washed 4X with Wash Buffer (150 mM NaCl, 0.1% Tween-20, pH 7.4).  Plate was then 
blocked with 100 μl Assay Buffer (PBS, 0.5% BSA, 0.1% Tween-20, pH 7.4) for 1 h at room 
temperature (RT) followed by 4 washes.  Supernatants from homogenized tissue were diluted 1:4 
in Assay buffer, and 100 μl of each sample, and cytokine standards, was added to plate and 
incubated for 2 h at RT.  After 2 h incubation and washing, 100 μl of detection antibody was 
added at a final concentration of 0.125 μg/ml (anti-IL-1β biotin) or 0.05 μg/ml (anti-IL-6 biotin) 
in Assay Buffer and incubated for 2 h at RT.  After 4 wash steps, 100 μl of streptavidin-HRP at a 
final concentration of 0.15 μg/ml (IL-1β) or 0.05 (IL-6) in Assay buffer and incubated for 30 min 
at RT.  Wells were washed 4X, and 100 μl of 1-Step Ultra-TMB substrate (Pierce) was incubated 
in each well for 15 min at RT.  The reaction was stopped by the addition of 100 μl 2M sulfuric 
acid.  The plate was read in a microplate reader at 450 nm.  The absorbances of cytokine 
standards were plotted against known concentrations to obtain a standard curve and the equation 
of the line of best fit to calculate the concentration of experimental samples.  
4.2.5 Assessment of CPE Complex Formation in Tissues 
To assess CPE binding and complex formation in intestinal, liver, and kidney tissue from mice 
that had been loop challenged with CPE, equal amounts of tissue (0.05 g) were homogenized in 
0.5 ml RIPA Buffer (50 mM Tris, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 
mM EDTA, Protease Inhibitor Cocktail, pH 7.4) + 5 μl benzonase (EMD Novagen) by 
sonication (as above).  25 μl of homogenates were added to 25 μl of 2X Laemmli Buffer, and 
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samples were loaded on 4% SDS-PAGE gels, followed by transfer to nitrocellulose membrane 
and Western blotting with a rabbit polyclonal anti-CPE antibody. 
To assess the ability of CPE to form complexes in cell suspensions of intestinal, liver, 
and kidney tissues, equal amounts of tissue (0.05 g) from untreated mice were homogenized in 
0.5 ml of Homogenization Buffer.  Protein concentration was measured using BCA Kit (Pierce), 
and it was determined that equal amounts of total protein (400-500 μg) was present in each 
tissue.  100 μl of each homogenate was transferred to an eppendorf tube, and 2.5 μg/ml of CPE 
was added to each CPE-treated sample, or left untreated for control samples.  Cell suspensions 
were incubated for 30 min with gentle rotation at 37°C.  Samples were spun down in a 
microcentrigute at full speed for 5 min to pellet material.  Pellets were washed 2X with PBS, and 
after final wash pellets were resuspended in 25 μl of PBS + 1 μl benzonase and then 25 μl of 2X 
Laemmli Buffer was added to each sample.  25 μl of each sample was analyzed by SDS-PAGE 
and Western blotting as above.  
4.2.6 Measuring CPE in Serum 
Mouse serum was analyzed for the presence of CPE by a sandwich ELISA which was developed 
for the first time in this current study.  Wells of an Immulon 1B plate were coated overnight with 
50 μl of a mouse anti-CPE antibody (Mab2, see above) diluted in PBS (pH 7.4) to a final 
concentration of 2 μg/ml.  After coating, the plate was washed 4X with Wash Buffer and blocked 
with 50 μl of Assay Buffer for 1 h at RT.  Following the blocking step and 4 washes, 50 μl of the 
serum samples and CPE standards were added to the plate and incubated for 2 h at RT.  After 4 
washes, an affinity purified rabbit anti-CPE antibody (purified from CPE rabbit anti-sera using 
Protein A columns (Pierce)) at a final concentration of 1 μg/ml and incubated for 2 h at RT.  
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After washing, an anti-rabbit-HRP conjugate (Sigma) secondary antibody was added at 1:30,000 
in Assay Buffer and incubated for 1 h at RT.  Following washing, TMB substrate was added for 
15 min and 2M sulfuric acid was added to stop the reaction.  Absorbance was read at 450 nm on 
a microplate reader.  The absorbances of CPE standards were plotted against known 
concentrations to obtain a standard curve and the equation of the line of best fit to calculate the 
concentration of unknown serum samples. 
4.2.7 CPE Treatment of HUVEC and MDCK Cells 
HUVEC cells were maintained in M200 media (Invitrogen) supplemented with Low Serum 
Growth Supplement Kit (Invitrogen, containing 2% FBS, 1 μg/ml hydrocortisone, 10 ng/ml 
human epidermal growth factor, 3 ng/ml basic fibroblast growth factor, 10 μg/ml heparin, and 
gentamicin) at 37°C with 5% CO2.  MDCK cells were cultured in DMEM with glutamine 
(Invitrogen) supplemented with 10% FBS and grown at 37°C with 5% CO2.  For CPE treatment, 
cells were seeded at a density of 1 x 105 cells/ml in 60 mm cell culture dishes.  When reaching 
confluency (4-5 days), monolayers were washed 2X with HBSS with Ca2+ (cHBSS) and CPE 
(2.5 μg/ml for MDCK; 0.5 μg/ml, 1.0 μg/ml, or 2.5 μg/ml for HUVEC) was added to the cells 
and incubated for 45 minutes (MDCK) or 6 h (HUVEC) at 37°C.  For MDCK cells, images of 
the plates were captured at 10, 30, and 45 min.  For HUVEC cells, pictures were taken every 15 
minutes for the first hour of treatment, and then once every hour after that.  After CPE treatment, 
cells were harvested by gentle scraping, pelleted by centrifugation, and washed 2X with cHBSS.  
Pellets were resuspended in 50 μl cHBSS + benzonase, and 50 μl of 2X Laemmli Buffer was 
added.  25 μl of samples were analyzed by 4% SDS-PAGE and Western blot as above. 
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4.2.8 Trace Element Screen 
The Trace Element Screen was performed by Dr. Birgit Puschner in the Veterinary Toxicology 
Lab at the CA Animal Health and Food Safety Laboratory System.  Serum was collected from 
mice at indicated times after intestinal loop treatment and was analyzed by ICP-AES.  Zinc, 
copper, iron, magnesium, sodium, phosphorus, calcium and potassium levels were measured in 
serum samples utilizing inductively coupled argon plasma emission spectrometer (FISONS, 
Accuris Model, Thermo Optek Corporation, Franklin, MA) (129).  After precipitation of 
proteins, the protein-free supernatant of each sample were analyzed simultaneously for the listed 
trace elements. Accuracy of ICP results for these elements was measured by analyzing quality 
assurance sera obtained from the Veterinary Laboratory Association Quality Assurance Program 
(Genzyme Diagnostics, Blaine, MD, USA).  Data were accepted if analyzed quality assurance 
serum values were within 2 standard deviations of the reference values. 
4.3 RESULTS 
4.3.1 Assessment of CPE-induced Cytokine Release 
To assess the ability of CPE to induce a localized inflammatory event, we wished to measure the 
ability of CPE to elicit the release of inflammatory cytokines in an in vivo intestinal challenge 
animal model.  To study the various aspects of CPE pathogenesis in vivo, rabbit ileal loops have 
been and are currently the most commonly employed animal model (125, 165, 173, 183).  
Unfortunately, reagents (i.e. antibodies) against proteins of rabbit origin are not readily available 
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to analyze the presence of cytokines.  We, therefore, wished to assess cytokine production in a 
more suitable animal model by using a mouse intestinal loop model.  The only published report 
using mouse ileal loops to assess CPE pathogenesis was from a Japanese group in 1979 (220), so 
we first needed to develop a mouse model of our own (see Materials and Methods). 
Ligated intestinal loops were challenged with buffer control (HBSS), 50 μg, 100 μg, or 
200 μg of CPE for 2 h, and intestinal fluid, intestinal tissue, and serum was collected from the 
animals.  Intestinal fluid and serum was analyzed by ELISA for the presence of the 
proinflammatory cytokines, IL-1β and IL-6.  No appreciable levels of either cytokine were 
detected in our ELISA assays (data not shown).  Additionally, intestinal fluid and serum were 
further analyzed for cytokine production by a Luminex multiplex assay for the presence of 10 
different cytokines (GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IFN-γ and 
TNF-α).  Again, no significant production of cytokines was detected in these samples (data not 
shown, most analytes were out of the range of detection).  We next analyzed homogenized 
intestinal tissue from control and CPE-treated loops and assayed for IL-1β and IL-6 production 
by ELISA.  Fig. 4.1A shows a dose-dependent increase in IL-1β production after CPE treatment.  
At this 2 h time point, the 50 μg dose did not induce production of IL-1β in animals as compared 
to buffer control animals.  The 100 μg dose induced a 2-fold increase in IL-1β production, 
however, it did not reach statistical significance.  However, the 200 μg dose did induced a 
statistically significant increase of ~10-fold in IL-1β production (p<0.02), at a value of ~130 
pg/ml.  A similar result is observed for IL-6 production; CPE elicited an increase in IL-6 
production in a dose-dependent manner (Fig. 4.1B).  For this cytokine, the increase is more 
pronounced for the 100 μg dose as compared with IL-1β with both the 100 μg and 200 μg doses 
producing ~4-fold more IL-6 than animals challenged with 50 μg of CPE.  
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Figure 4.1  Induction of Proinflammatory Cytokines by CPE.   
Homogenates of intestinal loops treated for 2 h with buffer control, 50 μg, 100 μg, and 200 μg of CPE 
were analyzed for the presence of IL-1β (A) and IL-6 (B) by ELISA as described in Materials and 
Methods. *p=0.02. 
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4.3.2 Formation of CPE Complexes in vivo 
Using cell culture models, such as Vero and Caco-2 cells, it has long been established that CPE 
forms large molecular weight complexes on the membrane surface of target cells (88, 158, 178).  
Additionally, the formation of these complexes is necessary for the pore-forming activity of the 
toxin (122), allowing permeability alterations to occur.  As evidenced by fluid accumulation seen 
in rabbit ileal loop models, these same permeability alterations observed in cell culture are also 
seen in vivo (125, 165).  Additionally, direct binding of CPE to intestinal tissue has been 
observed in vivo in rabbit ileal loops as well as ex vivo to human ileum (45, 183).  Despite this, 
formation of CPE complexes has never been observed in vivo.  Therefore, we sought to analyze 
CPE-treated mouse intestinal loops for the presence of CPE complex formation.  Intestinal tissue 
from CPE-treated mice was homogenized in detergent and lysates were analyzed by SDS-PAGE 
and Western blotting.  Results from Fig. 4.2A demonstrate the ability of CPE to form large 
complexes in vivo.  There is formation of a large CPE-containing complex of a molecular weight 
very similar to the CH-1 complex observed in Caco-2 cells.  A second complex of higher 
molecular weight is also observed reminiscent of the CH-2 complex.  However, this second 
complex is smaller than the CH-2 complex that is observed to form in Caco-2 cells.  Despite the 
discrepancies in sizes of the complexes observed as compared to those seen in cell culture 
models, this is a novel finding in that it is the first time larger molecular weight CPE complexes 
have been observed in vivo.  Furthermore, intestinal tissue from untreated mice was 
homogenized and subsequently treated   in a cell suspension with 2.5 μg/ml of CPE for 30 min 
(Fig. 4.2B).  After treatment, we are able to see the formation of the CH-1 complex.  However, 
no CH-2 complex was observed in this experiment. 
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Figure 4.2  Formation of CPE Complexes in the Mouse Intestine.  
A)  Lane 1:  SDS Lysates of Caco-2 cell monolayers treated with 2.5 μg/ml of CPE for 
45 min, and Lane 2:  RIPA homogenate lysates of mouse intestinal loops treated with 200 
μg of CPE for 2 h were analyzed by SDS-PAGE and Western blotted using a polyclonal 
rabbit anti-CPE antibody.  B)  Lane 1:  Lysates of Caco-2 cell monolayers treated with 
2.5 μg/ml of CPE for 45 min, Lanes 2 & 3:  Cell suspensions of homogenized control 
mouse intestines were either left untreated (Lane 2) or treated with 2.5 μg/ml of CPE for 
30 min (Lane 3).  Lysates were analyzed by SDS-PAGE and Western blot as in A).  
Numbers on the left represent molecular weight markers in kDa.  d.f. indicates the 
migration of the dye front of the gel. 
  
4.3.3 Mouse Survival in the Intestinal Loop Model 
This study has provided some novel findings up to this point.  We have established that CPE 
induces the expression of inflammatory cytokines and that CPE can form high molecular weight 
complexes in vivo.  An intriguing observation was made when we examined the survival of the 
mice used in our intestinal loop model (Table 4.1).  When mice were challenged with CPE for 2 
h there was complete survival at all doses (control, 50 μg, 100 μg, and 200 μg).  Interestingly, we 
observed a high mortality rate in mice at the 4 h time point with the administration of higher 
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doses of CPE (100 μg and 200 μg).  Full survival was seen for mice treated with buffer alone or 
the lower 50 μg CPE dose. 
Table 4.1  Survival of Intestinal Loop-Challenged Mice 
  2 h 4 h 
Treatment Control  50 µg 100 µg 200 µg Control 50 µg 100 µg 200 µg 
No. Survival 4/4 3/3 3/3 3/3 7/7 8/8 2/8 1/8 
Percent Survival 100 100 100 100 100 100 25 12.5 
 
This low survival effect in mice at the 4 h time point with the CPE high doses was 
reversed when CPE was pre-incubated with a neutralizing monoclonal antibody before 
administration into the intestinal loop (Table 4.2).  All mice (4/4) survived with this CPE 
neutralization experiment when challenged with 200 μg of CPE for 4 h.  This suggested that the 
death we were observing required the intestinal activity of CPE, and presumably the pathological 
effects due to CPE action, i.e. villous blunting and epithelial desquamation.  What was 
particularly striking was the effect we observed when mice were administered the neutralizing 
monoclonal antibody by the IV route prior to CPE challenge via the intestinal loop model (Table 
4.2).  Similar to the neutralizing experiment, survival of mice was fully restored with this 
systemic immunoprotection treatment.  The results from this immunoprotection experiment 
suggested that there may be a systemic component behind the high lethality observed, possibly 
due to CPE gaining access to the blood. 
Table 4.2 Neutralization and Immunoprotection of Mice 
Treatment Survival 
mAb Neutralization* 4/4 
mAb Protection** 4/4 
*Pre-incubation of mAb prior with 200 μg of CPE to 4 h loop challenge 
**IV administration of mAb prior to 4 h loop challenge with 200 μg of CPE 
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4.3.4 Histopathological Effects of Mouse Lethality Model 
As suggested above, the lethality observed appears to be dose-dependent.  Furthermore, the 
neutralization of CPE prior to intestinal challenge seems to prevent the observed lethality in our 
mouse model.  This suggests that intestinal damage may be contributing to lethality in some 
manner.  We, therefore, wished to analyze histological damage in our model at the various doses.  
Histology of control loops (Fig. 4.3A) show healthy villi and crypts with no significant damage.  
A small amount of shortening of the villi was observed with 50 μg of CPE at the 2 h time point 
(Fig. 4.3B), but ~75% of the villi remained intact.  In contrast, severe histological damage was 
observed by 2 h for the 100 μg and 200 μg doses (Fig 4.3C and D).  Desquamation and necrosis 
of the epithelium, necrosis of the lamina propria, and severe blunting of the villi was observed 
for these higher doses.  No evidence of edema was observed.  A summary of the histological 
observations is shown in Table 4.3.  Figure 4.4 graphically represents the overall severity of the 
lesions observed, taking into consideration all of the criteria outlined in Table 4.3.  All three 
doses (50 μg, 100 μg, and 200 μg) are statistically more severe as compared to buffer control 
treatment (p<0.01 for 50 μg, p<0.001 for 100 μg and 200 μg).  Additionally, both the 100 μg and 
200 μg histology scores are statistically more severe than the 50 μg dose (p<0.02).  However, 
there is no statistical difference between the 100 μg and 200 μg dose.  In general, there is an 
obvious dose-dependent relationship between overall histological damage and dose of CPE 
administered into the intestinal loops. 
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Figure 4.3  Histolopathogy Induced by CPE Doses.  
After 2 h of treatment, loop tissues were formalin fixed and embedded in paraffin. Hematoxylin and eosin 
was used to stain 4 mm-thick sections of intestinal tissue treated with buffer control (A), 50 µg (B), 100 
µg (C), or 200 µg (D). In each panel, L represents the intestinal lumen, while LP identifies the lamina 
propria.  Final magnification of each photomicrograph, 400X.  Histology was performed by Dr. Francisco 
Uzal. 
 
 
Table 4.3 Scoring of Individual Histological Criteria for CPE Doses 
Inoculum 
Desquamation 
epithelium 
Necrosis 
epithelium 
Necrosis 
lamina 
propria Inflammation 
Dilated 
lymphatics Edema  
Villous 
blunting 
Overall 
severity of 
lesions 
Control - - - - - - - - 
15 µg - - - - - - - - 
50 µg + + + - - - + + 
100 µg +++ +++ +++ - - - ++ +++ 
200 µg ++++ ++++ ++++ + - - +++ ++++ 
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Figure 4.4  Overall Histology Score.   
Taking into consideration the criteria from Table 4.3, an overall score of severity of histopathological 
damage was determined.  Histology scoring was performed blind by a veterinary pathologist and was 
based on a scale of 0 to 4, with 4 being the most severe.  Data is the mean of 4 mice per group (Control, 
50 μg, 100 μg, 200 μg) after 2 h of loop challenge.  Error bars represent the standard error of the mean.  
*p<0.01, **p<0.001, ***p<0.02. Histology was performed by Dr. Francisco Uzal. 
 
4.3.5 CPE Gains Access to the Circulation  
A recent epidemiology survey (19) of a food poisoning outbreak in Oklahoma at a residential 
care facility for mentally ill patients in 2001 was performed in 2 deaths were described and 
attributed to contamination by cpe+ type A C. perfringens.  Upon histological analysis, severe 
necrosis of the colons of those patients that died was observed (Fig. 4.5A).  The intestines of our 
mice had a similar phenotype in which punctuate areas of hemorrhaging can be seen (Fig. 4.5B), 
possibly a precursor to the severe necrosis seen in the Oklahoma patients.  The authors 
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concluded that the outstanding risk factor for these deaths was due to the constipation and fecal 
impaction as a result of the psychiatric medications the patients were taking.  It is thought that 
this constipation and fecal impaction impeded the ability of these individuals to flush out the 
released CPE in the intestine as usually accomplished through diarrhea.  As a result, CPE 
accumulated within the intestine, causing severe damage.  Ultimately, the authors conclude, this 
possibly led to the ability of CPE to cross the intestinal barrier and gain access to the blood 
stream, which caused the death of these individuals.  We, therefore, wished to explore this as a 
possible mechanism of lethality that we are observing in our mouse model. 
                              
Figure 4.5  Intestinal Gross Pathology.   
A)  Gross pathology of the colon of a patient that died from the Oklahoma outbreak reveals a large region 
of black, necrotic lesions.  Unaffected areas do exist.  Reproduced from (19).  B)  A representative 
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intestinal loop (from a mouse treated with 100 μg of CPE for 2 h) reveals punctuate areas of 
hemorrhaging (arrows). 
 
To this end, we analyzed the ability of CPE to gain access to the bloodstream.  For this, 
we analyzed serum collected from mice treated with varying doses of CPE for 2 h in the 
intestinal loop challenge model.  Serum was analyzed by an in-house developed sandwich 
ELISA for the presence of CPE after intestinal loop challenge with varying doses.  Figure 4.6 
shows that there is a significant amount of CPE within the serum after only 2 h treatment with 
the 200 μg dose (~800 ng/ml).  The lower 50 μg dose has far less CPE within the serum (~300 
ng/ml), and a lower 15 μg dose had undetectable levels of CPE.  These results demonstrate that 
CPE has the ability to gain access to the bloodstream, and this may be a mechanism by which 
mice in the model are dying.   
A possible mechanism to explain the ability of CPE to access the bloodstream is that CPE 
is cytotoxic to endothelial cells lining the microvasculature within the intestinal tissue.  To test 
the ability of CPE to be cytotoxic to endothelial cells, we assessed morphological damage to 
human umbilical vein endothelial cells (HUVEC) after CPE treatment.  Three doses of CPE (0.5 
μg/ml, 1.0 μg/ml, and 2.5 μg/ml) were used to treat HUVEC cells.  Morphological damage was 
assessed after 1 h of treatment.  No damage to the cells was observed after 1 h of treatment for 
any of the doses used (Fig. 4.7).  The morphology of the cells did not change as compared to 
untreated HUVEC cells (Fig. 4.7A).  There was no rounding or detachment of the cells which is 
typically observed when other cell types, such as Caco-2 or Vero cells, are treated with CPE 
(178).  HUVEC cytotoxicity was followed out to 6 h of CPE treatment, and still no 
morphological damage or CPE complex formation was seen (data not shown).  This suggests that 
endothelial cells, at least HUVEC cells, are insensitive to the cytotoxic effects of CPE treatment.  
Endothelial cells, like epithelial cells, form tight junctions between adjacent cells.  However, 
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claudin expression Western blots (data not shown) indicated no detectable levels of claudin in 
HUVEC cells.  Further cytotoxicity studies using other types of endothelial cells is necessary to 
determine if this is a plausible mechanism by which CPE is gaining access to the bloodstream in 
our mouse model. 
 
Figure 4.6  Analysis of Serum for the Presence of CPE within the Bloodstream.   
After 2 h of CPE treatment at indicated doses, serum was collected from mice.  Serum was analyzed by a 
sandwich ELISA specific for the presence of CPE.  ND = not dectected. 
 
4.3.6 Binding of CPE to Other Organs 
The results of Fig. 4.6 provides evidence for the presence of CPE within the circulation after 
CPE challenge in the intestinal loop model.  Previous studies examining the effects of IV 
administration of CPE revealed that the greatest quantities of CPE are distributed in the liver and, 
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to a lesser extent, the kidney, within 10-15 min after injection (180).  With this in mind, we 
hypothesized that due to the presence of CPE within the blood, a large amount of CPE may be 
binding to the liver, as well as the kidney.  We, therefore, wished to determine the ability of CPE 
to bind and form complexes within these systemic organs.  Livers and kidneys from CPE-treated 
mice were harvested and homogenized.  Homogenates were analyzed by SDS- PAGE and 
Western blotting with an anti-CPE antibody for the presence of CPE binding and complex 
formation. 
 
Figure 4.7 Assessment of Morphological Damage of HUVECs.   
Monolayers of HUVEC cells were left untreated (A) or treated with 0.5 μg/ml (B), 1.0 μg/ml (C), or 2.5 
μg/ml (D) of CPE for 1 h.  Morphological damage was assessed by light microscopy. 
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The data presented in Fig. 4.8A show significant immunoreactivity within the livers of mice 
treated with the 200 μg dose, however, much less immunoreactivity is observed for the lower 50 
μg dose.  This suggests that CPE has the ability to bind to the liver.  Despite the lack of a distinct 
complex comparable to the CH-1 or CH-2 complexes that is observed in CPE-treated Caco-2 
cells, higher molecular weight CPE-containing material is present within the homogenized liver 
tissue, suggesting CPE is interacting with additional host proteins.  Liver tissue from untreated 
mice was homogenized in detergent-free buffer and treated with 2.5 μg/ml of CPE for 30 min in 
a cell suspension.  Following toxin treatment, cell lysates were analyzed by Western blot and the 
results from this experiment (Fig. 4.8B) demonstrate that CPE has the ability to form, at least, the 
CH-1 complex.  However, no CH-2 complex formation was observed.  As evidenced by the 
formation of the CH-1 complex, it can be suggested that CPE can be cytotoxic to hepatocytes in 
the liver.   
Similar studies as described for the liver were performed for the kidneys of CPE-
challenged mice.  SDS-PAGE and Western blot analysis of homogenized kidneys of CPE-treated 
mice shows some binding to these organs (Fig. 4.8A).  The binding of CPE to the kidney appears 
to be less than that of CPE to the liver, despite similar amounts of total protein extracted (see 
Materials and Methods).  Again, as was observed with the livers of mice intestinally challenged 
with CPE, there is a lack of formation of distinct CPE complexes that are comparable to the CH-
1 or CH-2 that are observed in Caco-2 cells.  Yet, higher molecular weight immunoreactivity is 
seen which indicates CPE is possibly associating with host proteins.  As was done for liver 
tissues, kidneys from untreated mice were harvested and homogenized in detergent-free buffer.  
These kidney homogenates were treated for 30 min with 2.5 μg/ml of CPE in a cell suspension.  
Lysates of these CPE-treated kidney cell suspensions were then analyzed by SDS-PAGE and 
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Western blot.  Results from this experiment (Fig. 4.8B) show the ability of CPE to form the CH-
1 complex in isolated cells from the kidney.  This is in agreement with CPE treatment of Madin 
Darby Canine Kidney (MDCK) cells, an established cell line of kidney origin, in which 
significant changes in cell morphology is observed  and formations of CPE complexes occurs 
(Fig. 4.9).  Similar to what was observed for isolated hepatocytes treated in suspension, no CH-2 
formation in homogenized kidneys was detected in our Western blot analysis.   In summary, the 
data presented in Fig. 4.8 illustrate the ability of CPE to bind to systemic organs (liver and 
kidney) after gaining access to the bloodstream after damage to the intestinal epithelium due to 
toxin treatment in our intestinal loop model.  Additionally, the results shown in Fig.4.8 suggest 
that the necessary host proteins, presumably claudins, are present within both the liver and 
kidney which allow for the ability to form, at least the CH-1, the large CPE-containing 
complexes. 
              
Figure 4.8  CPE Complex Formation in Systemic Organs.   
A) Livers (L) and Kidneys (K) from mice treated with 50 μg or 200 μg of CPE for 2 h were harvested and 
homogenized in RIPA Buffer.  Lysates were analyzed by SDS-PAGE and Western blotting with a rabbit 
anti-CPE antibody.  SDS Lysates of Caco-2 cells treated with 2.5 μg/ml of CPE for 45 min were loaded 
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as controls for CH-1 and CH-2 complex formation.  B)  Livers and Kidneys from control mice were 
homogenized into cell suspensions and were left untreated (-) or treated (+) with 2.5 μg/ml of CPE for 30 
min.  Lysates were loaded on SDS-PAGE gels and analyzed by Western blotting as in A).  Numbers on 
left identify molecular weight markers in kDa.  d.f. marks the migration of the dye front. 
 
Figure 4.9  CPE-induced Cytotoxicity and Complex Formation in MDCK cells.   
A-G)  Assessment of morphological damage of MDCK cell monolayers treated with either 1 μg/ml (B-D) 
or 2.5 μg/ml (E-G) of CPE for 10 min (B, E), 30 min (C, F), or 45 min (D, G).  Untreated MDCK cell 
morphology is shown in A.  H)  MDCK cells treated for 45 min with 1.0 μg/ml (Lane 1) or 2.5 μg/ml 
(Lane 2) of CPE were harvested and lysates were run on 4% SDS-PAGE gels followed by Western 
blotting with a rabbit anti-CPE antibody.  Numbers on the left are molecular weight markers in kDA.  d.f. 
is the migration of the dye front.  Arrow shows the migration of the CH-1.  Arrowhead illustrates the 
migration of the CH-2 complex. 
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4.3.7 CPE Challenge Results in Elevated Levels of Potassium in the Serum 
In our mouse model of CPE lethality, the ability of CPE to damage the intestinal epithelium and 
gain access to the blood allows the toxin to preferentially bind to the liver and, to a lesser extent, 
the kidney.  These results are in agreement with the previous study by Skjelkvale et al. (180) that 
assessed the accumulation of toxin in various organs following IV administration of CPE, as 
introduced above.  Another study investigated the effects of IV administration of CPE in mice 
and rats in which animals died within 4-15 min (189).  In this study by Sugimoto et al., rapid 
changes in ECG patterns and a fall in blood pressure, followed by respiratory depression was 
observed.  The cardiac dysfunction associated with IV administration of CPE was found to be the 
result of increased levels of potassium within the blood of animals and not due to direct 
cytotoxicity of cardiac tissue by CPE.  Additionally, the source of the excess potassium was 
attributed to release from the damaged liver, thus, linking this study with that of Skjelkvale et al., 
suggesting a model where CPE preferentially binds to the liver, resulting in damage and lysis of 
hepatocytes and causing the release of potassium into the circulation.  These elevated levels of 
potassium in the blood, in turn, may cause cardiac dysfunction and eventual death. 
Because we were observing significant binding of CPE to the liver after intestinal 
challenge, we hypothesized that CPE may be causing the release of potassium from damage liver 
cells into the blood and this is responsible for the lethality we were observing.  Therefore, levels 
of potassium in the serum of mice challenged with different doses of CPE was assessed.  After 2 
or 3 h of incubation with 50 μg, 100 μg, or 200 μg of CPE, or buffer control, in intestinal loops, 
serum from treated mice was collected and analyzed for potassium levels by inductively coupled 
plasma atomic emission spectroscopy (ICP-AES).  As shown in Fig. 4.10A, the basal level of 
potassium in the serum of control animals is within the normal range at ~6 mM.  Intestinal loop 
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treatment with 50 μg of CPE for 2 h resulted in no statistically significant increase in levels of 
potassium.  Similarly, treatment with the 100 μg CPE dose also did not result in an increase in 
potassium levels in the serum of mice challenged for 2 h.  However, with the 200 μg dose of 
CPE, there was a statistically significant increase in potassium levels to ~14 mM in the serum 
after 2 h of treatment.  The increase that was observed is at a level that would be lethal to 
animals.  This 2 h data indicates that increased levels of potassium may potentially be playing a 
role in the lethality observed with the 200 μg dose. 
Despite the increased levels of potassium at 2 h for mice treated with 200 μg of CPE, we 
did not observe death until the 4 h time point (Table 4.1).  This suggests that there is a lag 
between increased potassium in the serum and actual death.  Additionally, when mice were 
challenged with 100 μg of CPE for 2 h, we did not observe an increase in potassium levels 
despite seeing a high rate of lethality at 4 h (Fig 4.10A and Table 4.1).  This discrepancy with the 
100 μg and 200 μg doses, where we are seeing lethality in both but only potassium increases 
with the 200 μg dose, prompted us to examine the effects of intestinal loop challenge at 3 h. 
When potassium levels in the serum of mice challenged for 3 h were analyzed by ICP-
AES (Fig. 4.10B), we observed a statistically significant increase in potassium levels with the 
100 μg dose to a lethal level (~16 mM).  This level is similar to that of what we observed for the 
200 μg dose at 2 h (Fig. 4.10A).  Mice treated with 200 μg of CPE for 3 h showed a continued 
rise in potassium in the serum to an exceedingly high level (~26 mM).  However, it must be 
noted that by this time point the majority of mice in these group were dead (Fig. 4.11), and 
autolysis may have occurred resulting in an inaccurate representation of the serum potassium 
profile of these mice.  Potassium levels in mice that were treated with 50 μg of CPE for 3 h still 
did not show an increase over buffer control mice.   
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When the 3 h lethality data is combined with our existing data for 2 h and 3h (Fig. 4.11), 
one can observed that between 2 and 3 h there is a drastic increase in the rate of lethality for the 
200 μg CPE dose (survival falling from 100% to 37.5%).  This interval seems to correlate with 
the increase in potassium in the serum of mice as illustrated in Fig. 4.10A.  Fig. 4.11 reveals only 
a modest increase in the rate of lethality between 2 and 3 h (survival falling only from 100% to 
75%) for the 100 μg CPE dose group.  However, severe lethality rates are observed for the 100 
μg group at 4 h (37.5% survival), which correlates to the observed potassium increase at 3 h (Fig. 
4.10B).  For the 50 μg CPE dose, survival remains at 100 % for 3 h, and only falls to 93.75% at 4 
h.  This correlates with the stable levels of potassium that is observed for this dose (Fig.4.10A 
and B).  Taken together, Figs. 4.10 and 4.11 demonstrate a dose and time-dependent relationship 
between CPE treatment in intestinal loops and lethality.  Furthermore, Figs. 4.10 and 4.11 
demonstrate that a rise in potassium levels within the blood precedes and is a likely cause of 
death in our mouse model. 
The dose and time-dependent change in potassium levels in the serum appears to be fairly 
specific to that one ion.  Analysis of the serum by ICP-AES allows for the simultaneous assaying 
of multiple ions in the same sample.  Therefore, we measured the levels other trace elements 
such as Mg2+, Ca2+, PO43-, Na+, Fe3+, Zn2+, and Cu2+ in the serum of mice that were intestinally 
challenged with the different doses of CPE at 2 h.  When comparing the serum levels of these 
elements between each dose, there are not statistically significant differences between the 3 
doses over buffer controls.  The only exception is for phosphorus, where the 200 μg group shows 
a statistically significant increase (p<0.008) in levels as compared to buffer control animals.  
However, the levels for this element between doses is somewhat variable.  For instance, the 50 
μg group has levels above control, whereas the 100 μg CPE dose group has similar levels as the 
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control group.  The significance of a phosphorus levels in the 200 μg CPE treatment group is 
unknown at this time.  Additionally, there is a trend towards a dose-dependent decrease in Cu2+ 
levels with increased dose, however, this observed decrease does not reach statistical 
significance for any data point (p=0.135). 
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Figure 4.10  CPE Challenge Results in Hyperpotassemia.   
After 2 h (A) or 3 h (B) of intestinal loop treatment with buffer control (orange bars), 50 µg (red bars), 
100 µg (green bars), or 200 µg (purple bars) of CPE, serum was collected from mice.  Serum was 
analyzed by utilizing inductively coupled argon plasma emission spectrometry.  After precipitation of 
proteins, the protein-free supernatant of each sample was analyzed for potassium levels.  Accuracy of 
results was measured by analyzing quality assurance sera obtained from the Veterinary Laboratory 
Association Quality Assurance Program.  Data were accepted if analyzed quality assurance serum values 
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were within 2 standard deviations of the reference values. Data is from the mean of 8 mice.  Error bars 
represent the standard error of the mean.  A) *p<0.01; B) *p<0.02, **p<0.0002 
 
 
Figure 4.11  Time and Dose-Dependent Representation of Mouse Survival.   
The percent survival of mice was calculated and plotted against the time of treatment (in 
hours, x-axis) for each dose of CPE at 2, 3, and 4 h.  Buffer control animals (-♦-), 50 μg 
treatment (-■-), 100 μg treatment (-▲-), 200 μg treatment  
(-●-).  Survival was calculated from 7 animals at 2 h, 8 animals for 3 h, and 15 animals 
at the 4 h time point for control, 50 μg, and 100 μg animals.  Survival was calculated 
from 7 mice at 2 h, 8 mice at 3 h, and 8 animals at 4 h for the 200 μg CPE dose.  Since 
the majority of mice die by 3 h with 200 μg of CPE, additional 4 h treatments with 200 
μg doses were eliminated to cut down on mouse usage.  
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Figure 4.12   Trace Element Screen.   
Serum was collected from control mice (orange bars) or mice treated for 2 h with 50 μg 
(red bars), 100 μg (green bars), or 200 μg (purple bars), and analyzed by ICP-AES for the 
levels of various elements.  Mg (magnesium), Ca (calcium), P (phosphorus), Na (sodium), 
Fe (iron), Zn (zinc), Cu (copper).  Data is the mean of 4 mice per group.  Error bars 
represent the standard error of the mean.  *p<0.008.  
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4.4 DISCUSSION 
4.4.1 Induction of Inflammatory Cytokines by CPE in a Mouse Model 
On a molecular level, a cell employs multiple mechanisms to undergo cell death depending on 
the stimuli exposed to the cell.  The various cell death pathways that have been described include 
apoptosis, oncosis, autophagy, and pyroptosis, among others (46, 97).  At a cellular level, the 
mechanism by which a cell undergoes cell death is important for controlling the inflammatory 
state of the environment.  In comparing apoptosis versus oncosis, a distinguishing characteristic 
of these two mechanisms is that apoptosis is non-inflammatory while oncosis is inflammatory.  
Multiple pathogens, including their products such as toxins, have been experimentally shown to 
induce apoptosis (54, 211).  However, more and more evidence is making it apparent that 
pathogens can also induce oncosis (4, 32, 55, 81, 149, 195, 227).  As many pathogens are 
reported to cause the induction of inflammatory cytokines in both cell culture and in animal 
models, it would not be surprising that oncosis is a common mechanism of cell death in 
infectious disease.   
Interestingly, CPE has been shown to induce both apoptosis and oncosis in a Caco-2 cell 
culture model (32).  As this was shown to be dependent upon toxin dose, CPE may induce 
inflammatory events at higher doses.  Prior studies demonstrated that treatment of human 
PBMCs in vitro with CPE elicited production of IL-6, however TNF-α, IFNγ, IL-1, and IL-2 
production was not detected (94).  We wished to determine the inflammatory cytokine profile in 
an in vivo mouse model.  Particularly, we were interested in measuring the local production of 
cytokines within the intestine, where CPE directly acts upon target cells.  A ligated ileal loop 
CPE challenge model was developed for this purpose.  This is in contrast to a previous study 
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looking at systemic cytokine production in the serum of mice challenged by the intraperitoneal 
(IP) and intragastric (IG) routes (210).  In our ileal loop model, we were able to detect significant 
levels of IL-1β and IL-6 production in homogenized intestinal tissue in response to CPE 
(Fig.4.1).  This induction of cytokines by CPE appears to be dose-dependent.  Further analysis of 
homogenized intestinal tissue at later time points is needed to determine the duration of this 
inflammatory response.  When intestinal fluid and serum were analyzed by Luminex for various 
cytokines, we did not observe any detectable levels of cytokines in either case.  Regarding the 
intestinal fluid, it may be that no significant amount of cytokines are secreted into the lumen as 
the only probable source would be epithelial cells.  Despite being able to produce pro-
inflammatory cytokines in response to various stimuli, we did not observe any detectable 
production of TNFα from supernatants of CPE-treated Caco-2 cells (data not shown).  Likewise, 
RT-PCR analysis of RNA extracted from CPE-treated Caco-2 cells did not show the production 
of IL-1β, IL-6, or TNFα (data not shown). 
CPE treatment of intestinal loops at high doses (100 μg and 200 μg) results in severe 
damage to the intestinal villi, leading to necrosis of the epithelial cells that compose the villi and 
the lamina propria that underlies the villi (Fig. 4.3, Table 4.3).  This high degree of tissue 
destruction is possibly a signal to inflammatory cells such as neutrophils to migrate to this area.  
Macrophages and monocytes are the primary sources for IL-1β production, however, dying cells 
can also produce this cytokine (176).  The IL-1β production we observe in the mouse intestine in 
response to CPE treatment may, therefore, be produced from neutrophils trafficking to the area 
or dying epithelial cells themselves.  Further experiments are required to distinguish between 
these possible sources of this cytokine. 
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Alarmins are a recently identified class of molecules, equivalent to pathogen-associated 
molecular patterns (PAMPs), which mediate signals to alert the body of tissue and cell damage 
(14).  HMBG1 is the best-characterized alarmin, and is produced by dying cells and by 
macrophages that have been exposed to factors such as LPS, TNFα, or IL-1.  HMGB1 is 
normally found within the nucleus, but cells undergoing non-apoptotic death (necrosis, possibly 
oncosis) passively release HMBG1 into the extracellular milieu, whereas those undergoing 
apoptotic death do not release HMGB1 (170).  HMGB1 mediates endothelial cell activation, 
angiogenesis, stem cell migration, and recruitment and activation of innate immune effectors 
(112).  Interestingly, although apoptotic cells do not release HMGB1, macrophages that engulf 
them are induced to secrete HMGB1 (156).  Therefore, it seems as though clearance of a small 
amount of apoptotic cells is not inflammatory, but clearance of a large number of apoptotic cells 
could be (14).  It is plausible then to be able to detect both the apoptotic and oncotic forms of cell 
death observed in Caco-2 cells in our in vivo model.  In our mouse model, HMGB1 may be 
mediating some of the inflammatory events that are being observed.  HMGB1 may be involved 
in the secretion of IL-1 that we detected, as shown below (Fig. 4.13), where dying cells may be 
releasing either IL-1 or HMGB1, and in turn, either IL-1 or the dying cells themselves are 
activating macrophages to produce HMGB1.  Analysis of intestinal loop tissue and fluid for the 
presence of HMGB1 would prove to be an interesting next step in characterizing the 
inflammatory response in our model.  HMGB1 release from CPE-treated Caco-2 cells could also 
be investigated. 
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Figure 4.13  Possible Mechanism of HMBG1 Production 
 
In human type A diseases, CPE is not the only C. perfringens toxin that may be 
contributing to disease, e.g. beta2 toxin may also be involved in AAD cases (47).  Furthermore, 
CPE is probably not the only C. perfringens bacterial product encountered by the host.  Many 
toxins and enzymes produced by C. perfringens, and particularly lipoteichoic acid (LTA) (38), 
could be immunostimulatory.  Therefore, to obtain a comprehensive picture of the innate 
immune events occurring during type A food poisoning, it may be prudent to use bacterial 
lysates or sporulating cultures to supplement this current study. 
4.4.2 In Vivo CPE Complex Formation 
Previous studies have examined the ability of CPE to bind to the intestinal epithelium in 
association with histological damage in rabbit animal models (183) and the human colon (45).  
These studies have demonstrated direct CPE binding to the intestine, however, binding is not 
sufficient to cause cytotoxicity in cell culture models (122, 126), and presumably histological 
damage in vivo.  Formation of the CPE-containing pore complexes (CH-1, and possibly CH-2) is 
necessary to induce the permeability alterations associated with the cytotoxicity of CPE action 
(122).  The CH-1 and CH-2 complexes are large, SDS-resistant complexes formed on target 
membranes in various cell culture models ((178), Fig. 4.9) and migrate at ~155 kDa and ~200 
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kDa, respectively, on SDS-PAGE.  Formation of the CH-1 and CH-2 complexes has never been 
demonstrated in vivo prior to this current study.  When intestinal tissue from CPE-treated mouse 
ileal loops were homogenized and analyzed by SDS-PAGE and Western blotting (Fig. 4.2A), we 
were able to show, for the first time, the formation of high molecular weight CPE-containing 
complexes that were comparable in size to the CH-1 and CH-2 complexes that are observed in 
Caco-2 cells.  There are small size difference between these instances and the difference of the 
complexes may be attributed to the access of CPE to various claudins in vivo.  Additionally, 
claudin expression may be altered between normal intestinal tissue and that of Caco-2 cells, an 
immortalized cancer cell line.  It is firmly established that claudins, particularly the CPE 
receptors, claudin-3 and -4, are overexpressed in cancers (89).  Expression levels of claudin-1,-
2,-3, and -4 and occludin are fairly consistent throughout the small intestine (75), whereas other 
claudins are quite variable in their expression along the intestine (51).  Furthermore, the 
similarity between human claudins and mouse claudins is quite high (~90%), and importantly, 
they share the same important motif for binding of CPE (FYNP for binding-capable cldn-3 and -
4, or FYDP for non-binding cldn-1 and -2 (157, 215)) (Fig. 4.14).   
However, it is not as though CPE cannot form toxin complexes, such as CH-1 and CH-2 
as observed in Caco-2 cells, when in contact with mouse intestinal cells.  We were able to 
demonstrate that CPE treatment of cells isolated from homogenized intestinal tissue from 
untreated mice results in the formation of the CH-1 complex (Fig. 4.2B), although no observable 
CH-2 formation was seen.  This suggests that mouse intestinal epithelia express the necessary 
proteins required for formation of the CH-1 complex.  Interestingly, early studies examining the 
molecular interactions of CPE with target cells, utilized brush border membranes (BBMs) 
isolated from rabbit intestines (217).  When treated with CPE, BBMs form the CH-1 complex 
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but do not form the CH-2 complex (182).  It is interesting to note that the procedure for isolating 
BBMs is very similar to that which was utilized for obtaining intestinal cells from the mice in 
this study.  Furthermore, when Caco-2 cells are grown as fully polarized monolayers in 
Transwell filters, formation of the CH-2 requires more extended CPE treatment times (Fig. 2.7, 
(178)).  Therefore, one must consider whether the formation of the CH-2 complex actually 
occurs in vivo when cells are in a fully differentiated and polarized state within a three-
dimensional tissue, or if the formation of this complex is merely an artefact of CPE treatment of 
cancerous Caco-2 cells in an unpolarized state. 
 126 
         
 127 
Figure 4.14  Sequence Alignment of Human and Mouse Claudins.   
Protein sequence alignment of human and mouse claudins shows >90% identity exists 
between species for cldn-1, -2, and -3 and >80% for cldn-4.  Yellow box highlights 
the motif shown to be important for CPE binding (FYxP, where x is an N for binding 
claudins or a D or S for non-binding claudins).  Alignment performed with SIM 
Alignment Tool accessed from ExPASy. 
 
4.4.3 Mouse Lethality Correlates with Histological Damage 
The ileal loop model was established long ago as a model for investigating the effects of CPE 
action (39).  The histopathological effects seen with CPE treatment include blunting of the villi 
tips and desquamation of the epithelial layer (125).  Secondly, CPE-induced permeability 
alterations result in the loss of fluid absorption and cause secretion of fluid into the intestinal 
lumen.  Fluid accumulation can be easily measured and is a common metric for the degree of 
CPE damage.  Rabbit ileal loops are the most commonly used model for investigating CPE 
action, however, a mouse ileal loop model was needed to assess the inflammatory response as 
discussed above.  Mouse ileal loops have only been used once to assess CPE action (220), and 
we needed to establish this model for ourselves.  CPE-treatment of mouse ileal loops resulted in 
dose- and time-dependent histopathologic damage that mimics what is observed in the rabbit 
(Figs. 4.3 and 4.4, and Table 4.3).  When employing rabbit ileal loops, death of the animals is 
rarely seen.  However, we observed a high rate of lethality in mice treated with 100 μg and 200 
μg of CPE (Table 4.1 and Fig. 4.11), particularly after 3-4 h of CPE treatment.  The degree of 
histologic damage correlated with the rate of lethality that was observed.  Interestingly, we did 
not observe detectable changes in fluid accumulation in the loops of treated mice as compared to 
control (data not shown).  The reason behind this lack of fluid accumulation is not known.  It 
may be that the damage to the intestinal epithelia is too rapid for passive fluid accumulation to 
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occur.  It was shown, however, that histologic damage induced by CPE treatment is necessary for 
lethality because neutralization of CPE with a monoclonal antibody prior to injection into the 
ileal loop prevented death of mice at the highest 200 μg dose (Table 4.2). 
4.4.4 Lethality is Associated with CPE in the Circulation 
Not only does neutralization of CPE in the intestinal loop prevent lethality of mice, but so does 
passive immunization, i.e. IV administration of a neutralization monoclonal antibody prior to 
intestinal loop challenge with CPE (Table 4.2).  The results from this experiment suggest that 
CPE is gaining access to the blood, and that neutralization of CPE within the circulation is 
sufficient to reverse the lethality that is observed.  This was further proven by ELISA analysis of 
serum collected from control and CPE-treated mice (Fig. 4.6), where significant amounts of CPE 
was detected  in  the serum of mice with  loops treated  with  200  μg of CPE.   Far less CPE was 
detected in mice that received the 50 μg dose, and an even lower dose of 15 μg did not produce 
any detectable levels of CPE within the serum (Fig. 4.6).  Intriguingly, despite very little 
intestinal damage by the 50 μg dose (Fig. 4.3), some CPE was detected in the blood.  In fact, it 
must be noted that the percentage of total CPE administered that was present in the blood for the 
lower 50 μg dose was greater than the 200 μg dose (0.6% vs. 0.4%).  This suggests that severe 
damage might not be entirely required for CPE to gain access to the circulation.  Many studies 
are investigating CPE as a tool for drug delivery, and have shown that non-toxic CPE fragments 
are capable of increasing intestinal permeability simply by interacting with claudins in the tight 
junctions (93, 201).  Perhaps there is a threshold at lower concentrations of toxin where fully 
active CPE can initiate permeability alterations without causing severe damage. 
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The association between CPE within the circulation and mouse lethality is suggestive of 
an enterotoxemia.  Enterotoxemias are common diseases in animals caused by C. perfringens.  
Type C strains of C. perfringens cause severe and often fatal diseases in humans and animals.  
Deaths attributed to type C infections are most often due to enterotoxemias where toxins are 
produced in the intestine and subsequently absorbed into the circulation (186).  It has been 
demonstrated that CPB toxin is the major virulence determinant in type C disease (169, 207) and 
lethality (202).  Interestingly, in the recently developed model for type C enterotoxemia, lethality 
is observed in the absence of any marked intestinal damage even though severe necrotizing 
enteritis is normally observed in animals that die from entertoxemias (202), which is in contrast 
to what we observe in this current CPE lethality model where we are able to mimic both the 
intestinal and systemic effects of CPE lethal disease (19). 
4.4.5 Access to the Blood Allows for CPE Binding to Other Organs 
One result of the ability of CPE to gain access to the blood after severe tissue destruction in the 
intestine is to allow CPE binding to other organs besides the intestine.  We show that CPE can 
bind to the livers and kidneys of mice challenged with high toxin doses (Fig. 4.8).  Additionally, 
homogenized control liver and kidney tissue was treated with CPE in cell suspensions and the 
formation of the CH-1 complex was detected in these cells (Fig. 4.8).  The ability of CPE to bind 
to liver and kidney is not surprising since claudin expression is relatively high in these tissues 
(37).  In addition, we demonstrated that MDCK cells are quite sensitive to CPE treatment, and 
can form both CH-1 and CH-2 complexes (Fig. 4.9).  Also of note is that hepatitis C virus, a 
virus that targets the liver, uses claudin-1 as a receptor for entry into hepatocytes (43), and can 
utilize other claudins as co-receptors (128, 226), further supporting the expression of claudins 
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within the liver.  Similar to isolated intestinal cells (Fig. 4.2), no formation of the CH-2 complex 
was detected in liver or kidney CPE-treated cells.  This again brings up the issue of the CH-2 
complex as discussed above.  Immunohistochemistry and histological analyses of liver and 
kidney tissue are ongoing to determine where CPE binding is occurring in these organs, and to 
determine the extent of damage to these tissues due to CPE binding. 
The mechanism by which CPE gains access to the bloodstream is not known at the 
present time.  CPE treatment of endothelial HUVEC cells did not result is any observable 
cytotoxicity or binding (Fig. 4.7, data not shown), suggesting this is not a plausible mechanism.  
Previous studies have shown, however, that CPE has capillary permeability and vasodilatation 
activities (144, 188).  Claudin expression in HUVEC cells is not well-characterized, and claudin-
5, a non-receptor for CPE, seems to be the only claudin identified as being expressed in these 
cells (49, 159).  Western blot analysis of HUVEC cell lysates showed no presence of claudin-1 
or -4 (data not shown).  Claudin expression may be quite different in the endothelial cells that 
line the intestinal microvasculature, so the binding capability and cytotoxicity of other types of 
endothelial cells should be investigated.  More likely, CPE is gaining access to the blood simply 
due to the overwhelming tissue destruction in the intestine, where the underlying 
microvasculature is becoming exposed.  Specifically, the portal vein system connects the GI tract 
directly to the liver, which would explain the abundance of CPE binding to this organ. 
4.4.6 Hyperpotassemia Plays a Role in Lethality 
As mentioned above, IV injection of CPE into animals results in binding to the liver and kidneys 
and elevated levels of potassium in the blood which results in cardiac dysfunction and eventually 
respiratory depression and death (180, 189).  Because we were observing a high degree of toxin 
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binding to the liver of dying mice, we analyzed the levels of potassium in the serum of these 
mice.  We found both a dose- and time-dependent increase in potassium with lethal levels 
(normal levels: 4-6 mM, lethal levels: >7 mM) being reached at 2 h for the 200 μg dose mice and 
3 h for the 100 μg dose group (Fig. 4.10).  Both of these time points just precede the drastic drop 
in survival of the mice in each group (Fig 4.11) which suggests a cause and effect relationship.  
Based on the previous study documenting CPE-induced hyperpotassemia (189), it is 
hypothesized that the source of the elevated levels of potassium in this study is from the liver.  
Liver function tests, such as measuring the serum levels of alanine transaminase and aspartate 
transaminase (25), are needed to confirm this suggestion.   
4.4.7 A Model for CPE Lethality in Humans? 
The current study has developed a novel mouse model of CPE lethality where intestinal 
challenge with CPE mimics some of the characteristics of IV CPE challenge, such as liver 
targeting and hyperpotassemia.  More importantly, the model developed here mimics the case 
reports of deaths associated with type A food poisoning (19, 155) both experimentally (i.e. 
ligation of the intestine to model constipation) and histopathologically (i.e. necrosis of the 
intestine, Fig. 4.5).  In this regard, intestinal challenge that results in lethality due to absorption 
of toxin from the GI tract to systemic circulation, more closely models a real-life scenario in 
humans, as opposed to IV injection.  Although intestinal ligation can be considered as the 
extreme model of constipation, it would be interesting to administer to mice the drugs 
individuals were reported to be taking that resulted in the constipation and was attributed to their 
deaths.  Since we are able to delineate between a lethal CPE dose (200 μg) and one that is not 
lethal (50 μg), in addition to study lethality as an endpoint, we are able to investigate why CPE 
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rarely results in death in humans.  Moreover, this model lends itself to investigation of the 
involvement of innate immune responses in CPE action in vivo, as discussed above.  Finally, this 
model can prove to be a valuable tool in modeling other toxins in which complications of 
enterotoxemias can occur. 
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5.0  FINAL SUMMATION 
C. perfringens type A food poisoning is a significant contributor to bacterial foodborne-related 
illness in the US.  Type A food poisoning is the result of contamination of food products by 
CPE-producing C. perfringens isolates.  CPE has a complex and unique mechanism of action 
that involves close association with proteins in the membranes of target cells resulting in the 
formation of a series of toxin complexes on the surface of cells.  These interactions ultimately 
results in the demise of the cell that encountered the CPE insult.  Understanding the intimate 
associations between CPE and intestinal epithelial cells can help to provide better therapies for 
CPE-related diseases.  With this in mind, three Specific Aims were stated at the start of this 
dissertation to investigate the mechanisms in which CPE interacts with target cells and elicits 
host responses.  These proposed aims were i) to investigate the role of lipid rafts in the molecular 
mechanism of action of CPE, ii) to develop a method for CPE complex isolation and 
compositional analysis by mass spectrometry, and iii) to develop and characterize a mouse model 
of CPE-induced inflammation and lethality.   
The research presented in this dissertation directly addresses the questions proposed in 
the Specific Aims.  First, the data presented here clearly indicates that CPE is a novel pore-
forming toxin which does NOT require lipid rafts for its action.  To this date, there are no other 
reports of other bacterial toxins where lipid rafts do not play a role in toxin action.  Binding, 
oligomerization, and cytotoxicity are all steps in the mechanism of CPE that do not appear to 
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rely on membrane rafts.  This lipid raft study provides evidence for the non-raft-association of 
the CPE-receptor, claudin, as well.  CPE treatment and complex formation results in the removal 
of occludin from raft domains. 
Secondly, significant effort has been devoted to establishing a valuable method for 
purification of the CH-1 and CH-2 complexes.  This was accomplished by the using a two-step 
method incorporating electroelution and immunoprecipitation in tandem.  Despite the inability to 
obtain usable MS data in this current study, this method can prove to be useful in future 
endeavors where the purification of large protein complexes is necessary.  Antibody experiments 
revealed that other tight junction proteins such as JAM-A and MUPP1 are not present in the CPE 
complexes.  However, experiments did demonstrate that multiple claudins are most likely 
associated with CPE complexes. 
Lastly, a mouse intestinal loop model has been developed which allows for the study of 
CPE-induced inflammation and lethality.  Inflammatory cytokines were shown to be produced in 
response to CPE-induced intestinal damage.  This mouse model lends itself to the design of 
future experiments investigating the in vivo innate immune responses of CPE.  CPE complex 
formation was also shown to occur in vivo.  This model helps to transition from in vitro work 
that has been done with CPE into an animal model.  The hope is to demonstrate that the 
mechanisms of CPE action elucidated in cell culture can be reproduced in vivo.  Additionally, the 
development of this model closely mimics the absorption of CPE from the intestine into the 
circulation that is seen in some instances of death associated with type A food poisoning. 
A unifying theme of these 3 Aims is the ability of CPE to form toxin complexes on the 
membrane of target cells dictates cell death.  The data presented in Aim 1 illustrates the unique 
toxin-host interactions at play in the mechanism of action of CPE.  It appears that the formation 
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of the CH-1 and CH-2 complexes does not involve an elegant mechanism in which specialized 
microdomains (lipid rafts) are required.  Importantly, the ability to form pore complexes is 
mediated by the ability of CPE to bind target cells via claudin.  Because claudins are mainly 
localized to non-raft domains, the formation of CPE oligomers occurs independently of lipid 
rafts.  An important distinction between CPE and many other pore-forming toxins that require 
lipid rafts for their action is that CPE binds to an identified proteinaceous receptor.  For example, 
the CDC toxin family binds cholesterol and aerolysin binds to the GPI-anchor of proteins, both 
of which are enriched in raft domains.  Furthermore, CPE is the only PFT that has been 
demonstrated to have its protein receptor associated with its toxin oligomer.  This was further 
examined in Aim 2 where it was apparent that only claudins may be present in the CH-1 
complex.  These observations regarding claudin illustrate how claudin expression drives the 
complex formation and the action of CPE. 
Despite demonstrating a correlation between cytotoxicity and enterotoxicity, where toxin 
mutants that are non-cytotoxic in cell culture also do not elicit damage in vivo, CPE complex 
formation has never been demonstrated to occur in vivo prior to the research presented here.  
Additionally, a rCPE mutant (TM1), in which the putative transmembrane stem domain has been 
deleted, is non-cytotoxic to Caco-2 cells, yet can still form CPE oligomers in a pre-pore state.  
To fully correlate in vivo complex formation with the ability to cause damage to the intestinal 
epithelium, it would be interesting to determine if the TM1 mutant also forms the pre-pore 
complex when administered in an animal model.  In addition to demonstrating complex 
formation in the intestinal tissue of CPE-treated mice, we also showed the ability of CPE to bind 
and form high molecular weight complexes in livers and kidneys.  In all three instances 
(intestine, liver, and kidney) the sizes of the CPE complexes were somewhat different that what 
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is observed in CPE-treated Caco-2 cells.  Using the EE/IP procedure established in Aim 2, 
followed by MS analysis, would be an advantageous way to determine the compositional 
differences between the complexes that form in Caco-2 cells and those that form in tissues of 
mice.  
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Table 1:  MS Analysis of CH-1 (Trypsin) 
 
Human 
      
  Reference     P (pro) Score Coverage MW 
  Scan(s) Peptide MH+ P (pep) XC DeltaCn Sp 
1 Gene_Symbol=RRBP1 Isoform 3 of Ribosome-binding protein 1 
  
5.92E-05 10.21 
 
152470.8 
 
927 - 934 R.DALNQATSQVESK.Q 1391.46643 5.92E-05 4.25 0.61 1681.1 
        
 
C. perfringens 
      
  Reference     P (pro) Score Coverage MW 
  Scan(s) Peptide MH+ P (pep) XC DeltaCn Sp 
1 
ELTB_CLOPE RecName: Full=Heat-labile enterotoxin B chain; 
Flags: Precursor 
  
1.00E+00 20.20 
 
35330.2 
 
662 
K.TSADSLGNIDQGSLIETGE
R.C 2064.15405 1.00E+00 4.09 0.51 1848.4 
 
1091 - 1442 K.EVFLISEDLK.T 1193.37109 1.00E+00 2.79 0.22 900.1 
2 
chromosome segregation protein SMC [Clostridium perfringens 
SM101] 
  
1.00E+00 10.12 
 
136081.2 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
str. 13] 
  
1.00E+00 10.12 
 
136009.2 
3 948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
ATCC 13124] 
  
1.00E+00 10.12 
 
136141.4 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
4 
chromosome segregation protein SMC [Clostridium perfringens 
ATCC 13124] 
  
1.00E+00 10.12 
 
136141.4 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
D str. JGS1721] 
  
1.00E+00 10.12 
 
136056.2 
5 948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
NCTC 8239] 
  
1.00E+00 10.12 
 
136018.2 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
6 
chromosome segregation protein SMC [Clostridium perfringens 
NCTC 8239] 
  
1.00E+00 10.12 
 
136018.2 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
D str. JGS1721] 
  
1.00E+00 10.12 
 
136056.2 
7 948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
CPE str. F4969] 
  
1.00E+00 10.12 
 
136120.3 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
8 
chromosome segregation protein SMC [Clostridium perfringens 
B str. ATCC 3626] 
  
1.00E+00 10.12 
 
136124.4 
 
948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
chromosome segregation protein SMC [Clostridium perfringens 
CPE str. F4969] 
  
1.00E+00 10.12 
 
136120.3 
9 948 - 952 -.YKDKLTNM*K.- 1157.36548 1.00E+00 2.32 0.08 641.0 
 
CLPB_CLOPE RecName: Full=Chaperone protein clpB 
  
1.00E+00 10.10 
 
97938.3 
 
1107 -.AELDEARGLAEK.- 1302.41602 1.00E+00 2.08 0.28 839.3 
10 phosphoesterase [Clostridium perfringens str. 13] 
  
9.98E-01 10.10 
 
31171.1 
 
847 - 854 -.VKVNILGMFEKPK.- 1503.87756 9.98E-01 2.08 0.02 342.1 
11 
phage minor structural protein [Clostridium perfringens CPE str. 
F4969] 
  
1.00E+00 10.10 
 
111405.4 
 
944 - 947 -.IVYEKYIEFSNLKFK.- 1922.25513 1.00E+00 2.00 0.04 163.9 
12 helicase [Clostridium perfringens D str. JGS1721] 
  
1.00E+00 8.11 
 
112032.2 
 
1091 - 1442 -.VKSFKNIDLK.- 1192.43274 1.00E+00 2.18 0.31 425.2 
13 
sensory box protein/histidinol phosphate phosphatase family 
protein [Clostridium perfringens SM101] 
  
1.00E+00 8.11 
 
73070.8 
 
948 - 952 K.YIKCIKEFL.- 1157.45020 1.00E+00 2.14 0.16 854.6 
14 
glycerophosphoryl diester phosphodiesterase family protein 
[Clostridium perfringens ATCC 13124] 
  
9.98E-01 8.10 
 
27579.5 
 
847 - 854 -.LNVDIKLGVLYEK.- 1504.79578 9.98E-01 2.04 0.07 581.3 
15 beta-galactosidase [Clostridium perfringens SM101] 
  
1.00E+00 8.10 
 
92534.2 
 
662 
-
.SM*NKLEVTPDNLELSLDK. 2063.31579 1.00E+00 2.02 0.52 351.2 
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Table 2:  BSA (Trypsin) 
  Reference     P (pro) Score Coverage MW 
  Scan(s) Peptide MH+ P (pep) XC DeltaCn Sp 
1 Gene_Symbol=ALB Serum albumin 
  
2.32E-06 160.30 26.60 69513.3 
 
383 - 391 K.LVTDLTK.V 789.94010 1.00E+00 1.80 0.27 561.5 
 
384 - 407 K.CCTESLVNR.R 1025.18585 5.27E-01 2.03 0.22 734.8 
 
434 - 438 K.AEFVEVTK.L 923.04499 3.22E-02 2.36 0.05 655.3 
 
439 - 442 R.FKDLGEEHFK.G 1250.38445 3.78E-03 4.30 0.30 2524.6 
 
440 K.AEFVEVTK.L 923.04499 1.82E-01 1.88 0.01 575.5 
 
443 - 644 K.AEFVEVTK.L 923.04499 2.96E-01 2.04 0.12 889.7 
 
447 - 450 R.FKDLGEEHFK.G 1250.38445 7.03E-03 3.25 0.29 1172.5 
 
555 - 562 K.YLYEIAR.R 928.06646 6.33E-02 2.00 0.00 238.1 
 
563 - 566 K.HLVDEPQNLIK.Q 1306.49269 2.32E-01 2.58 0.28 530.7 
 
570 - 582 K.YLYEIAR.R 928.06646 3.08E-01 2.62 0.00 542.1 
 
595 - 600 K.LVVSTQTALA.- 1003.17478 3.16E-02 2.41 0.41 677.9 
 
604 - 606 R.KVPQVSTPTLVEVSR.S 1640.90605 1.46E-04 4.25 0.42 1695.0 
 
607 - 610 R.KVPQVSTPTLVEVSR.S 1640.90605 9.74E-03 3.99 0.54 970.0 
 
622 - 626 R.RHPEYAVSVLLR.L 1440.67507 4.46E-05 4.99 0.48 2743.2 
 
623 - 627 R.RHPEYAVSVLLR.L 1440.67507 2.32E-06 3.91 0.50 1339.3 
 
651 - 654 K.VPQVSTPTLVEVSR.S 1512.73313 2.85E-06 3.27 0.52 1352.4 
 
672 - 1683 K.LVNELTEFAK.T 1164.33301 2.84E-02 3.11 0.32 731.3 
 
676 - 980 K.LVNELTEFAK.T 1164.33301 1.00E+00 2.17 0.20 546.1 
 
750 - 763 K.LGEYGFQNALIVR.Y 1480.69283 3.33E-04 4.69 0.53 1596.9 
 
755 - 831 R.RHPYFYAPELLYYANK.Y 2046.31490 3.19E-06 5.92 0.59 2345.1 
 
756 - 759 R.RHPYFYAPELLYYANK.Y 2046.31490 4.69E-04 5.57 0.62 1577.8 
 
811 - 814 R.HPYFYAPELLYYANK.Y 1890.12854 2.60E-03 3.79 0.59 653.5 
 
874 - 1594 K.DAFLGSFLYEYSR.R 1568.71057 1.92E-04 4.63 0.48 1681.4 
 
880 - 883 K.DAFLGSFLYEYSR.R 1568.71057 1.00E+00 2.36 0.31 158.9 
 
958 - 964 K.GLVLIAFSQYLQQCPFDEHVK.L 2436.81362 1.76E-02 3.52 0.51 750.1 
 
1680 - 1815 K.YLYEIAR.R 928.06646 6.78E-01 2.32 0.00 425.5 
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Table 3:  CPE (Trypsin) 
  Reference     P (pro) Score Coverage MW 
  Scan(s) Peptide MH+ P (pep) XC DeltaCn Sp 
1 enterotoxin [Clostridium perfringens] 
  
2.41E-09 196.40 
 
35330.2 
 
243 - 398 K.LEQSLGDGVK.D 1046.15649 9.95E-01 2.46 0.37 718.8 
 
283 - 287 K.LEQSLGDGVK.D 1046.15649 1.00E+00 2.15 0.25 499.2 
 
426 - 490 R.ISHGNISDDGSIYK.L 1506.59912 1.44E-08 4.06 0.54 1778.0 
 
530 - 626 R.SSNSYPWTQK.L 1198.26636 2.30E-03 2.50 0.36 660.9 
 
543 - 546 R.SSNSYPWTQK.L 1198.26636 9.20E-02 1.52 0.18 261.9 
 
575 - 1024 R.SVSTTAGPNEYVYYK.V 1679.80811 2.48E-05 5.04 0.49 1000.8 
 
592 R.SVSTTAGPNEYVYYK.V 1679.80811 3.00E-02 2.49 0.49 453.5 
 
595 - 600 R.SVSTTAGPNEYVYYK.V 1679.80811 3.54E-02 2.20 0.41 311.2 
 
639 - 644 R.C#VLTVPSTDIEK.E 1362.57458 9.21E-01 2.10 0.12 462.9 
 
662 - 1092 -.M*LSNNLNPM*VFENAK.E 1755.00973 1.17E-03 5.94 0.48 1482.0 
 
671 - 1200 K.TSADSLGNIDQGSLIETGER.C 2064.15405 8.95E-08 5.46 0.61 1249.8 
 
675 - 988 K.TSADSLGNIDQGSLIETGER.C 2064.15405 4.98E-09 5.60 0.57 1513.1 
 
680 K.LNLHLTITATGQK.Y 1410.64404 3.49E-05 3.58 0.44 1007.0 
 
698 - 706 K.EILDLAAATER.L 1202.33960 1.50E-01 3.44 0.54 1829.7 
 
699 - 735 -.MLSNNLNPM*VFENAK.E 1739.01033 3.92E-05 5.04 0.26 1008.5 
 
699 - 735 -.M*LSNNLNPMVFENAK.- 1739.01033 6.31E-01 2.95 0.51 438.4 
 
703 - 707 K.EILDLAAATER.L 1202.33960 8.76E-01 1.51 0.22 157.7 
 
710 - 1224 K.LTGIWLSK.T 918.11469 1.37E-01 2.75 0.37 439.0 
 
711 - 715 K.LTGIWLSK.T 918.11469 1.00E+00 1.99 0.30 467.5 
 
752 - 1055 K.TPINITNSNSNLSDGLYVIDK.G 2279.48950 5.93E-09 5.31 0.65 1758.6 
 
780 - 1339 K.EVFLISEDLK.T 1193.37109 2.02E-01 2.70 0.25 829.0 
 
783 - 1004 K.EVFLISEDLK.T 1193.37109 1.01E-01 2.99 0.15 734.4 
 
822 - 1320 K.ANSSYSGNYPYSILFQK.- 1940.10107 1.43E-03 4.28 0.59 707.6 
 
823 - 827 K.ANSSYSGNYPYSILFQK.- 1940.10107 2.89E-02 5.27 0.53 1646.0 
 
831 - 1084 K.IVDFNIYSNNFNNLVK.L 1915.13794 4.01E-02 4.63 0.38 960.0 
 
847 - 852 K.IVDFNIYSNNFNNLVK.L 1915.13794 9.73E-01 5.26 0.36 1458.3 
 
858 - 1208 R.LNLTDALNSNPAGNLYDWR.S 2148.32080 2.41E-09 6.30 0.65 2276.4 
 
859 - 1062 R.LNLTDALNSNPAGNLYDWR.S 2148.32080 6.40E-02 5.44 0.46 1756.6 
 
915 K.IVDFNIYSNNFNNLVK.L 1915.13794 1.51E-02 3.01 0.49 603.4 
 
922 - 926 K.GDGWILGEPSVVSSQILNPNETGTFSQSLTK.S 3263.55713 1.40E-07 8.06 0.55 3590.7 
 
932 K.TSADSLGNIDQGSLIETGER.C 2064.15405 1.74E-02 2.93 0.53 648.3 
 
942 - 946 K.ANSSYSGNYPYSILFQKF.- 2087.27588 3.31E-05 4.28 0.58 726.2 
 
944 - 948 K.ANSSYSGNYPYSILFQKF.- 2087.27588 4.33E-02 4.22 0.43 954.2 
 
958 K.ANSSYSGNYPYSILFQK.- 1940.10107 4.42E-01 2.85 0.55 526.1 
 
1010 - 1014 R.C#VLTVPSTDIEKEILDLAAATER.L 2545.89162 4.95E-02 3.36 0.46 517.9 
 
1030 - 1052 K.ANSSYSGNYPYSILFQK.- 1940.10107 1.27E-02 3.23 0.59 667.3 
 
1095 K.TSADSLGNIDQGSLIETGER.C 2064.15405 2.59E-02 3.03 0.47 744.6 
 
1188 - 1190 K.TPINITNSNSNLSDGLYVIDK.G 2279.48950 2.79E-06 5.42 0.62 1858.3 
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1258 K.ANSSYSGNYPYSILFQK.- 1940.10107 1.58E-04 2.88 0.56 615.9 
 
1467 R.LNLTDALNSNPAGNLYDWR.S 2148.32080 1.62E-01 2.98 0.57 458.0 
 
1475 K.IVDFNIYSNNFNNLVK.L 1915.13794 1.73E-01 2.70 0.46 800.4 
 
1516 - 1519 K.EVFLISEDLK.T 1193.37109 4.74E-01 2.96 0.11 878.6 
 
1556 - 1560 K.LTGIWLSK.T 918.11469 2.23E-02 2.19 0.45 446.9 
 
 142 
BIBLIOGRAPHY 
 
1. Abrami, L., S. H. Leppla, and F. G. van der Goot. 2006. Receptor palmitoylation and 
ubiquitination regulate anthrax toxin endocytosis. J Cell Biol 172:309-320. 
2. Adak, G. K., S. M. Long, and S. J. O'Brien. 2002. Trends in indigenous foodborne 
disease and deaths, England and Wales: 1992 to 2000. Gut 51:832-841. 
3. Agarwal, R., T. D'Souza, and P. J. Morin. 2005. Claudin-3 and claudin-4 expression in 
ovarian epithelial cells enhances invasion and is associated with increased matrix 
metalloproteinase-2 activity. Cancer Res 65:7378-7385. 
4. Agu, C. A., R. Klein, J. Lengler, F. Schilcher, W. Gregor, T. Peterbauer, U. Blasi, B. 
Salmons, W. H. Gunzburg, and C. Hohenadl. 2007. Bacteriophage-encoded toxins: the 
lambda-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic 
cells. Cell Microbiol 9:1753-1765. 
5. Al-Sadi, R., M. Boivin, and T. Ma. 2009. Mechanism of cytokine modulation of 
epithelial tight junction barrier. Front Biosci 14:2765-2778. 
6. Anderson, J. M., and C. M. Van Itallie. 2009. Physiology and function of the tight 
junction. Cold Spring Harb Perspect Biol 1:a002584. 
7. Asha, N. J., D. Tompkins, and M. H. Wilcox. 2006. Comparative analysis of 
prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea 
due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin 
Microbiol 44:2785-2791. 
8. Asha, N. J., and M. H. Wilcox. 2002. Laboratory diagnosis of Clostridium perfringens 
antibiotic-associated diarrhoea. J Med Microbiol 51:891-894. 
9. Awad, M. M., A. E. Bryant, D. L. Stevens, and J. I. Rood. 1995. Virulence studies on 
chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange 
provide genetic evidence for the essential role of alpha-toxin in Clostridium perfringens-
mediated gas gangrene. Mol Microbiol 15:191-202. 
10. Awad, M. M., D. M. Ellemor, R. L. Boyd, J. J. Emmins, and J. I. Rood. 2001. 
Synergistic effects of alpha-toxin and perfringolysin O in Clostridium perfringens-
mediated gas gangrene. Infect Immun 69:7904-7910. 
11. Balda, M. S., and K. Matter. 2008. Tight junctions at a glance. J Cell Sci 121:3677-
3682. 
12. Bartholomew, B. A., M. F. Stringer, G. N. Watson, and R. J. Gilbert. 1985. 
Development and application of an enzyme linked immunosorbent assay for Clostridium 
perfringens type A enterotoxin. J Clin Pathol 38:222-228. 
 143 
13. Beeman, N. E., H. K. Baumgartner, P. G. Webb, J. B. Schaack, and M. C. Neville. 
2009. Disruption of occludin function in polarized epithelial cells activates the extrinsic 
pathway of apoptosis leading to cell extrusion without loss of transepithelial resistance. 
BMC Cell Biol 10:85. 
14. Bianchi, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. 
J Leukoc Biol 81:1-5. 
15. Birkhead, G., R. L. Vogt, E. M. Heun, J. T. Snyder, and B. A. McClane. 1988. 
Characterization of an outbreak of Clostridium perfringens food poisoning by 
quantitative fecal culture and fecal enterotoxin measurement. J Clin Microbiol 26:471-
474. 
16. Borriello, S. P., F. E. Barclay, A. R. Welch, M. F. Stringer, G. N. Watson, R. K. 
Williams, D. V. Seal, and K. Sullens. 1985. Epidemiology of diarrhoea caused by 
enterotoxigenic Clostridium perfringens. J Med Microbiol 20:363-372. 
17. Borriello, S. P., H. E. Larson, A. R. Welch, F. Barclay, M. F. Stringer, and B. A. 
Bartholomew. 1984. Enterotoxigenic Clostridium perfringens: a possible cause of 
antibiotic-associated diarrhoea. Lancet 1:305-307. 
18. Borriello, S. P., and R. K. Williams. 1985. Treatment of Clostridium perfringens 
enterotoxin-associated diarrhoea with metronidazole. J Infect 10:65-67. 
19. Bos, J., L. Smithee, B. McClane, R. F. Distefano, F. Uzal, J. G. Songer, S. Mallonee, 
and J. M. Crutcher. 2005. Fatal necrotizing colitis following a foodborne outbreak of 
enterotoxigenic Clostridium perfringens type A infection. Clin Infect Dis 40:e78-83. 
20. Brett, M. M., J. C. Rodhouse, T. J. Donovan, G. M. Tebbutt, and D. N. Hutchinson. 
1992. Detection of Clostridium perfringens and its enterotoxin in cases of sporadic 
diarrhoea. J Clin Pathol 45:609-611. 
21. Briehl, M. M., and R. L. Miesfeld. 1991. Isolation and characterization of transcripts 
induced by androgen withdrawal and apoptotic cell death in the rat ventral prostate. Mol 
Endocrinol 5:1381-1388. 
22. Brown, D. A. 2006. Lipid rafts, detergent-resistant membranes, and raft targeting signals. 
Physiology (Bethesda) 21:430-439. 
23. Brown, D. A., and E. London. 1998. Functions of lipid rafts in biological membranes. 
Annu Rev Cell Dev Biol 14:111-136. 
24. Brown, D. A., and J. K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-
enriched membrane subdomains during transport to the apical cell surface. Cell 68:533-
544. 
25. Calvaruso, V., and A. Craxi. 2009. Implication of normal liver enzymes in liver disease. 
J Viral Hepat 16:529-536. 
26. Camacho, N., C. Espinoza, C. Rodriguez, and E. Rodriguez. 2008. Isolates of 
Clostridium perfringens recovered from Costa Rican patients with antibiotic-associated 
diarrhoea are mostly enterotoxin-negative and susceptible to first-choice antimicrobials. J 
Med Microbiol 57:343-347. 
27. Capaldo, C. T., and A. Nusrat. 2009. Cytokine regulation of tight junctions. Biochim 
Biophys Acta 1788:864-871. 
28. Carman, R. J., S. Sayeed, J. Li, C. W. Genheimer, M. F. Hiltonsmith, T. D. Wilkins, 
and B. A. McClane. 2008. Clostridium perfringens toxin genotypes in the feces of 
healthy North Americans. Anaerobe 14:102-108. 
 144 
29. Cascales, E., S. K. Buchanan, D. Duche, C. Kleanthous, R. Lloubes, K. Postle, M. 
Riley, S. Slatin, and D. Cavard. 2007. Colicin biology. Microbiol Mol Biol Rev 
71:158-229. 
30. Cato, E. P., W. L. George, and S. M. Finegold. 1984. Clostridium, p. 1141-1200. In P. 
H. A. Sneath, N. S. Mair, M. E. Sharpe, and J. G. Holt (ed.), Bergey's Manual of 
Systematic Bacteriology, vol. 2. Williams and Wilkins, Baltimore. 
31. Chakrabarti, G., and B. A. McClane. 2005. The importance of calcium influx, calpain 
and calmodulin for the activation of CaCo-2 cell death pathways by Clostridium 
perfringens enterotoxin. Cell Microbiol 7:129-146. 
32. Chakrabarti, G., X. Zhou, and B. A. McClane. 2003. Death pathways activated in 
CaCo-2 cells by Clostridium perfringens enterotoxin. Infect Immun 71:4260-4270. 
33. Collie, R. E., J. F. Kokai-Kun, and B. A. McClane. 1998. Phenotypic characterization 
of enterotoxigenic Clostridium perfringens isolates from non-foodborne human 
gastrointestinal diseases. Anaerobe 4:69-79. 
34. Collie, R. E., and B. A. McClane. 1998. Evidence that the enterotoxin gene can be 
episomal in Clostridium perfringens isolates associated with non-food-borne human 
gastrointestinal diseases. J Clin Microbiol 36:30-36. 
35. Cornillot, E., B. Saint-Joanis, G. Daube, S. Katayama, P. E. Granum, B. Canard, 
and S. T. Cole. 1995. The enterotoxin gene (cpe) of Clostridium perfringens can be 
chromosomal or plasmid-borne. Mol Microbiol 15:639-647. 
36. Czeczulin, J. R., P. C. Hanna, and B. A. McClane. 1993. Cloning, nucleotide 
sequencing, and expression of the Clostridium perfringens enterotoxin gene in 
Escherichia coli. Infect Immun 61:3429-3439. 
37. D'Souza, T., C. A. Sherman-Baust, S. Poosala, J. M. Mullin, and P. J. Morin. 2009. 
Age-related changes of claudin expression in mouse liver, kidney, and pancreas. J 
Gerontol A Biol Sci Med Sci 64:1146-1153. 
38. Draing, C., S. Sigel, S. Deininger, S. Traub, R. Munke, C. Mayer, L. Hareng, T. 
Hartung, S. von Aulock, and C. Hermann. 2008. Cytokine induction by Gram-positive 
bacteria. Immunobiology 213:285-296. 
39. Duncan, C. L., and D. H. Strong. 1969. Ileal loop fluid accumulation and production of 
diarrhea in rabbits by cell-free products of Clostridium perfringens. J Bacteriol 100:86-
94. 
40. Duraisamy, Y., D. Lambert, A. O'Neill C, and P. J. Padfield. 2007. Differential 
incorporation of docosahexaenoic acid into distinct cholesterol-rich membrane raft 
domains. Biochem Biophys Res Commun 360:885-890. 
41. Ebihara, C., M. Kondoh, M. Harada, M. Fujii, H. Mizuguchi, S. Tsunoda, Y. 
Horiguchi, K. Yagi, and Y. Watanabe. 2007. Role of Tyr306 in the C-terminal 
fragment of Clostridium perfringens enterotoxin for modulation of tight junction. 
Biochem Pharmacol 73:824-830. 
42. Ebihara, C., M. Kondoh, N. Hasuike, M. Harada, H. Mizuguchi, Y. Horiguchi, M. 
Fujii, and Y. Watanabe. 2006. Preparation of a claudin-targeting molecule using a C-
terminal fragment of Clostridium perfringens enterotoxin. J Pharmacol Exp Ther 
316:255-260. 
43. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wolk, T. 
Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a 
hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. 
 145 
44. Fernandez-Miyakawa, M. E., B. H. Jost, S. J. Billington, and F. A. Uzal. 2008. Lethal 
effects of Clostridium perfringens epsilon toxin are potentiated by alpha and 
perfringolysin-O toxins in a mouse model. Vet Microbiol 127:379-385. 
45. Fernandez Miyakawa, M. E., V. Pistone Creydt, F. A. Uzal, B. A. McClane, and C. 
Ibarra. 2005. Clostridium perfringens enterotoxin damages the human intestine in vitro. 
Infect Immun 73:8407-8410. 
46. Fink, S. L., and B. T. Cookson. 2005. Apoptosis, pyroptosis, and necrosis: mechanistic 
description of dead and dying eukaryotic cells. Infect Immun 73:1907-1916. 
47. Fisher, D. J., K. Miyamoto, B. Harrison, S. Akimoto, M. R. Sarker, and B. A. 
McClane. 2005. Association of beta2 toxin production with Clostridium perfringens type 
A human gastrointestinal disease isolates carrying a plasmid enterotoxin gene. Mol 
Microbiol 56:747-762. 
48. Fivaz, M., L. Abrami, Y. Tsitrin, and F. G. van der Goot. 2001. Aerolysin from 
Aeromonas hydrophila and related toxins. Curr Top Microbiol Immunol 257:35-52. 
49. Fontijn, R. D., J. Rohlena, J. van Marle, H. Pannekoek, and A. J. Horrevoets. 2006. 
Limited contribution of claudin-5-dependent tight junction strands to endothelial barrier 
function. Eur J Cell Biol 85:1131-1144. 
50. Francis, S. A., J. M. Kelly, J. McCormack, R. A. Rogers, J. Lai, E. E. Schneeberger, 
and R. D. Lynch. 1999. Rapid reduction of MDCK cell cholesterol by methyl-beta-
cyclodextrin alters steady state transepithelial electrical resistance. Eur J Cell Biol 
78:473-484. 
51. Fujita, H., H. Chiba, H. Yokozaki, N. Sakai, K. Sugimoto, T. Wada, T. Kojima, T. 
Yamashita, and N. Sawada. 2006. Differential expression and subcellular localization 
of claudin-7, -8, -12, -13, and -15 along the mouse intestine. J Histochem Cytochem 
54:933-944. 
52. Fujita, K., J. Katahira, Y. Horiguchi, N. Sonoda, M. Furuse, and S. Tsukita. 2000. 
Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a 
tight junction integral membrane protein. FEBS Lett 476:258-261. 
53. Furuse, M., H. Sasaki, and S. Tsukita. 1999. Manner of interaction of heterogeneous 
claudin species within and between tight junction strands. J Cell Biol 147:891-903. 
54. Gao, L., and Y. Abu Kwaik. 2000. Hijacking of apoptotic pathwaysby bacterial 
pathogens. Microbes Infect 2:1705-1719. 
55. Goldmann, O., I. Sastalla, M. Wos-Oxley, M. Rohde, and E. Medina. 2009. 
Streptococcus pyogenes induces oncosis in macrophages through the activation of an 
inflammatory programmed cell death pathway. Cell Microbiol 11:138-155. 
56. Gouaux, J. E., O. Braha, M. R. Hobaugh, L. Song, S. Cheley, C. Shustak, and H. 
Bayley. 1994. Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and 
on membranes: a heptameric transmembrane pore. Proc Natl Acad Sci U S A 91:12828-
12831. 
57. Granum, P. E. 1985. The effect of Ca++ and Mg++ on the action of Clostridium 
perfringens enterotoxin on Vero cells. Acta Pathol Microbiol Immunol Scand B 93:41-
48. 
58. Granum, P. E., and M. Richardson. 1991. Chymotrypsin treatment increases the 
activity of Clostridium perfringens enterotoxin. Toxicon 29:898-900. 
 146 
59. Granum, P. E., J. R. Whitaker, and R. Skjelkvale. 1981. Trypsin activation of 
enterotoxin from Clostridium perfringens type A: fragmentation and some 
physicochemical properties. Biochim Biophys Acta 668:325-332. 
60. Greber, U. F., and M. Gastaldelli. 2007. Junctional gating: the achilles' heel of 
epithelial cells in pathogen infection. Cell Host Microbe 2:143-146. 
61. Gu, J. M., S. O. Lim, Y. M. Park, and G. Jung. 2008. A novel splice variant of 
occludin deleted in exon 9 and its role in cell apoptosis and invasion. FEBS J 275:3145-
3156. 
62. Guillemot, L., S. Paschoud, P. Pulimeno, A. Foglia, and S. Citi. 2008. The 
cytoplasmic plaque of tight junctions: a scaffolding and signalling center. Biochim 
Biophys Acta 1778:601-613. 
63. Guttman, J. A., and B. B. Finlay. 2009. Tight junctions as targets of infectious agents. 
Biochim Biophys Acta 1788:832-841. 
64. Hale, M. L., J. C. Marvaud, M. R. Popoff, and B. G. Stiles. 2004. Detergent-resistant 
membrane microdomains facilitate Ib oligomer formation and biological activity of 
Clostridium perfringens iota-toxin. Infect Immun 72:2186-2193. 
65. Han, X., M. P. Fink, and R. L. Delude. 2003. Proinflammatory cytokines cause NO*-
dependent and -independent changes in expression and localization of tight junction 
proteins in intestinal epithelial cells. Shock 19:229-237. 
66. Hanna, P. C., T. A. Mietzner, G. K. Schoolnik, and B. A. McClane. 1991. 
Localization of the receptor-binding region of Clostridium perfringens enterotoxin 
utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids 
define a functional binding region. J Biol Chem 266:11037-11043. 
67. Hanna, P. C., E. U. Wieckowski, T. A. Mietzner, and B. A. McClane. 1992. Mapping 
of functional regions of Clostridium perfringens type A enterotoxin. Infect Immun 
60:2110-2114. 
68. Harada, M., M. Kondoh, C. Ebihara, A. Takahashi, E. Komiya, M. Fujii, H. 
Mizuguchi, S. Tsunoda, Y. Horiguchi, K. Yagi, and Y. Watanabe. 2007. Role of 
tyrosine residues in modulation of claudin-4 by the C-terminal fragment of Clostridium 
perfringens enterotoxin. Biochem Pharmacol 73:206-214. 
69. Harrison, B., D. Raju, H. S. Garmory, M. M. Brett, R. W. Titball, and M. R. Sarker. 
2005. Molecular characterization of Clostridium perfringens isolates from humans with 
sporadic diarrhea: evidence for transcriptional regulation of the beta2-toxin-encoding 
gene. Appl Environ Microbiol 71:8362-8370. 
70. Hartlova, A., L. Cerveny, M. Hubalek, Z. Krocova, and J. Stulik. 2010. Membrane 
rafts: a potential gateway for bacterial entry into host cells. Microbiol Immunol 54:237-
245. 
71. Hauschild, A. H., L. Niilo, and W. J. Dorward. 1970. Enteropathogenic factors of 
food-poisoning Clostridium perfringens type A. Can J Microbiol 16:331-338. 
72. Hauschild, A. H., L. Niilo, and W. J. Dorward. 1971. The role of enterotoxin in 
Clostridium perfringens type A enteritis. Can J Microbiol 17:987-991. 
73. Hauser, D., M. W. Eklund, P. Boquet, and M. R. Popoff. 1994. Organization of the 
botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium 
botulinum C 468. Mol Gen Genet 243:631-640. 
 147 
74. Heikinheimo, A., M. Lindstrom, P. E. Granum, and H. Korkeala. 2006. Humans as 
reservoir for enterotoxin gene--carrying Clostridium perfringens type A. Emerg Infect 
Dis 12:1724-1729. 
75. Holmes, J. L., C. M. Van Itallie, J. E. Rasmussen, and J. M. Anderson. 2006. Claudin 
profiling in the mouse during postnatal intestinal development and along the 
gastrointestinal tract reveals complex expression patterns. Gene Expr Patterns 6:581-588. 
76. Horiguchi, Y., T. Uemura, S. Kozaki, and G. Sakaguchi. 1986. Effects of Ca2+ and 
other cations on the action of Clostridium perfringens enterotoxin. Biochim Biophys Acta 
889:65-71. 
77. Hulkower, K. I., A. P. Wnek, and B. A. McClane. 1989. Evidence that alterations in 
small molecule permeability are involved in the Clostridium perfringens type A 
enterotoxin-induced inhibition of macromolecular synthesis in Vero cells. J Cell Physiol 
140:498-504. 
78. Iacovache, I., F. G. van der Goot, and L. Pernot. 2008. Pore formation: an ancient yet 
complex form of attack. Biochim Biophys Acta 1778:1611-1623. 
79. Itoh, M., M. Furuse, K. Morita, K. Kubota, M. Saitou, and S. Tsukita. 1999. Direct 
binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the 
COOH termini of claudins. J Cell Biol 147:1351-1363. 
80. Joshy, L., R. Chaudhry, B. Dhawan, L. Kumar, and B. K. Das. 2006. Incidence and 
characterization of Clostridium perfringens isolated from antibiotic-associated diarrhoeal 
patients: a prospective study in an Indian hospital. J Hosp Infect 63:323-329. 
81. Kalischuk, L. D., G. D. Inglis, and A. G. Buret. 2007. Strain-dependent induction of 
epithelial cell oncosis by Campylobacter jejuni is correlated with invasion ability and is 
independent of cytolethal distending toxin. Microbiology 153:2952-2963. 
82. Katahira, J., N. Inoue, Y. Horiguchi, M. Matsuda, and N. Sugimoto. 1997. Molecular 
cloning and functional characterization of the receptor for Clostridium perfringens 
enterotoxin. J Cell Biol 136:1239-1247. 
83. Kinugasa, T., T. Sakaguchi, X. Gu, and H. C. Reinecker. 2000. Claudins regulate the 
intestinal barrier in response to immune mediators. Gastroenterology 118:1001-1011. 
84. Knox, R., and E. K. MacDonald. 1943. Outbreaks of food poisoning in certain Leicester 
institutions. Medical Officer 69:21-22. 
85. Kohler, H., T. Sakaguchi, B. P. Hurley, B. J. Kase, H. C. Reinecker, and B. A. 
McCormick. 2007. Salmonella enterica serovar Typhimurium regulates intercellular 
junction proteins and facilitates transepithelial neutrophil and bacterial passage. Am J 
Physiol Gastrointest Liver Physiol 293:G178-187. 
86. Kokai-Kun, J. F., K. Benton, E. U. Wieckowski, and B. A. McClane. 1999. 
Identification of a Clostridium perfringens enterotoxin region required for large complex 
formation and cytotoxicity by random mutagenesis. Infect Immun 67:5634-5641. 
87. Kokai-Kun, J. F., and B. A. McClane. 1997. Deletion analysis of the Clostridium 
perfringens enterotoxin. Infect Immun 65:1014-1022. 
88. Kokai-Kun, J. F., and B. A. McClane. 1996. Evidence that a region(s) of the 
Clostridium perfringens enterotoxin molecule remains exposed on the external surface of 
the mammalian plasma membrane when the toxin is sequestered in small or large 
complexes. Infect Immun 64:1020-1025. 
89. Kominsky, S. L. 2006. Claudins: emerging targets for cancer therapy. Expert Rev Mol 
Med 8:1-11. 
 148 
90. Kominsky, S. L., P. Argani, D. Korz, E. Evron, V. Raman, E. Garrett, A. Rein, G. 
Sauter, O. P. Kallioniemi, and S. Sukumar. 2003. Loss of the tight junction protein 
claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive 
ductal carcinoma of the breast. Oncogene 22:2021-2033. 
91. Kominsky, S. L., B. Tyler, J. Sosnowski, K. Brady, M. Doucet, D. Nell, J. G. 
Smedley, 3rd, B. McClane, H. Brem, and S. Sukumar. 2007. Clostridium perfringens 
Enterotoxin as a Novel-Targeted Therapeutic for Brain Metastasis. Cancer Res 67:7977-
7982. 
92. Kominsky, S. L., M. Vali, D. Korz, T. G. Gabig, S. A. Weitzman, P. Argani, and S. 
Sukumar. 2004. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis 
of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J 
Pathol 164:1627-1633. 
93. Kondoh, M., A. Masuyama, A. Takahashi, N. Asano, H. Mizuguchi, N. Koizumi, M. 
Fujii, T. Hayakawa, Y. Horiguchi, and Y. Watanbe. 2005. A novel strategy for the 
enhancement of drug absorption using a claudin modulator. Mol Pharmacol 67:749-756. 
94. Krakauer, T., B. Fleischer, D. L. Stevens, B. A. McClane, and B. G. Stiles. 1997. 
Clostridium perfringens enterotoxin lacks superantigenic activity but induces an 
interleukin-6 response from human peripheral blood mononuclear cells. Infect Immun 
65:3485-3488. 
95. Kristan, K. C., G. Viero, M. Dalla Serra, P. Macek, and G. Anderluh. 2009. 
Molecular mechanism of pore formation by actinoporins. Toxicon 54:1125-1134. 
96. Kuske, C. R., S. M. Barns, C. C. Grow, L. Merrill, and J. Dunbar. 2006. 
Environmental survey for four pathogenic bacteria and closely related species using 
phylogenetic and functional genes. J Forensic Sci 51:548-558. 
97. Labbe, K., and M. Saleh. 2008. Cell death in the host response to infection. Cell Death 
Differ 15:1339-1349. 
98. Lafont, F., L. Abrami, and F. G. van der Goot. 2004. Bacterial subversion of lipid 
rafts. Curr Opin Microbiol 7:4-10. 
99. Lambert, D., C. A. O'Neill, and P. J. Padfield. 2005. Depletion of Caco-2 cell 
cholesterol disrupts barrier function by altering the detergent solubility and distribution of 
specific tight-junction proteins. Biochem J 387:553-560. 
100. Lambert, D., P. J. Padfield, J. McLaughlin, S. Cannell, and C. A. O'Neill. 2007. 
Ochratoxin A displaces claudins from detergent resistant membrane microdomains. 
Biochem Biophys Res Commun 358:632-636. 
101. Li, J., and B. A. McClane. 2006. Comparative effects of osmotic, sodium nitrite-
induced, and pH-induced stress on growth and survival of Clostridium perfringens type A 
isolates carrying chromosomal or plasmid-borne enterotoxin genes. Appl Environ 
Microbiol 72:7620-7625. 
102. Li, J., and B. A. McClane. 2006. Further comparison of temperature effects on growth 
and survival of Clostridium perfringens type A isolates carrying a chromosomal or 
plasmid-borne enterotoxin gene. Appl Environ Microbiol 72:4561-4568. 
103. Li, J., and B. A. McClane. 2008. A novel small acid soluble protein variant is important 
for spore resistance of most Clostridium perfringens food poisoning isolates. PLoS 
Pathog 4:e1000056. 
104. Li, J., K. Miyamoto, and B. A. McClane. 2007. Comparison of virulence plasmids 
among Clostridium perfringens type E isolates. Infect Immun 75:1811-1819. 
 149 
105. Li, J., S. Sayeed, and B. A. McClane. 2007. Prevalence of enterotoxigenic Clostridium 
perfringens Isolates in Pittsburgh (Pennsylvania) area soils and home kitchens. Appl 
Environ Microbiol 73:7218-7224. 
106. Lindsay, J. A. 1988. The effect of a Clostridium perfringens 8-6 enterotoxin on viability 
and macromolecular synthesis in Vero cells. Biochem Biophys Res Commun 151:1371-
1377. 
107. Lingwood, D., J. Ries, P. Schwille, and K. Simons. 2008. Plasma membranes are 
poised for activation of raft phase coalescence at physiological temperature. Proc Natl 
Acad Sci U S A 105:10005-10010. 
108. Litkouhi, B., J. Kwong, C. M. Lo, J. G. Smedley, B. A. McClane, M. Aponte, Z. Gao, 
J. L. Sarno, J. Hinners, W. R. Welch, R. S. Berkowitz, S. C. Mok, E. I. Garner. 
2007. Claudin-4 overexpression in epithelial ovarian cancer is associated with 
hypomethylation and is a potential target for modulation of tight junction barrier function 
using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9:304-
314. 
109. Loffler, A., and R. Labbe. 1986. Characterization of a parasporal inclusion body from 
sporulating, enterotoxin-positive Clostridium perfringens type A. J Bacteriol 165:542-
548. 
110. Lohrberg, D., E. Krause, M. Schumann, J. Piontek, L. Winkler, I. E. Blasig, and R. 
F. Haseloff. 2009. A strategy for enrichment of claudins based on their affinity to 
Clostridium perfringens enterotoxin. BMC Mol Biol 10:61. 
111. Long, H., C. D. Crean, W. H. Lee, O. W. Cummings, and T. G. Gabig. 2001. 
Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in 
prostate cancer epithelium. Cancer Res 61:7878-7881. 
112. Lotze, M. T., H. J. Zeh, A. Rubartelli, L. J. Sparvero, A. A. Amoscato, N. R. 
Washburn, M. E. Devera, X. Liang, M. Tor, and T. Billiar. 2007. The grateful dead: 
damage-associated molecular pattern molecules and reduction/oxidation regulate 
immunity. Immunol Rev 220:60-81. 
113. Lynch, M., J. Painter, R. Woodruff, and C. Braden. 2006. Surveillance for 
Foodborne-Disease Outbreaks --- United States, 1998--2002. Morb. Mortal. Wkly. Rep. 
Surveill. Summ. 55:1-34. 
114. Lynch, R. D., S. A. Francis, K. M. McCarthy, E. Casas, C. Thiele, and E. E. 
Schneeberger. 2007. Cholesterol depletion alters detergent-specific solubility profiles of 
selected tight junction proteins and the phosphorylation of occludin. Experimental Cell 
Research 313:2597-2610. 
115. Manes, S., G. del Real, and A. C. Martinez. 2003. Pathogens: raft hijackers. Nat Rev 
Immunol 3:557-568. 
116. Masuyama, A., M. Kondoh, H. Seguchi, A. Takahashi, M. Harada, M. Fujii, H. 
Mizuguchi, Y. Horiguchi, and Y. Watanabe. 2005. Role of N-terminal amino acids in 
the absorption-enhancing effects of the c-terminal fragment of Clostridium perfringens 
enterotoxin. J Pharmacol Exp Ther 314:789-795. 
117. Matsuda, M., K. Ozutsumi, H. Iwahashi, and N. Sugimoto. 1986. Primary action of 
Clostridium perfringens type A enterotoxin on HeLa and Vero cells in the absence of 
extracellular calcium: rapid and characteristic changes in membrane permeability. 
Biochem Biophys Res Commun 141:704-710. 
 150 
118. McClane, B. A. 1994. Clostridium perfringens enterotoxin acts by producing small 
molecule permeability alterations in plasma membranes. Toxicology 87:43-67. 
119. McClane, B. A., and J. L. McDonel. 1980. Characterization of membrane permeability 
alterations induced in Vero cells by Clostridium perfringens enterotoxin. Biochim 
Biophys Acta 600:974-985. 
120. McClane, B. A., and J. L. McDonel. 1979. The effects of Clostridium perfringens 
enterotoxin on morphology, viability, and macromolecular synthesis in Vero cells. J Cell 
Physiol 99:191-200. 
121. McClane, B. A., and J. L. McDonel. 1981. Protective effects of osmotic stabilizers on 
morphological and permeability alterations induced in Vero cells by Clostridium 
perfringens enterotoxin. Biochim Biophys Acta 641:401-409. 
122. McClane, B. A., and A. P. Wnek. 1990. Studies of Clostridium perfringens enterotoxin 
action at different temperatures demonstrate a correlation between complex formation 
and cytotoxicity. Infect Immun 58:3109-3115. 
123. McDonel J.L., D. F. 1986. The role of toxins in bacterial pathogenesis. In D. J. Dorner F. 
(ed.), Pharmacology of Bacterial Toxins. Pergamon Press, New York. 
124. McDonel, J. L. 1980. Binding of Clostridium perfringens [125I]enterotoxin to rabbit 
intestinal cells. Biochemistry 19:4801-4807. 
125. McDonel, J. L., and C. L. Duncan. 1975. Histopathological effect of Clostridium 
perfringens enterotoxin in the rabbit ileum. Infect Immun 12:1214-1218. 
126. McDonel, J. L., and B. A. McClane. 1979. Binding versus biological activity of 
Clostridium perfringens enterotoxin in Vero cells. Biochem Biophys Res Commun 
87:497-504. 
127. McDonel, J. L., and B. A. McClane. 1988. Production, purification, and assay of 
Clostridium perfringens enterotoxin. Methods Enzymol 165:94-103. 
128. Meertens, L., C. Bertaux, L. Cukierman, E. Cormier, D. Lavillette, F. L. Cosset, and 
T. Dragic. 2008. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for 
hepatitis C virus. J Virol 82:3555-3560. 
129. Melton, L. A., M. L. Tracy, and G. Moller. 1990. Screening trace elements and 
electrolytes in serum by inductively-coupled plasma emission spectrometry. Clin Chem 
36:247-250. 
130. Melville, S. B., R. Labbe, and A. L. Sonenshein. 1994. Expression from the 
Clostridium perfringens cpe promoter in C. perfringens and Bacillus subtilis. Infect 
Immun 62:5550-5558. 
131. Michl, P., M. Buchholz, M. Rolke, S. Kunsch, M. Lohr, B. McClane, S. Tsukita, G. 
Leder, G. Adler, and T. M. Gress. 2001. Claudin-4: a new target for pancreatic cancer 
treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678-684. 
132. Mietzner, T. A., J. F. Kokai-Kun, P. C. Hanna, and B. A. McClane. 1992. A 
conjugated synthetic peptide corresponding to the C-terminal region of Clostridium 
perfringens type A enterotoxin elicits an enterotoxin-neutralizing antibody response in 
mice. Infect Immun 60:3947-3951. 
133. Mitic, L. L., V. M. Unger, and J. M. Anderson. 2003. Expression, solubilization, and 
biochemical characterization of the tight junction transmembrane protein claudin-4. 
Protein Sci 12:218-227. 
134. Miyamoto, K., D. J. Fisher, J. Li, S. Sayeed, S. Akimoto, and B. A. McClane. 2006. 
Complete sequencing and diversity analysis of the enterotoxin-encoding plasmids in 
 151 
Clostridium perfringens type A non-food-borne human gastrointestinal disease isolates. J 
Bacteriol 188:1585-1598. 
135. Miyamoto, K., Q. Wen, and B. A. McClane. 2004. Multiplex PCR genotyping assay 
that distinguishes between isolates of Clostridium perfringens type A carrying a 
chromosomal enterotoxin gene (cpe) locus, a plasmid cpe locus with an IS1470-like 
sequence, or a plasmid cpe locus with an IS1151 sequence. J Clin Microbiol 42:1552-
1558. 
136. Miyata, S., O. Matsushita, J. Minami, S. Katayama, S. Shimamoto, and A. Okabe. 
2001. Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium 
perfringens epsilon-toxin in the synaptosomal membrane. J Biol Chem 276:13778-
13783. 
137. Miyata, S., J. Minami, E. Tamai, O. Matsushita, S. Shimamoto, and A. Okabe. 2002. 
Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-
insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J 
Biol Chem 277:39463-39468. 
138. Modi, N., and M. H. Wilcox. 2001. Evidence for antibiotic induced Clostridium 
perfringens diarrhoea. J Clin Pathol 54:748-751. 
139. Mpamugo, O., T. Donovan, and M. M. Brett. 1995. Enterotoxigenic Clostridium 
perfringens as a cause of sporadic cases of diarrhoea. J Med Microbiol 43:442-445. 
140. Myers, G. S., D. A. Rasko, J. K. Cheung, J. Ravel, R. Seshadri, R. T. DeBoy, Q. Ren, 
J. Varga, M. M. Awad, L. M. Brinkac, S. C. Daugherty, D. H. Haft, R. J. Dodson, R. 
Madupu, W. C. Nelson, M. J. Rosovitz, S. A. Sullivan, H. Khouri, G. I. Dimitrov, K. 
L. Watkins, S. Mulligan, J. Benton, D. Radune, D. J. Fisher, H. S. Atkins, T. Hiscox, 
B. H. Jost, S. J. Billington, J. G. Songer, B. A. McClane, R. W. Titball, J. I. Rood, S. 
B. Melville, and I. T. Paulsen. 2006. Skewed genomic variability in strains of the 
toxigenic bacterial pathogen, Clostridium perfringens. Genome Res 16:1031-1040. 
141. Nagahama, M., S. Hayashi, S. Morimitsu, and J. Sakurai. 2003. Biological activities 
and pore formation of Clostridium perfringens beta toxin in HL 60 cells. J Biol Chem 
278:36934-36941. 
142. Nagahama, M., A. Yamaguchi, T. Hagiyama, N. Ohkubo, K. Kobayashi, and J. 
Sakurai. 2004. Binding and internalization of Clostridium perfringens iota-toxin in lipid 
rafts. Infect Immun 72:3267-3275. 
143. Nichols, L. S., R. Ashfaq, and C. A. Iacobuzio-Donahue. 2004. Claudin 4 protein 
expression in primary and metastatic pancreatic cancer: support for use as a therapeutic 
target. Am J Clin Pathol 121:226-230. 
144. Niilo, L. 1971. Mechanism of Action of the Enteropathogenic Factor of Clostridium 
perfringens Type A. Infect Immun 3:100-106. 
145. Nusrat, A., C. A. Parkos, P. Verkade, C. S. Foley, T. W. Liang, W. Innis-
Whitehouse, K. K. Eastburn, and J. L. Madara. 2000. Tight junctions are membrane 
microdomains. J Cell Sci 113 ( Pt 10):1771-1781. 
146. O'Brien, D. K., and S. B. Melville. 2004. Effects of Clostridium perfringens alpha-toxin 
(PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the 
phagosomes of macrophages, and on persistence of C. perfringens in host tissues. Infect 
Immun 72:5204-5215. 
 152 
147. Ogawa-Goto, K., K. Tanaka, T. Ueno, T. Kurata, T. Sata, and S. Irie. 2007. p180 is 
involved in the interaction between the endoplasmic reticulum and microtubules through 
a novel microtubule-binding and bundling domain. Mol Biol Cell 18:3741-3751. 
148. Ouban, A., and A. A. Ahmed. 2010. Claudins in human cancer: a review. Histol 
Histopathol 25:83-90. 
149. Pei, J., J. E. Turse, Q. Wu, and T. A. Ficht. 2006. Brucella abortus rough mutants 
induce macrophage oncosis that requires bacterial protein synthesis and direct interaction 
with the macrophage. Infect Immun 74:2667-2675. 
150. Philippe, V. A., M. B. Mendez, I. H. Huang, L. M. Orsaria, M. R. Sarker, and R. R. 
Grau. 2006. Inorganic phosphate induces spore morphogenesis and enterotoxin 
production in the intestinal pathogen Clostridium perfringens. Infect Immun 74:3651-
3656. 
151. Pigott, C. R., and D. J. Ellar. 2007. Role of receptors in Bacillus thuringiensis crystal 
toxin activity. Microbiol Mol Biol Rev 71:255-281. 
152. Pike, L. J. 2006. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and 
Cell Function. J Lipid Res 47:1597-1598. 
153. Pituch, H., N. van den Braak, A. van Belkum, W. Van Leeuwen, P. Obuch-
Woszczatynski, M. Luczak, H. Verbrugh, F. Meisel-Mikolajczyk, and G. 
Martirosian. 2002. Characterization of Clostridium perfringens strains isolated from 
Polish patients with suspected antibiotic-associated diarrhea. Med Sci Monit 8:BR85-88. 
154. Prevention, C. f. D. C. a. 2009. Clostridium perfringens infection among inmates at a 
county jail--Wisconsin, August 2008. MMWR Morb Mortal Wkly Rep 58:138-141. 
155. ProMED-mail. 2010. C. perfringens food intoxication, fatal - USA: (LA) nosocomial. 
ProMED-mail 2010, vol. 30 May. 
156. Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, M. Rosas-Ballina, C. J. 
Czura, J. M. Huston, E. Miller, X. Lin, B. Sherry, A. Kumar, G. Larosa, W. 
Newman, K. J. Tracey, and H. Yang. 2006. Role of HMGB1 in apoptosis-mediated 
sepsis lethality. J Exp Med 203:1637-1642. 
157. Robertson, S. L., J. G. Smedley, 3rd, and B. A. McClane. 2010. Identification of a 
claudin-4 residue important for mediating the host cell binding and action of Clostridium 
perfringens enterotoxin. Infect Immun 78:505-517. 
158. Robertson, S. L., J. G. Smedley, 3rd, U. Singh, G. Chakrabarti, C. M. Van Itallie, J. 
M. Anderson, and B. A. McClane. 2007. Compositional and stoichiometric analysis of 
Clostridium perfringens enterotoxin complexes in Caco-2 cells and claudin 4 fibroblast 
transfectants. Cell Microbiol. 
159. Rodewald, M., D. Herr, W. C. Duncan, H. M. Fraser, G. Hack, R. Konrad, F. 
Gagsteiger, R. Kreienberg, and C. Wulff. 2009. Molecular mechanisms of ovarian 
hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro 
is associated with increased endothelial permeability. Hum Reprod 24:1191-1199. 
160. Rupnik, M., M. H. Wilcox, and D. N. Gerding. 2009. Clostridium difficile infection: 
new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. 
161. Saeki, R., M. Kondoh, H. Kakutani, S. Tsunoda, Y. Mochizuki, T. Hamakubo, Y. 
Tsutsumi, Y. Horiguchi, and K. Yagi. 2009. A novel tumor-targeted therapy using a 
claudin-4-targeting molecule. Mol Pharmacol 76:918-926. 
162. Samuel, S. C., P. Hancock, and D. A. Leigh. 1991. An investigation into Clostridium 
perfringens enterotoxin-associated diarrhoea. J Hosp Infect 18:219-230. 
 153 
163. Santin, A. D., S. Bellone, E. R. Siegel, J. K. McKenney, M. Thomas, J. J. Roman, A. 
Burnett, G. Tognon, E. Bandiera, and S. Pecorelli. 2007. Overexpression of 
Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine 
Carcinosarcomas. Clin Cancer Res 13:3339-3346. 
164. Santin, A. D., S. Cane, S. Bellone, M. Palmieri, E. R. Siegel, M. Thomas, J. J. 
Roman, A. Burnett, M. J. Cannon, and S. Pecorelli. 2005. Treatment of 
chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by 
intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 
65:4334-4342. 
165. Sarker, M. R., R. J. Carman, and B. A. McClane. 1999. Inactivation of the gene (cpe) 
encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe-positive 
C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. 
Mol Microbiol 33:946-958. 
166. Sarker, M. R., R. P. Shivers, S. G. Sparks, V. K. Juneja, and B. A. McClane. 2000. 
Comparative experiments to examine the effects of heating on vegetative cells and spores 
of Clostridium perfringens isolates carrying plasmid genes versus chromosomal 
enterotoxin genes. Appl Environ Microbiol 66:3234-3240. 
167. Sayeed, S., J. Li, and B. A. McClane. 2010. Characterization of virulence plasmid 
diversity among Clostridium perfringens type B isolates. Infect Immun 78:495-504. 
168. Sayeed, S., J. Li, and B. A. McClane. 2007. Virulence plasmid diversity in Clostridium 
perfringens type D isolates. Infect Immun 75:2391-2398. 
169. Sayeed, S., F. A. Uzal, D. J. Fisher, J. Saputo, J. E. Vidal, Y. Chen, P. Gupta, J. I. 
Rood, and B. A. McClane. 2008. Beta toxin is essential for the intestinal virulence of 
Clostridium perfringens type C disease isolate CN3685 in a rabbit ileal loop model. Mol 
Microbiol 67:15-30. 
170. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 
by necrotic cells triggers inflammation. Nature 418:191-195. 
171. Severson, E. A., and C. A. Parkos. 2009. Structural determinants of Junctional 
Adhesion Molecule A (JAM-A) function and mechanisms of intracellular signaling. Curr 
Opin Cell Biol 21:701-707. 
172. Shandera, W. X., C. O. Tacket, and P. A. Blake. 1983. Food poisoning due to 
Clostridium perfringens in the United States. J Infect Dis 147:167-170. 
173. Sherman, S., E. Klein, and B. A. McClane. 1994. Clostridium perfringens type A 
enterotoxin induces tissue damage and fluid accumulation in rabbit ileum. J Diarrhoeal 
Dis Res 12:200-207. 
174. Shimizu, T., K. Ohtani, H. Hirakawa, K. Ohshima, A. Yamashita, T. Shiba, N. 
Ogasawara, M. Hattori, S. Kuhara, and H. Hayashi. 2002. Complete genome 
sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc Natl Acad Sci U S A 
99:996-1001. 
175. Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569-
572. 
176. Sims, J. E., and D. E. Smith. 2010. The IL-1 family: regulators of immunity. Nat Rev 
Immunol 10:89-102. 
177. Singh, A. B., and R. C. Harris. 2004. Epidermal growth factor receptor activation 
differentially regulates claudin expression and enhances transepithelial resistance in 
Madin-Darby canine kidney cells. J Biol Chem 279:3543-3552. 
 154 
178. Singh, U., L. L. Mitic, E. U. Wieckowski, J. M. Anderson, and B. A. McClane. 2001. 
Comparative biochemical and immunocytochemical studies reveal differences in the 
effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero 
cells. J Biol Chem 276:33402-33412. 
179. Singh, U., C. M. Van Itallie, L. L. Mitic, J. M. Anderson, and B. A. McClane. 2000. 
CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large 
complex species, one of which contains the tight junction protein occludin. J Biol Chem 
275:18407-18417. 
180. Skjelkvale, R., H. Tolleshaug, and T. Jarmund. 1980. Binding of enterotoxin from 
Clostridium perfringens type A to liver cells in vivo and in vitro. The enterotoxin causes 
membrane leakage. Acta Pathol Microbiol Scand B 88:95-102. 
181. Skjelkvale, R., and T. Uemura. 1977. Experimental Diarrhoea in human volunteers 
following oral administration of Clostridium perfringens enterotoxin. J Appl Bacteriol 
43:281-286. 
182. Smedley, J. G., 3rd, and B. A. McClane. 2004. Fine mapping of the N-terminal 
cytotoxicity region of Clostridium perfringens enterotoxin by site-directed mutagenesis. 
Infect Immun 72:6914-6923. 
183. Smedley, J. G., 3rd, J. Saputo, J. C. Parker, M. E. Fernandez-Miyakawa, S. L. 
Robertson, B. A. McClane, and F. A. Uzal. 2008. Noncytotoxic Clostridium 
perfringens enterotoxin (CPE) variants localize CPE intestinal binding and demonstrate a 
relationship between CPE-induced cytotoxicity and enterotoxicity. Infect Immun 
76:3793-3800. 
184. Smedley, J. G., III, F. A. Uzal, and B. A. McClane. 2007. Identification of a Prepore 
Large-Complex Stage in the Mechanism of Action of Clostridium perfringens 
Enterotoxin. Infect. Immun. 75:2381-2390. 
185. Song, L., M. R. Hobaugh, C. Shustak, S. Cheley, H. Bayley, and J. E. Gouaux. 1996. 
Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 
274:1859-1866. 
186. Songer, J. G. 1996. Clostridial enteric diseases of domestic animals. Clin Microbiol Rev 
9:216-234. 
187. Sonoda, N., M. Furuse, H. Sasaki, S. Yonemura, J. Katahira, Y. Horiguchi, and S. 
Tsukita. 1999. Clostridium perfringens enterotoxin fragment removes specific claudins 
from tight junction strands: Evidence for direct involvement of claudins in tight junction 
barrier. J Cell Biol 147:195-204. 
188. Stark, R. L., and C. L. Duncan. 1971. Biological characteristics of Clostridium 
perfringens type A enterotoxin. Infect Immun 4:89-96. 
189. Sugimoto, N., Y. M. Chen, S. Y. Lee, M. Matsuda, and C. Y. Lee. 1991. 
Pathodynamics of intoxication in rats and mice by enterotoxin of Clostridium perfringens 
type A. Toxicon 29:751-759. 
190. Sugimoto, N., K. Ozutsumi, and M. Matsuda. 1985. Morphological alterations and 
changes in cellular cations induced by Clostridium perfringens type A enterotoxin in 
tissue culture cells. Eur J Epidemiol 1:264-273. 
191. Sugimoto, N., M. Takagi, K. Ozutsumi, S. Harada, and M. Matsuda. 1988. 
Enterotoxin of Clostridium perfringens type A forms ion-permeable channels in a lipid 
bilayer membrane. Biochem Biophys Res Commun 156:551-556. 
 155 
192. Takahashi, A., E. Komiya, H. Kakutani, T. Yoshida, M. Fujii, Y. Horiguchi, H. 
Mizuguchi, Y. Tsutsumi, S. Tsunoda, N. Koizumi, K. Isoda, K. Yagi, Y. Watanabe, 
and M. Kondoh. 2008. Domain mapping of a claudin-4 modulator, the C-terminal region 
of C-terminal fragment of Clostridium perfringens enterotoxin, by site-directed 
mutagenesis. Biochem Pharmacol 75:1639-1648. 
193. Takahashi, A., M. Kondoh, A. Masuyama, M. Fujii, H. Mizuguchi, Y. Horiguchi, 
and Y. Watanabe. 2005. Role of C-terminal regions of the C-terminal fragment of 
Clostridium perfringens enterotoxin in its interaction with claudin-4. Journal of 
Controlled Release 108:56-62. 
194. Tanaka, D., K. Kimata, M. Shimizu, J. Isobe, M. Watahiki, T. Karasawa, T. 
Yamagishi, S. Kuramoto, T. Serikawa, F. Ishiguro, M. Yamada, K. Yamaoka, M. 
Tokoro, T. Fukao, M. Matsumoto, R. Hiramatsu, C. Monma, and Y. Nagai. 2007. 
Genotyping of Clostridium perfringens isolates collected from food poisoning outbreaks 
and healthy individuals in Japan based on the cpe locus. Jpn J Infect Dis 60:68-69. 
195. Thumbikat, P., T. Dileepan, M. S. Kannan, and S. K. Maheswaran. 2005. 
Mechanisms underlying Mannheimia haemolytica leukotoxin-induced oncosis and 
apoptosis of bovine alveolar macrophages. Microb Pathog 38:161-172. 
196. Tilley, S. J., and H. R. Saibil. 2006. The mechanism of pore formation by bacterial 
toxins. Current Opinion in Structural Biology 16:230-236. 
197. Titball, R. W. 1993. Bacterial phospholipases C. Microbiol Rev 57:347-366. 
198. Todd, E. C. 1989. Costs of acute bacterial foodborne disease in Canada and the United 
States. Int J Food Microbiol 9:313-326. 
199. Tsukita, S., M. Furuse, and M. Itoh. 2001. Multifunctional strands in tight junctions. 
Nat Rev Mol Cell Biol 2:285-293. 
200. Tweten, R. K. 2005. Cholesterol-dependent cytolysins, a family of versatile pore-
forming toxins. Infect Immun 73:6199-6209. 
201. Uchida, H., M. Kondoh, T. Hanada, A. Takahashi, T. Hamakubo, and K. Yagi. 
2010. A claudin-4 modulator enhances the mucosal absorption of a biologically active 
peptide. Biochem Pharmacol 79:1437-1444. 
202. Uzal, F. A., J. Saputo, S. Sayeed, J. E. Vidal, D. J. Fisher, R. Poon, V. Adams, M. E. 
Fernandez-Miyakawa, J. I. Rood, and B. A. McClane. 2009. Development and 
application of new mouse models to study the pathogenesis of Clostridium perfringens 
type C Enterotoxemias. Infect Immun 77:5291-5299. 
203. Vaishnavi, C., and S. Kaur. 2008. Clostridium perfringens enterotoxin in antibiotic-
associated diarrhea. Indian J Pathol Microbiol 51:198-199. 
204. Van Itallie, C. M., and J. M. Anderson. 2004. The molecular physiology of tight 
junction pores. Physiology (Bethesda) 19:331-338. 
205. Van Itallie, C. M., L. Betts, J. G. Smedley, 3rd, B. A. McClane, and J. M. Anderson. 
2008. Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J 
Biol Chem 283:268-274. 
206. Varga, J., V. L. Stirewalt, and S. B. Melville. 2004. The CcpA protein is necessary for 
efficient sporulation and enterotoxin gene (cpe) regulation in Clostridium perfringens. J 
Bacteriol 186:5221-5229. 
207. Vidal, J. E., B. A. McClane, J. Saputo, J. Parker, and F. A. Uzal. 2008. Effects of 
Clostridium perfringens beta-toxin on the rabbit small intestine and colon. Infect Immun 
76:4396-4404. 
 156 
208. Vieira, F. S., G. Correa, M. Einicker-Lamas, and R. Coutinho-Silva. 2010. Host-cell 
lipid rafts: a safe door for micro-organisms? Biol Cell 102:391-407. 
209. Waheed, A. A., Y. Shimada, H. F. Heijnen, M. Nakamura, M. Inomata, M. Hayashi, 
S. Iwashita, J. W. Slot, and Y. Ohno-Iwashita. 2001. Selective binding of 
perfringolysin O derivative to cholesterol-rich membrane microdomains (rafts). Proc Natl 
Acad Sci U S A 98:4926-4931. 
210. Wallace, F. M., A. S. Mach, A. M. Keller, and J. A. Lindsay. 1999. Evidence for 
Clostridium perfringens enterotoxin (CPE) inducing a mitogenic and cytokine response 
in vitro and a cytokine response in vivo. Curr Microbiol 38:96-100. 
211. Weinrauch, Y., and A. Zychlinsky. 1999. The induction of apoptosis by bacterial 
pathogens. Annu Rev Microbiol 53:155-187. 
212. Wen, Q., and B. A. McClane. 2004. Detection of enterotoxigenic Clostridium 
perfringens type A isolates in American retail foods. Appl Environ Microbiol 70:2685-
2691. 
213. Wieckowski, E. U., J. F. Kokai-Kun, and B. A. McClane. 1998. Characterization of 
membrane-associated Clostridium perfringens enterotoxin following pronase treatment. 
Infect Immun 66:5897-5905. 
214. Wieckowski, E. U., A. P. Wnek, and B. A. McClane. 1994. Evidence that an 
approximately 50-kDa mammalian plasma membrane protein with receptor-like 
properties mediates the amphiphilicity of specifically bound Clostridium perfringens 
enterotoxin. J Biol Chem 269:10838-10848. 
215. Winkler, L., C. Gehring, A. Wenzel, S. L. Muller, C. Piehl, G. Krause, I. E. Blasig, 
and J. Piontek. 2009. Molecular determinants of the interaction between Clostridium 
perfringens enterotoxin fragments and claudin-3. J Biol Chem 284:18863-18872. 
216. Wnek, A. P., and B. A. McClane. 1983. Identification of a 50,000 Mr protein from 
rabbit brush border membranes that binds Clostridium perfringens enterotoxin. Biochem 
Biophys Res Commun 112:1099-1105. 
217. Wnek, A. P., and B. A. McClane. 1989. Preliminary evidence that Clostridium 
perfringens type A enterotoxin is present in a 160,000-Mr complex in mammalian 
membranes. Infect Immun 57:574-581. 
218. Wnek, A. P., R. J. Strouse, and B. A. McClane. 1985. Production and characterization 
of monoclonal antibodies against Clostridium perfringens type A enterotoxin. Infect 
Immun 50:442-448. 
219. Wong, V. 1997. Phosphorylation of occludin correlates with occludin localization and 
function at the tight junction. Am J Physiol 273:C1859-1867. 
220. Yamamoto, K., I. Ohishi, and G. Sakaguchi. 1979. Fluid accumulation in mouse 
ligated intestine inoculated with Clostridium perfringens enterotoxin. Appl Environ 
Microbiol 37:181-186. 
221. Yamazaki, Y., K. Okawa, T. Yano, and S. Tsukita. 2008. Optimized proteomic 
analysis on gels of cell-cell adhering junctional membrane proteins. Biochemistry 
47:5378-5386. 
222. Young, J. A., and R. J. Collier. 2007. Anthrax toxin: receptor binding, internalization, 
pore formation, and translocation. Annu Rev Biochem 76:243-265. 
223. Yu, A. S., K. M. McCarthy, S. A. Francis, J. M. McCormack, J. Lai, R. A. Rogers, 
R. D. Lynch, and E. E. Schneeberger. 2005. Knockdown of occludin expression leads 
 157 
to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol 
288:C1231-1241. 
224. Yuan, X., X. Lin, G. Manorek, I. Kanatani, L. H. Cheung, M. G. Rosenblum, and S. 
B. Howell. 2009. Recombinant CPE fused to tumor necrosis factor targets human ovarian 
cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 8:1906-
1915. 
225. Zhao, Y., and S. B. Melville. 1998. Identification and characterization of sporulation-
dependent promoters upstream of the enterotoxin gene (cpe) of Clostridium perfringens. J 
Bacteriol 180:136-142. 
226. Zheng, A., F. Yuan, Y. Li, F. Zhu, P. Hou, J. Li, X. Song, M. Ding, and H. Deng. 
2007. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J 
Virol 81:12465-12471. 
227. Zhou, X., M. E. Konkel, and D. R. Call. 2009. Type III secretion system 1 of Vibrio 
parahaemolyticus induces oncosis in both epithelial and monocytic cell lines. 
Microbiology 155:837-851. 
228. Zitzer, A., O. Zitzer, S. Bhakdi, and M. Palmer. 1999. Oligomerization of Vibrio 
cholerae cytolysin yields a pentameric pore and has a dual specificity for cholesterol and 
sphingolipids in the target membrane. J Biol Chem 274:1375-1380. 
 
 
